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1 
Summary 
Fibroblast growth factor 2 (FGF2) is a potent mitogen involved in many physiological 
processes such as cell proliferation, differentiation as well as angiogenesis and, therefore, 
has a prominent function in tumor growth. FGF2 is secreted via an unconventional pathway 
using a route that is independent from the endoplasmic reticulum and the Golgi apparatus. 
Secretion of FGF2 occurs by direct translocation across the plasma membrane in a folded 
state, which is initiated by binding to phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) at the 
inner leaflet of the plasma membrane. In the extracellular space, membrane proximal 
heparan sulfate proteoglycans (HSPGs) are required to complete translocation as well as to 
store and protect FGF2 on cell surfaces. The interaction with PI(4,5)P2 was shown to 
facilitate oligomerization of FGF2 leading to the formation of a lipidic membrane pore that 
has been interpreted as an intermediate structure in FGF2 membrane translocation. In 
addition, Tec kinase was discovered as a factor regulating FGF2 secretion by 
phosphorylating tyrosine 82 in FGF2. Recent evidence suggests that phosphorylation 
stabilizes the formation of FGF2 oligomers, which favors the arrangement of a transient 
hydrophilic pore constituted by FGF2 molecules in the plasma membrane. 
Based on a genome-wide ribonucleic acid interference (RNAi) screen this study aimed for 
the identification of further proteinaceous components that regulate or facilitate FGF2 
secretion. Pharmacological studies previously implicated the sodium potassium pump 
(Na+/K+-ATPase) as a potential factor involved in FGF2 secretion, which indeed was a major 
hit in the genome-wide RNAi screen described in this thesis. Therefore, the main goal of this 
study was to validate these findings and to obtain mechanistic insight into the role of the 
Na+/K+-ATPase in the overall process of FGF2 secretion. 
Since the Na+/K+-ATPase is formed of a heterodimeric complex that consists of the α- and 
β-subunit, cell-based secretion experiments identified the α1-subunit (ATP1A1) as the 
component involved in FGF2 secretion. Furthermore, a direct interaction between the 
cytoplasmic domains of ATP1A1 with FGF2 could be demonstrated. In addition, both 
proteins were shown to co-localize at the plasma membrane in HeLa cells. Therefore, it is 
highly likely that a direct interaction of FGF2 and ATP1A1 occurs at the cytoplasmic leaflet 
facilitating export of FGF2 from cells. 
Based on an alpha screening setup analyzing a large library of small molecules, compounds 
were identified that block the interaction between FGF2 and ATP1A1. Therefore, this study 
provides new tools for future investigations on the mechanism of FGF2 secretion as well as 
lead compounds with a high potential for the development of novel anti-angiogenic drugs.   
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Zusammenfassung 
Fibroblastenwachstumsfaktor 2 (FGF2) ist ein potentes Mitogen, das diverse physiologische 
Prozesse wie Zellproliferation, Zelldifferenzierung und die Bildung von Blutgefäßen 
beeinflusst. Im pathophysiologischen Zusammenhang spielt FGF2 eine besondere Rolle, 
sowohl bei der Tumor-induzierten Angiogenese als auch bei der Resistenz von Tumorzellen 
gegenüber Chemotherapien. Deshalb ist FGF2 ein validiertes Zielmoleküle zur Entwicklung 
von Strategien zur Begrenzung von Tumorwachstum. Die Freisetzung von FGF2 durch 
Zellen verläuft unabhängig vom endoplasmatischen Retikulum und dem Golgi Apparat. Die 
unkonventionelle Sekretion von FGF2 erfolgt in gefaltetem Zustand durch eine direkte 
Translokation über die Plasmamembran. Bisher konnten zwei Faktoren identifiziert werden, 
die für diesen Sekretionsprozess essentiell sind. Zum einen das Phosphoinositid (PI(4,5)P2) 
an der Innenseite der Plasmamembran, welches für die Rekrutierung von FGF2 zuständig 
ist. Zum anderen Heparansulfat-Proteoglykane, die für einen späten Schritt in der 
Translokation notwendig sind und FGF2 auf der Zelloberfläche präsentieren. Die Bindung an 
PI(4,5)P2 induziert die Oligomerisierung von FGF2 und in der Folge die Bildung einer 
transienten Membranpore, die als Translokationsintermediat interpretiert wurde. Weiterhin ist 
die Tec Kinase eine wichtige regulatorische Komponente für die Sekretion von FGF2. Es 
wurde kürzlich gezeigt, dass eine Phosphorylierung von Tyrsoin 82 in FGF2 durch die Tec 
Kinase zu einer Stabilisierung der oligomeren Struktur von FGF2 führt und hierdurch die 
Entstehung einer Membranpore begünstigt wird. 
Anhand einer genomweiten Analyse - basierend auf RNA Interferenz (RNAi) - sollten in 
dieser Studie weitere Faktoren ermittelt werden, die maßgeblich an der Sekretion von FGF2 
beteiligt sind. Hierbei wurde die Natrium-Kalium ATPase (Na+/K+-ATPase) als eine 
essentielle Komponente der FGF2 Sekretion entdeckt. Diese Befunde bestätigen frühere 
pharmakologische Studien, in denen eine solche Rolle bereits diskutiert wurde. Im Zuge der 
vorliegenden Arbeit wurde diese Funktion validiert und einer mechanistischen Analyse 
unterzogen. 
Die Na+/K+-ATPase besteht aus einem heterodimeren Komplex, zusammengesetzt aus einer 
α- und β-Untereinheit. In einem in vivo Sekretionsexperiment konnte gezeigt werden, dass 
ausschließlich die α1-Untereinheit (ATP1A1) an der Sekretion von FGF2 beteiligt ist. 
Biochemische Analysen deckten außerdem eine direkte Interaktion zwischen den 
zytoplasmatischen Domänen von ATP1A1 und FGF2 auf. Im zellulären Kontext konnte eine 
entsprechende Kolokalisation an der Plasmamembran von HeLa Zellen beobachtet werden. 
Dies deutet stark darauf hin, dass eine direkte Interaktion zwischen FGF2 und ATP1A1 
notwendig ist, um die Sekretion von FGF2 zu ermöglichen. 
Um diese Frage weiter molekular analysieren zu können, wurden im dritten Teil dieser Arbeit 
kleine Moleküle identifiziert, die die Interaktion von ATP1A1 und FGF2 blockieren. Hierzu 
wurde ein Alpha Screening Ansatz etabliert und eine Bibliothek von etwa 4000 Molekülen 
nach Inhibitoren durchsucht. Die identifizierten Moleküle können nun in vielfältiger Weise 
eingesetzt werden, sowohl zur weiteren Analyse des molekularen Mechanismus der FGF2 
Sekretion als auch zur Entwicklung von Wirkstoffen, die die Inhibierung der Tumor-
induzierten Angiogenese anstreben. 
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1 Introduction 
A eukaryotic cell is characterized by the presence of an elaborated membrane system that is 
defined by highly organized membrane compartments known as organelles. It is surrounded 
by the plasma membrane, which forms a biological barrier between the extracellular and 
intracellular environment and is essential for maintaining cell integrity. The genome is found 
in the nucleus and is encoded by deoxyribonucleic acid (DNA). Once, genes are translated 
into newly synthesized polypeptides they have to reach their final destination. This can either 
be a subset of organelles, the plasma membrane, or the extracellular space. Here, the 
organelles fulfill specific functions during the process of protein biogenesis, modification, 
sorting and secretion. The vast majority of secretory proteins are secreted via the classical 
secretory pathway through the ER and Golgi apparatus en route to the plasma membrane. 
However, there is a growing list of proteins that follow a distinct pathway and are externalized 
independent of the ER and Golgi apparatus.  
1.1 The classical secretory pathway 
Proteins that enter the secretory pathway are synthesized on free ribosomes in the 
cytoplasm. Soon after the amino terminal (N-terminal) hydrophobic signal sequence emerges 
from the nascent polypeptide chain a signal-recognition particle (SRP) recognizes the 
sequence to target the ribosomal-nascent chain complex to the ER (Blobel and Dobberstein, 
1975). This is mediated in a guanosine triphosphate (GTP) dependent manner through the 
binding of the SRP to the SRP-receptor that is located on the ER membrane. Concomitant 
with GTP hydrolysis and SRP release the nascent polypeptide is handed over to the 
translocon, a trimeric Sec61 complex, that forms a protein conducting channel that allows the 
polypeptide to cross the ER membrane. The signal sequence of the polypeptide chain is 
cleaved immediately after the entry into the ER by a signal peptidase, while the ribosome 
completes the synthesis of the protein (Corsi and Schekman, 1996; Dalbey and von Heijne, 
1992; Görlich et al., 1992; Lee et al., 2004; Rapoport, 1992; Walter et al., 1981). Soluble 
proteins are completely transferred into the ER lumen. In contrast transmembrane proteins 
laterally diffuse with their hydrophobic transmembrane segment into the lipid bilayer of the 
ER (Shao and Hegde, 2011). The ER itself provides an environment for protein folding, 
maturation and assembly into multisubunit complexes. Proteins are subjected to asparagine-
linked glycosylation (N-glycosylation), modifications, that serve as substrates for a variety of 
chaperones that facilitate protein folding (Bukau and Horwich, 1998). 
Introduction 
 
 
4 
 
 
Figure 1: The classical secretion pathway. Adapted from Nickel and Rabouille, 2009. Nature 
Review Molecular Cell Biology 2009, 10:148-55 
 
The three dimensional structure of proteins is further determined by the formation of disulfide 
bonds, which are mainly formed in the oxidative milieu of the ER (Freedman, 1995).  A 
complex quality control system ensures that abnormally folded proteins are removed from 
the ER. The ER-associated degradation (ERAD) system delivers misfolded proteins back to 
the cytosol where they undergo ployubiquitinylation and finally degradation by the 
proteasome (Ellgaard and Helenius, 2001, 2003; Taxis et al., 2002). Properly folded proteins 
leave the ER at specific landmarks, the ER exit sites, where cargo is packed into 
Coat-protein-complex II (COPII) vesicles (Kuge et al., 1994; Orci et al., 1991; Pagano et al., 
1999). COPII vesicles mediate anterograde transport, from the ER to the Golgi, where the 
cargo arrives and fuses with the cis-Golgi network (CGN). Retrograde transport from the 
CGN to the ER occurs via Coat-protein-complex I (COPI)-coated vesicles to recycle proteins 
that have to be retrieved in the ER. The CGN is a vesicular tubular cluster of ER derived 
vesicles that subsequently build up the cis-cisterna of the Golgi. The Golgi apparatus is a 
polarized organelle where proteins move in a sequential manner from the cis- to the medial- 
and trans- cisternae (Glick, 2000). Each compartment contains a subset of specific enzymes, 
glycosyl transferases that gradually modify N-glycans added in the ER to produce more 
complex oligosaccharide chains (Roth, 2002). Furthermore, the Golgi apparatus is the place 
where glycosylation occurs to hydroxyl groups of serine or threonine (O-linked glycosylation) 
and where glycosaminoglycan chains are added to proteins to form proteoglycans (Prydz 
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and Dalen, 2000). The trans-Golgi network (TGN) sorts the proteins according to their final 
destination. These can be lysosomes (via endosomal compartments) regulated by 
clathrin-coated vesicles (Le Borgne and Hoflack, 1998a, 1998b), delivery to secretory 
vesicles for regulated secretion and constitutive secretion to the cell surface (Burgess and 
Kelly, 1987).   
1.2 Unconventional secretion 
Beside the transport along the classical secretory route, which is an ER/Golgi-dependent 
pathway, eukaryotic cells employ various alternatives for cell surface delivery of both soluble 
and membrane proteins. There are common features that account for almost all proteins that 
are secreted via unconventional means. This is the absence of a N-terminal signal peptide 
and their secretion is not affected by the treatment with brefeldin A (BFA). The latter is an 
inhibitor of anterograde protein transport from ER to Golgi apparatus, which interferes with 
vesicular trafficking, thus, resulting in protein accumulation inside the ER (Lippincott-
Schwartz et al., 1989).  In general, there are two types of unconventional protein secretion 
that involve non-vesicular or vesicular mechanisms. The former are based on direct 
translocation of cytoplasmic proteins across the plasma membrane and are subsequently 
deposited on cell surfaces or released into the extracellular space (Nickel and Rabouille, 
2009). On the other hand, vesicular mechanisms of unconventional protein secretion depend 
on intracellular membrane-bound intermediates (such as secretory lysosomes, 
microvesicular bodies or autophagosomes), which need to fuse with the plasma membrane 
in order to enable cargo release into the extracellular space. Just lately, a more defined 
categorization was made (Rabouille et al., 2012). Here, unconventional secreted proteins 
were classified into four different subgroups from Type I to Type IV. Type I resembles 
proteins that follow the non-vesicular pathway and are secreted by direct translocation 
across the plasma membrane. Type II secretion proteins are released through an 
ABC-transporter system and lipidated proteins or peptides. Type III pathway comprises 
proteins that are secreted via a vesicular intermediate. Finally, proteins that bypass the Golgi 
apparatus are assigned to type IV secretion (Rabouille et al., 2012). The following table gives 
an overview of some proteins that are transported by unconventional means and categorizes 
them according to their different subgroups. In the next section proteins of each class will be 
described in more detail.  
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Table 1: Overview of unconventionally secreted proteins classified according to their secretion 
mechanisms. Modified table was from Rabouille et al., 2012. Journal of Cell Science 2012,125:5251-
5255. 
 
 Mechanism Cargo and Reference  
N
on
-v
es
ic
ul
ar
 
Type I 
Self-
sustained 
membrane 
translocation 
FGF1 (Prudovsky et al., 2013) 
FGF2 (Engling et al., 2002; Nickel et al., 2009) 
Tat (Ensoli et al., 1990; Rayne et al., 2010a, 2010b) 
Annexin A2 (Deora et al., 2004; Rescher and Gerke, 
2008) 
C
yt
op
la
sm
ic
 p
ro
te
in
s 
Type II 
ABC 
transporter-
based 
secretion 
(Lipidated 
proteins and 
peptides) 
Yeast a-factor mating pheromone, prenylated 
polypeptide (McGrath and Varshavsky, 1989; Michaelis, 
1993) 
Leishmania hydrophilic acylated surface protein B 
(HASPB) protein (Denny et al., 2000; Maclean et al., 
2012; Stegmayer et al., 2005) 
Plasmodium falciparum acylated protein kinase 
(PfCDPK1) (Möskes et al., 2004)  
Ve
si
cu
la
r 
Type III 
Autophagy 
and 
vesicular 
based 
secretion 
Acb1/AcbA (Cabral et al., 2010; Duran et al., 2010; 
Manjithaya et al., 2010) 
Interleukin1-β (IL1β) (Dupont et al., 2011; Keller et al., 
2008; Lopez-Castejon and Brough, 2011) 
High mobility group box 1 (HMGB1) protein (Bonaldi et 
al., 2003; Gardella et al., 2002) 
Type IV 
Golgi 
bypass 
CFTR (Gee et al., 2011; Yoo et al., 2002) 
αPS1 integrin (Schotman et al., 2008) 
Connexin 26 and 30 (George et al., 1999; Qu et al., 
2009) 
Pannexin 1 and 3 (Penuela et al., 2007) 
Tyrosine phosphatase (CD45) (Baldwin and Ostergaard, 
2001) T
ra
ns
m
em
br
an
e 
pr
ot
ei
ns
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1.2.1 FGF1 and FGF2 – examples for Type I secretion 
Fibroblast growth factor (FGF) 1 and 2 are both absent of a signal peptide and are released 
from cells without entering the ER or Golgi compartment. They have in common that they 
pass the plasma membrane by direct translocation and are subsequently immobilized on the 
cell surface on HSPGs (Cao and Pettersson, 1993; Zehe et al., 2006).  
Secretion of FGF1 is mainly induced due to cellular stress conditions such as heat shock 
(Jackson et al., 1995), hypoxia (Mouta Carreira et al., 2001), and serum starvation (Shin et 
al., 1996). Secretion is facilitated by a multiprotein complex, in which FGF1 is associated with 
sphingosine kinase 1, p40 synaptotagmin 1, and S100A13 (Mohan et al., 2010; Prudovsky et 
al., 2013). It is believed that the assembly of the complex occurs prior to secretion in the 
cytosol close to the inner plasma membrane leaflet (Mohan et al., 2010). A prerequisite for 
FGF1 secretion is the formation of a FGF1 homodimer, which is part of the multiprotein 
complex. Dimer formation occurs intermolecular between the cysteines 30 mediated through 
oxidative conditions of copper (Cu2+), which is tightly associated to shingosine kinase 1 and 
p40 synaptotagmin 1 of the multiprotein complex (Engleka and Maciag, 1992; Landriscina et 
al., 2001). Furthermore, it has been shown that FGF1, p40 synaptotagmin 1, and S100A13 
can bind to acidic phospholipids leading to a destabilization of liposomes. Therefore, it is 
believed that binding of the multiprotein complex at the inner side of the plasma membrane 
to acidic phospholipids plays a major role in externalization of FGF1, which might involve a 
flipping mechanism after binding to the phospholipids (Graziani et al., 2009; Prudovsky et al., 
2008). However, a detailed mechanism on how FGF1 can traverse the plasma membrane 
being released at the extracellular space is currently unknown.  
Constitutive secretion of FGF2 from cells is dependent on several components (Nickel, 
2010). FGF2 is recruited to the inner plasma membrane leaflet by binding to PI(4,5)P2 
(Temmerman et al., 2008), which has been shown to induce the formation of FGF2 
oligomers. These oligomers stimulate the formation of a lipidic pore through which FGF2 can 
traverse the plasma membrane. In addition, phosphorylation of FGF2 at the cytoplasmic side 
contributes to the stabilization of such FGF2 oligomers. This is mediated by Tec kinase an 
essential regulatory component of this secretion process (Ebert et al., 2010; Steringer et al., 
2012). To date the structure of such a FGF2 pore is still under investigation. A detailed 
description of the FGF2 secretion mechanism will be revisited in section 1.4.4.  
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1.2.2 Tat – an example for Type I secretion  
Tat stands for “trans-activator of transcription” and is a protein with a molecular weight of 
11 kDa that is encoded from the human immunodeficiency virus type 1 (HIV-1). In the 
replication cycle of HIV-1, Tat plays a crucial role to enhance transcription of viral genes, 
acting as a transactivating protein (Jeang et al., 1999). Despite the lack of a signal sequence 
it has been reported that Tat is secreted from HIV-1 infected CD4 positive T cells (Ensoli et 
al., 1990) and does not pass the ER or Golgi compartment (Chang et al., 1997; Rayne et al., 
2010b). The extracellular role of Tat is not fully understood but different studies point to the 
direction that it is involved in the development of acquired immune deficiency syndrome and 
Kaposi’s sarcoma (Barillari et al., 1999; Campbell et al., 2004). Tat is recruited to the inner 
leaflet of the plasma membrane by binding to PI(4,5)P2 with its basic domain (residues 
arginine (R) 49, lysine (K) 50 and K51. Interestingly, a tryptophan (W) at position 11 is 
needed to stabilize this interaction between Tat and PI(4,5)P2, which subsequently leads to 
membrane insertion (Rayne et al., 2010a). Concomitantly, such an insertion is required for 
secretion of the protein since a mutant where W 11 is replaced by tyrosine (Y) is strongly 
impaired to be detected in the supernatant (Rayne et al., 2010a; Yezid et al., 2009). Details 
of the secretion mechanism are currently unknown. On the cell surface Tat is able to interact 
with multiple receptors such as lipoprotein receptor-related protein (Liu et al., 2000), 
chemokine receptor 4 (CXCR4) (Ghezzi et al., 2000) and HSPGs (Tyagi et al., 2001) to fulfill 
its biological function.  
1.2.3 The a-factor mating pheromone – an example for Type II secretion 
The second secretion pathway describes a non-vesicular pathway that makes use of an 
energy-dependent transport mediated through a superfamily of proteins termed adenosine 
triphosphate (ATP)-binding cassette (ABC) transporters. Evolutionary ABC-transporters are 
well conserved from bacteria to eukaryotes. They consist of two homolog transmembrane 
domains that both have the ability to bind ATP (Ketchum et al., 2001). With the help of ATP 
hydrolysis they transport a variety of substrates ranging from ions, carbohydrates, amino 
acids, phospholipids, and peptides across extra- and intracellular membranes (Bauer et al., 
1999). One example is the Ste6p ABC-transporter, which was discovered in the yeast 
Saccaromyces cerivisiae. It is required for the export of a-factor mating pheromone (Kuchler 
et al., 1989). Mating in yeast occurs when two haploid cells of the two opposite mating types 
a and α fuse to form a diploid cell. This is achieved through the secretion of either a-factor or 
α-factor mating pheromone from a haploid cell. Neighboring cells can sense their 
corresponding opposite mating type, from an outgrowth, and fuse with each other (Cross et 
al., 1988). Interestingly, secretion of a-factor was still maintained when the classical 
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secretory pathway of yeast was blocked by growing temperature-sensitive 
secretion-defective (sec) mutants (Schekman, 1985) at restrictive temperature, whereas 
α-factor secretion of the opposite mating type was inhibited (Kuchler et al., 1989). 
Pro-a-factor is synthesized in the cytosol as a 36 or 38 amino acid precursor peptide lacking 
any N-terminally hydrophobic signal sequence. On the C-terminus a farnesyl moiety and a 
methyl group is attached to the cysteine 33, which is needed for its biological activity. 
Subsequently, the precursor protein is processed on its N-terminus to form the mature 
lipopeptide (12 amino acid in length) that is secreted via the Ste6 ABC-transporter by active 
transport across the plasma membrane (Michaelis, 1993).  
1.2.4 Acb1/AcbA – an example for Type III secretion 
Another example for a protein that lacks a N-terminal secretion signal is the 
acyl-coenzyme A (CoA)-binding protein (Acb1) in yeast. Homolog proteins are expressed in 
humans (ACBP) and Dictyostelium discoideum (AcbA). All proteins are very small in size 
(10 kDa). In Dictyostelium discoideum secretion of AcbA was found to be dependent on the 
Golgi reassembly and stacking protein (GRASP) (Kinseth et al., 2007), which is in 
mammalian cells required for Golgi stacking of the cisternae (Feinstein and Linstedt, 2008). 
During the development of Dictyostelium discoideum, AcbA is getting secreted from 
pre-spore cells. Once secreted, AcbA will be proteolytically cleaved into a 34 amino acid 
spore differentiation factor-2 peptide that can induce sporulation (Anjard and Loomis, 2005). 
The secretion mechanism was further investigated by two different studies in yeast (Duran et 
al., 2010; Manjithaya et al., 2010). The major findings revealed that secretion of Acb1 is not 
only dependent on Grh1 (yeast homolog of GRASP) but also on autophagosomal structures 
that subsequently fuse with endosomal compartments, finally being directed for vesicular 
fusion with the plasma membrane. The onset of secretion in yeast is initiated by nutrition 
starvation giving raise to a concerted release of the biological active (34 amino acids) peptide 
after 3 h (Duran et al., 2010). Concomitant with the starvation process it has been reported 
that punctuated structures form near the ER exit sites, so called compartments for 
unconventional protein secretion (CUPS) (Bruns et al., 2011). This compartment is enriched 
of phosphatidylinositol 3-phosphate and proteins such as Grh1. Moreover, autophagy related 
proteins  (Atg-8 and Atg-9) and Vps23 are recruited to it, all of them being essential factors 
for Acb1 secretion (Bruns et al., 2011). Vps23 might be required for the fusion of CUPS with 
endosomal compartments, such as multivesicular bodies. Vps23 is a component of the 
endosomal sorting complex-I (ESCRT-I), which is needed for sorting of proteins into 
multivesicular bodies (Katzmann et al., 2003). To date it is not clear how these vesicles can 
escape the multivesicular bodies to be directed to the plasma membrane.                 
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However, a plasma membrane specific t-SNARE (soluble N-ethylmaleimide sensitive factor 
attachment protein receptor on the target membrane) Sso1 was identified as a factor 
mediating the fusion of vesicles to the plasma membrane and thus, allowing the release of 
Acb1 into the extracellular space (Malhotra, 2013).  
1.2.5 CFTR – an example for Type IV secretion  
The last secretion pathway describes proteins that typically enter the ER but during the 
following secretion process are absent from the Golgi apparatus. One of the best-studied 
members in this group is the cystic fibrosis transmembrane conductance regulator (CFTR), 
which is a cyclic adenosine monophosphate (cAMP)-activated anion channel involved in 
transport of chloride throughout epithelia. Mutations in the CFTR gene lead to the 
development of a very severe disease named cystic fibrosis. The perturbation of the 
epithelial electrolyte transport gives rise to sticky mucus that most critically affects the lungs, 
pancreas and intestines (Quinton, 2010). In mammalian cells CFTR is found in two different 
states, as a core-glycosylated immature form (band B) in the ER and as a fully glycosylated 
protein (band C) (Amaral, 2004). Under normal growth conditions the glycosylated form is 
found on the plasma membrane. Yoo and colleagues could show that dominant negative 
mutants of Sar1 a component of the COPII complex and Arf1 a component of the COPI 
complex blocked the maturation of CFTR, which remains in the band B form. This was also 
observed when syntaxin 5 was overexpressed in cells. Syntaxin 5 is a 
N-ethylmaleimide-sensitive factor that is involved in fusion of COPII vesicles with Golgi 
membranes (Yoo et al., 2002). However, the effect of Arf1 and sytaxin 5 seemed to be cell 
type specific. Interestingly, under these conditions when the ER to Golgi pathway was 
blocked, suddenly the core-glycosylated version of CFTR appeared to be on the plasma 
membrane. Measuring chloride currents showed that the protein was still functional (Gee et 
al., 2011). It could be shown that this unconventional route of secretion was triggered by 
ER-stress, during which a signaling cascade was activated leading to the phosphorylation of 
GRSP55 (mammalian homolog of GRASP) in HEK293T cells. In addition, CFTR can directly 
bind to a specific PDZ-domain region of GRSP55 that is absolutely essential for the delivery 
of CFTR to the plasma membrane (Gee et al., 2011). This is another example where 
unconventional protein secretion is linked to GRASP, which was already suggested to be 
involved in the secretion of Acb1/AcbA (see section 1.2.4). 
  
Introduction 
 
 
11 
1.3 Fibroblast growth factor (FGF) gene family 
In vertebrates, the FGF gene family consists of 22 genes with an overall identity of 30-60% of 
their amino acid sequence and a conserved 120 amino acid core region (Itoh and Ornitz, 
2004). They range in size from 17-34 kDa (Ornitz and Itoh, 2001) and contribute to a wide 
variety of biological functions. FGFs have a high affinity for extracellular HSPGs present in 
close proximity on the cell surface. Binding to HSPGs protects FGFs from proteolysis and it 
is essential to form a ternary complex with high-affinity FGF tyrosine kinase receptors (FGFR 
1-4) to activate the signaling cascade (Nugent and Iozzo, 2000; Pellegrini et al., 1998). The 
conserved core region provides a stretch of 10 amino acids that interact with the FGF 
receptors (Plotnikov et al., 2000). Considering their extracellular roles, most of the FGFs 
contain a signal peptide that targets them to the classical ER/Golgi-dependent secretory 
pathway (FGFs 3-8, 10, 17-19, 21-23). Another class of FGFs lacking the signal peptide 
(FGFs 11-14) has exclusively an intracellular localization. In contrast, even though            
FGF 1, 2, 9, 16 and 20 lack an obvious signal peptide, they are still secreted (Itoh and Ornitz, 
2004). Regarding their mode of secretion FGF1 and FGF2 are the best-characterized growth 
factors. Both of them are released from cells by means of an ER/Golgi-independent pathway. 
The underlying secretion mechanism of FGF2 will be discussed in detail in the following 
sections. 
1.4 Fibroblast growth factor 2 (FGF2) 
1.4.1 FGF2 isoforms 
As described above FGF2 belongs to the family of heparin binding proteins. In vertebrates, 
five different isoforms were found, all of them lacking a N-terminal signal sequence. The 
18 kDa form is often referred as basic or low molecular weight (LMW) FGF2. Its translation is 
initiated from the AUG start codon of the mRNA. Four additional alternative CUG initiation 
codons are present upstream of the canonical AUG. This results in the translation of four 
high molecular weight (HMW) isoforms with electrophoretic mobility of 22, 22.5, 24 and 
34 kDa (Delrieu, 2000; Prats et al., 1989). The HMW isoforms carry a nuclear localization 
signals (NLS) and are predominantly found in the nucleus where they fulfill their biological 
functions such as cell proliferation and differentiation (Couderc et al., 1991; Dini et al., 2002; 
Dvorak et al., 2005; Renko et al., 1990). The LMW FGF2 is found in the nucleus and the 
cytoplasm (depending on the cell line) but is also secreted from cells (Florkiewicz et al., 
1995a; Sheng et al., 2004). Upon secretion FGF2 can interact with HSPGs and the high 
affinity receptors (FGFR1-4) to exert its function in an autocrine and paracrine manner 
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(Turner and Grose, 2010). The expression patterns of FGF2 isoforms are largely dependent 
on the cell type, developmental stage and can also be influenced in response to heat shock 
or oxidative stress (Giordano et al., 1992; Vagner et al., 1996). In the following parts of this 
thesis the 18 kDa, LMW will be referred to as FGF2. 
1.4.2 Biological function of FGF2 
FGF2 is a potent mitogen that plays a major role in various cellular processes that involve 
cell migration, proliferation and differentiation (Bikfalvi et al., 1997).  For example, it has been 
reported that expression of endogenous FGF2 is required for the migration of bovine 
capillary endothelial cells and human fibroblast cells (Sato and Rifkin, 1988) and also has an 
impact on cell growth (Neufeld et al., 1988; Sasada et al., 1988). In addition, FGF2 is 
involved in many physiological and pathological processes such as tumor angiogenesis and 
tumor growth (Presta et al., 2005; Wang and Becker, 1997), vasculogenesis (Murakami and 
Simons, 2008), wound healing (Barrientos et al., 2008) and neural development (Giordano et 
al., 1992; Vescovi et al., 1993). Angiogenesis supports the formation of new blood vessels 
from a pre-existing vascular system. It has been reported that FGF2 is needed for the 
stimulation of vascular endothelial growth factor (VEGF) expression, which is one of the most 
critical growth factors that induce angiogenesis (Seghezzi et al., 1998). The growth of new 
blood assures the supply of oxygen and nutrition and concomitantly, supports tumor growth.    
1.4.3 Structural aspects of FGF2 
The 18 kDa form of FGF2 consists of 155 amino acids that are arranged in a trigonal pyramid 
of 12 antiparallel β-sheets of which 6 form a β-barrel (Ago et al., 1991; Eriksson et al., 1991, 
1993; Zhang et al., 1991; Zhu et al., 1991). Later on high-resolution nuclear magnetic 
resonance (NMR) spectroscopy experiments revealed only 11 β-sheets and a helical 
structure in the region of 131 - 136 amino acids, which replaces the β-sheet 11 (Figure 2) 
(Moy et al., 1996). This is also the major region involved in heparin binding. Co-crystallization 
of FGF2 with heparin (hexasaccharide) as well as in a ternary complex with heparin and 
FGFR revealed the following residues involved in heparin binding: asparagine (N) 36, R129, 
threonine (T) 130, lysine (K) 134, K138, glutamine (Q) 143, K144 and alanine (A) 145 (the 
numbering was chosen starting with methionine at position 1) (Faham et al., 1996; 
Schlessinger et al., 2000). Interestingly, the co-crystallization experiments demonstrate that 
FGF2 can simultaneously bind to FGFR and heparin on the cell surface. In agreement with 
different studies, the first 28 amino acids are largely unstructured indicating a high flexibility 
(Kastrup et al., 1997; Moy et al., 1996). 
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Figure 2: Three-dimensional structure of human FGF2. The protein backbone of FGF2 consists of 
12 antiparallel β-sheets organized in a pyramidal structure. The pink regions between β-sheet 1 and 2 
as well as between β-sheet 11 and 12 representing binding regions to heparin. In green, red and blue 
contacted sites to FGFR are shown. The N-terminus and C-terminus is labeled with NT and CT, 
respectively. According to Eriksson et al., this structure is lacking the first 19 amino acids (Eriksson et 
al., 1991). Adapted from Ornitz and Itoh, 2001. Genome Biol. 2001; 2(3): reviews3005.1-12, copyright 
BioMed Central Ltd, 2001 
 
1.4.4 Unconventional secretion of FGF2 
Even though FGF2 lacks a classical signal peptide, it is still released from cells but it does 
not follow the ER/Golgi-dependent export route (Abraham et al., 1986; Mignatti et al., 1992; 
Muesch et al., 1990; Nickel, 2005). This was demonstrated by treatments of cells with the 
drug BFA, which commonly blocks the classical secretory pathway and hence had no effect 
on FGF2 secretion (Florkiewicz et al., 1995b; Mignatti et al., 1992). Furthermore, subcellular 
fractionation experiments primarily localized FGF2 in the cytosolic fractions that were not 
associated with secretory vesicles (Renko et al., 1990). Early studies proposed a mechanism 
by which FGF2 is released from dead or injured cells (McNeil et al., 1989; Schweigerer et al., 
1987). In contrast to these findings, it could be clearly demonstrated that FGF2 is secreted 
from intact cells in a constitutive manner without compromising cell integrity (Engling et al., 
2002; Florkiewicz et al., 1995b). This points towards a specific mechanism of non-classical 
protein release from cells. Different models of secretion mechanisms have been proposed so 
far. This is (i) membrane blebbing and shedding of the vesicles to the extracellular space 
(Schiera et al., 2007; Taverna et al., 2003) (ii) release by multivesicular bodies (iii) and direct 
translocation of FGF2 across the plasma membrane. Release of FGF2 by membrane 
shedding (i) was observed from hepatocarcinoma and fibroblast cells that were subjected to 
serum starvation followed by the onset of FGF2 secretion stimulated by the addition of serum 
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(Taverna et al., 2003). It remains questionable if serum starvation reflects the physiological 
conditions of FGF2 secretion. In contrast, inhibition of the Rho kinase a critical factor, which 
blocks plasma membrane blebs had no influence on the secretion efficiency of FGF2-GFP 
from CHO cells and FGF2-GFP was not found in plasma membrane-bound vesicles 
(Seelenmeyer et al., 2008). Ceccarelli and colleagues observed that the oncogene latent 
membrane protein 1 (LMP1) of Epstein-Barr virus could induce export and release of FGF2 
from cells (Ceccarelli et al., 2007). This study argues for a distinct unconventional pathway of 
secretion mediated through exosomes (ii), which were derived from multivesicular bodies. 
There are controversial findings describing FGF2 secretion. However, secretion routes might 
vary with different cell types and conditions such as transfection with Epstein-Barr virus or 
with different treatments of cells as described for serum starvation. To date, the third model 
(iii) of direct translocation across the plasma membrane is believed to be the most probable 
one. A key finding was that in a cell free system using inside-out vesicles derived from 
plasma membrane FGF2 was able to pass through the membrane into the lumen of these 
vesicles. This translocation occurred in an ATP independent manner and did not require an 
electrochemical gradient (Schäfer et al., 2004a). 
Current findings supporting this mechanism (iii) are summarized in Figure 3. FGF2 is 
synthesized on free ribosomes in the cytoplasm and subsequently recruited to the inner 
leaflet of the plasma membrane by binding to the phosphoinositide PI(4,5)P2. Externalization 
of FGF2 is controlled by the binding of FGF2 to Translokin, which functions as a molecular 
shuttle. Translokin itself can interact with a motor protein, a member of the type II kinesin 
family (KIF3A), which in turn can move along microtubules and can deliver FGF2 to the 
periphery of the cell. Translokin is also believed to facilitate retrograde transport of FGF2 
from the cell surface after internalization to the nucleus (Bossard et al., 2003; Meunier et al., 
2009).  
At least one posttranslational modification of FGF2 is required for FGF2 secretion and occurs 
presumably at the plasma membrane after binding to PI(4,5)P2. It has been shown that this 
interaction to PI(4,5)P2 is crucial for secretion. Mutation of the PI(4,5)P2 binding site at 
residue K128 and R129 impaired both FGF2 binding to PI(4,5)P2 containing liposomes and 
export from cells.  Interestingly, the lipid background also influenced binding of FGF2. It was 
shown that a lipid mixture that resembles plasma membranes, containing cholesterol and 
sphingomyelin, favors PI(4,5)P2  dependent binding of FGF2 (Temmerman et al., 2008). This 
might be due to a local enrichment of PI(4,5)P2 through the formation of cholesterol and 
sphingomyelin dependent microdomains (Pike, 2008; Temmerman et al., 2008). To date, it is 
not entirely clear how FGF2 can traverse the plasma membrane. One possibility could be a 
protein-conducting channel. Well-characterized transporter systems are already known.  
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Figure 3: Molecular secretion mechanism of FGF2. Modified from Nickel, 2010. Current Opinion in 
Biotechnology 2010, 21:621-626 
 
For example the Sec61 protein-conducting channel or the TIM/TOM complex that ensures 
protein import into mitochondria (Neupert and Herrmann, 2007; Rapoport, 1992). However, 
these systems have in common that the cargo protein has to be unfolded during 
translocation. None of these factors or transporters could be identified with the genome-wide 
RNAi screen that was carried out lately to reveal new components involved in FGF2 
secretion (doctoral thesis, Antje Ebert 2009). However, recent data could clearly demonstrate 
that FGF2 is translocated across the plasma membrane in a folded state (Backhaus et al., 
2004; Torrado et al., 2009). Arguing for an intrinsic quality control mechanism to assure that 
only correctly folded and biologically active FGF2 molecules can be secreted (Torrado et al., 
2009).  
A study of Ebert and co-workers identified the Tec kinase in a genome-wide RNAi screen. It 
was demonstrated that Tec kinase phosphorylates FGF2 at tyrosine 82, which is a 
prerequisite for FGF2 secretion (Ebert et al., 2010). Tec kinase is a non-receptor tyrosine 
kinase that is recruited to membranes through binding to phophatidylinsoitol-
3,4,5-triphosphate (PI(3,4,5)P3) with its pleckstrin homology (PH) domain. Complete 
activation of Tec kinase occurs after binding to PI(3,4,5)P3 and phosphorylation by Src family 
kinases followed by subsequent auto-phosphorylation (Schaeffer and Schwartzberg, 2000).  
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Interestingly, a recent study of Steringer and colleagues could demonstrated that binding of 
FGF2 to a plasma membrane like lipid background, containing PI(4,5)P2, induced the 
formation of FGF2 oligomers. In addition, binding of FGF2 to model membranes enriched in 
PI(4,5)P2 allowed for the passage of a small tracer molecules (∼1 kDa) into the vesicles 
(Steringer et al., 2012). This indicates that a stable structure or lipidic pore is formed after 
binding of FGF2 to the lipid bilayer. More precisely, data from a transbilayer diffusion assay 
indicated the formation of a toroidal pore (Steringer et al., 2012). This means that after FGF2 
induced pore formation lipids can freely diffuse between the two leaflets of the lipid bilayer 
(Qian et al., 2008). In addition to these findings it was shown that a phosphomimetic protein 
of FGF2 (tyrosine 82 was replaced by the unnatural amino acid p-carboxyl-
methylphenylalanine) exerted a much higher membrane activity (Steringer et al., 2012; 
Young et al., 2010). A possible mechanism could be that the phosphate stabilizes the 
oligomeric structures, which in turn enhances the process of pore formation. More recent 
results point to the direction that surface localized cysteines of FGF2 have the ability to form 
inter-disulfide bridges, which might provide the building block of such oligomeric structures 
(personal communication, Dr. Hans-Michael Müller). However, the defined molecular 
structure of such a lipidic FGF2 pore remains elusive. 
It is well-established that on the extracellular space membrane proximal HSPGs act as a 
molecular trap to extract FGF2 from the plasma membrane and subsequently, immobilize 
FGF2 molecules on the cell surface since it is not released into the medium (Engling et al., 
2002; Trudel et al., 2000). Neither truncation mutants of FGF2, lacking the HSPG binding 
region, nor HSPG deficient cells were able to secrete FGF2. A rescue of the secretion defect 
in HSPG deficient cells was achieved by co-cultivation with HSPG positive cells. This was 
only observed when co-cultured cells had close contact to HSPG deficient cells. Therefore, 
HSPGs are absolutely essential for the secretion mechanism of FGF2 and their close 
proximity to the plasma membrane is necessary to maintain FGF2 secretion (Nickel, 2007; 
Zehe et al., 2006).  
Many years ago, pharmacological studies implicated the sodium potassium ATPase 
(Na+/K+-ATPase) as a potential factor involved in FGF2 secretion. It was shown that 
inhibition of the Na+/K+-ATPase by ouabain impaired FGF2 release from cells (Dahl et al., 
2000; Florkiewicz et al., 1998). In contrast, an ouabain insensitive mutant was able to 
reverse this phenotype. However, these studies were lacking functional data and furthermore 
a direct interaction between FGF2 and the Na+/K+-ATPase was not clearly demonstrated.  
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1.5 Sodium potassium ATPase (Na+/K+-ATPase) 
The Na+/K+-ATPase is an integral membrane protein found in most of the higher eukaryotes 
and is located in the plasma membrane of cells. It was first described by Skou in 1957 as a 
membrane bound ATPase that facilitates cation transport (Skou, 1957). Since then, many 
studies were carried out to understand its physiological function in cells. Beside its main role 
in transport of sodium and potassium ions across the plasma membrane it was implemented 
in cellular processes such as signal transduction after binding of cardiotonic steroids.   
1.5.1 P-type ATPase family 
The Na+/K+-ATPase belongs to a large family P-type ATPases comprised of more then 
300 members. Among those, the well-characterized sarco(endo)plasmatic Ca2+-ATPase 
(calcium pump) and H+/K+-ATPase (proton pump) are listed (Scarborough, 1999). All of them 
are enzymes that function in ion transport to maintain the electrochemical gradient across 
cellular membranes and undergo auto-phosphorylation during their catalytic cycle. The 
electrochemical gradient is a driving force to control many physiological processes in 
mammalian cells such as absorption and secretion of molecules, signal transduction, nerve 
impulse transmission, excitation and contraction of muscle cells as well as growth and 
differentiation (Scarborough, 1999). Characteristics that are shared among the P-type 
ATPases are their ability to form a transient high-energy aspartyl-phophoanhydride 
intermediate. Phosphorylation of the aspartate takes place at a highly conserved amino acid 
region (DKTGT), which is homologues in almost all P-type pumps (Kaplan, 2002). In general 
P-type ATPases cycle between two different conformational states shown in Figure 4B 
and C, which corresponds to E1 and E2 state, respectively. The alteration between these two 
states is necessary to facilitate binding, occlusion and release of the transported ions. The 
energy of this process is utilized by the hydrolysis of ATP. The P-type ATPases have been 
classified into five different subgroups according to their cationic and lipid substrates. The 
Na+/K+-ATPase is assigned to the subgroup PIIC together with the H+/K+-ATPase (Axelsen 
and Palmgren, 1998; Tang et al., 1996). The catalytically active subunit (termed α-subunit) is 
an integral membrane protein usually comprised of 6-12 α-helices. Among the P-type 
ATPases these α-subunits have very similar domain architecture. They commonly consist of 
the N-domain (nucleotide binding domain), the P-domain (phosphorylation domain), and the 
A-domain (actuator domain), needed for ATP hydrolysis (see Figure 4A; Bublitz et al., 2010). 
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Figure 4: General structure of P-type ATPases. (A) Illustration of the Na+/K+-ATPase with the 
10 transmembrane segments of the α-subunit that carries all the catalytically domains (Domain A, P, 
and N) for ion transport. The α-subunit is closely bound to the glycosylated single pass membrane 
protein β-subunit and the accessory FXYD that is mostly associated with the Na+/K+-ATPase. In (B) 
and (C) the crystal structures of the Ca2+-ATPase in a Ca2+ occluded E1 state and a Ca2+ free E2 state 
are depicted. This represents the common domain architecture of P-type ATPases that also accounts 
for the Na+/K+-ATPase. Adapted from Horisberger 2004. Journal of Physiology 2004;19:377-387.  
 
To carry out their catalytic activity some P-type ATPases have to be assembled in a 
heterodimeric complex. This concerns members of the PIIC and PIV subgroups where the 
α-subunit is assembled with the β-subunit or CDC50 subunit, respectively (Poulsen et al., 
2008; Scheiner-Bobis and Farley, 1994). In contrast, the sarco(endo)plasmatic reticulum 
Ca2+-ATPase (subgroup PIIA) exists as a monomeric ATPase (Olesen et al., 2007).  
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1.5.2 Structural and catalytically aspects of the Na+/K+-ATPase 
As mentioned above, the α-subunit is the catalytic subunit of the enzyme. It consists of 
10 transmembrane α-helices (M1-M10) and has a molecular weight of about 100 kDa. The 
C- as well as the N-terminus are localized to the cytoplasmic side. The main catalytically 
active domains are positioned in two loop regions that face towards the cytoplasmic side. 
This is the A-domain between M2-M3 and the P- and N-domain, which are enclosed by the 
transmembrane domains M4-M5 (see schematic drawing of the Na+/K+-ATPase in Figure 
2A). The α-subunit is tightly associated with the β-subunit in a 1:1 stoichiometry. The 
β-subunit interacts with the α-subunit at the extracellular loop region between M7-M8 (Chow 
and Forte, 1995; Lemas et al., 1994).  
The β-subunit consists of only one transmembrane segment and a rather small N-terminal 
cytoplasmic domain in comparison to its C-terminal extracellular glycosylated portion. 
Furthermore, it has 6 cysteines that form 3 disulfide bonds on its extracellular side. The 
positioning of the cysteines is very conserved in all the β-subunits that belong to the P-type 
ATPase family, arguing that the structural arrangement of this subunit is very important for 
the enzyme function (Beggah et al., 1997; Noguchi et al., 1994). The β-subunit has a 
molecular weight of approximately 34 kDa but due to its glycosylation it appears as a diffuse 
band migrating between 50-70 kDa on a SDS-PAGE. It has been shown that the β-subunit is 
critically important for the maturation of the enzyme because it is required for the correct 
insertion of the transmembrane regions M5-M10 into the ER membrane and the subsequent 
delivery to the plasma membrane (Beggah et al., 1999; Hasler et al., 2001). Furthermore, it 
has also been observed that the association of the β-subunit with the α-subunit stabilizes the 
α-subunit, protects it from intracellular degradation (Chen et al., 1998) and is also involved in 
K+ occlusion of the enzyme (Lutsenko and Kaplan, 1993). It is generally accepted in the field 
and also early studies in Xenopus oocytes could demonstrate that the α-subunit has to be 
assembled with the β-subunit in a heterodimeric complex to form a fully active pump 
(Noguchi et al., 1987). However, the role of glycosylation of the β-subunit seems to be 
unclear. It has been reported that the sites of glycosylation of the β-subunits can vary within 
different species and even in different isoforms of the enzyme (Chow and Forte, 1995) but 
the removal of the glycosylation sites had no influence on the biogenesis and activity of the 
pump (Zamofing et al., 1988).  
Additionally, the Na+/K+-ATPase as a heterodimeric complex is associated with an accessory 
FXYD protein, a small hydrophobic polypeptide with a molecular weight of 8-14 kDa (see 
Figure 4A). This family consists of 7 members and is expressed in a tissue specific manner 
(Sweadner and Rael, 2000). It has been reported, that it can modulate the activity of the 
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Na+/K+-ATPase by increasing the affinity of K+ or Na+ to the ATPase (Crambert et al., 2002). 
This is regulated on the basis of the physiological requirements of the tissue (Geering, 2005).  
To balance sodium and potassium concentrations inside and outside of the cell the 
Na+/K+-ATPase has to transport constantly ions against a steep concentration gradient. This 
is achieved by the active transport of 3 Na+ exported from the cell in exchange of 2 K+ that 
are taken in. During this catalytic cycle the Na+/K+-ATPase undergoes various conformational 
changes that will be described in the following section referring to the illustration depicted in 
Figure 5. 
 
 
Figure 5: Catalytic cycle of the Na+/K+-ATPase. Adapted from Horisberger 2004. Journal of 
Physiology 2004;19:377-387.  
 
In the E1 state the Na+/K+-ATPase has a high affinity for ATP and Na+ (1). Once the ATP and 
Mg2+ are bound to the N-domain 3 Na+ can enter (2). Subsequently, the N-domain undergoes 
a rotation to be in close proximity to the P- and A-domain. Auto-phosphorylation takes place 
at a conserved amino acid sequence (DKTGT) located on the P-domain, which gives rise to 
a phorphrylated aspartate (D376) and the E1P state of the ATPase (3). With this 
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phosphorylation a conformational change is induced in the enzyme that opens the 
extracellular gate (4) to release the Na+ towards the extracellular space (5).  This E2-P state 
has now a high affinity for K+ (6). Two K+ bind (7) and after dephophorylation, (8) the 
extracellular gate can close causing a conformational change leading to the original state of 
the pump. Phosphorylation occurs with the help of the A-domain. The glutamate at the TGES 
motive can position a water molecule for hydrolysis to release the phosphoryl group. ATP 
can bind again and 2 K+ are released to the cytoplasmic side (9-10), giving the possibility to 
initiate a new reaction cycle. 
1.5.3 Isoforms of the Na+/K+-ATPase 
The expression pattern of the α- and β-isoforms is regulated in a tissue-specific manner. In 
humans four isoforms of the α-subunit (α1-α4) have been discovered. The α1-isoform is 
ubiquitously expressed in almost all tissues and is the predominant version found in the 
kidney together with β1-subunit. The α2-isoform is mostly expressed in adipocytes (Lytton, 
1985), in the brain (McGrail et al., 1991), vascular smooth muscles (Zhang et al., 2005) 
skeletal and heart muscles (Hundal et al., 1992; Lavoie et al., 1997; Zahler et al., 1992). The 
α3-isoform is a primary source in neurons (Hieber et al., 1991) whereas the α4-isoform is 
only expressed in the testes (Shamraj and Lingrel, 1994). For the β-subunit, commonly three 
isoforms have been suggested (β1, β2, and β3) (Blanco and Mercer, 1998; Morth et al., 
2011). However, there is evidence for a fourth (β4) isoform in humans but its existence is not 
clearly linked to be a part of the Na+/K+-ATPase (Okamura et al., 2003; Pestov et al., 1999). 
The β-isoforms are reflecting a similar distribution as the α-subunits. Also here the 
β1-isoform is found in almost all tissues, β2 is mainly expressed in neurons and skeletal 
muscle (Lavoie et al., 1997; Peng et al., 1997). The β3-isoform is present in a variety of 
tissues like kidney, lung, stomach, colon, spleen, and liver (Malik et al., 1996). Different 
Isoform combinations have been discovered in mammalian tissue and a study in insect cells 
could demonstrate that various combinations of the α- and β-isoforms can still form a 
functional enzyme (Blanco et al., 1995a, 1995b). This indicates that there is a wealth of 
possibilities for the regulation of the Na+/K+-ATPase that is certainly not completely 
understood so far.  
1.5.4 Physiological role of the Na+/K+-ATPase 
By regulating the Na+ and K+ balance in the cell and the extracellular milieu the 
Na+/K+-ATPase is essential to guarantee the cellular homeostasis. This involves regulation of 
osmosis (Sáez et al., 2009), maintenance of the electrochemical gradient and resetting of the 
membrane potential after neuronal excitation (Brodie et al., 1987) as well as skeletal muscle 
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contractility (Clausen, 2003). In addition to these functions it plays a crucial role in the renal 
tubular epithelial cells to maintain the sodium gradient for continuous reabsorption of 
Na+ from the glomerular filtrate (Bagrov et al., 2009). Furthermore, the energy stored in the 
Na+ gradient drives a secondary transport system to move molecules across the plasma 
membrane leading to the uptake of nutrition such as amino acids and glucose into cells 
(Blanco and Mercer, 1998).  
The Na+/K+-ATPase and more precisely the extracellular side of the α-subunit serves as a 
specific target for cardiotonic steroids. Binding of cardiotonic steroids to the α-subunits 
results in an inhibition of the Na+/K+-ATPase (Palasis et al., 1996). Extracts from plants or 
dried skin of toads, enriched in cardiotonic steroids, were already known for a long time in 
traditional medicine and used for the treatment of heart dysfunctions. In 1875 the first pure 
cardiotonic steroids called “digitoxin” was isolated from the foxglove plant (Digitalis purpurea) 
and was pharmacologically used for the treatment of congestive heart failure (Diefenbach 
and Meneely, 1949). Later on, it was replaced by a slightly modified cardiotonic steroid 
“digoxin” from Digitalis lanata (Gheorghiade et al., 2006). Binding of digoxin to the 
Na+/K+-ATPase exerts a positive ionotrophic effect. Partial inhibition of the Na+/K+-ATPase in 
the heart increases the intracellular Na+ concentration and couples the increase of 
intracellular Ca2+ concentration by the activation of the Na+/Ca2+-exchanger. In turn 
Ca2+ influx affects the strength of the myocardial contractility to overcome congestive heart 
failure (Langer, 1977). However, nowadays there are more effective drugs on the market for 
the treatment of this disease (Belz et al., 2001). It is important to note that cardiotonic 
steroids have shown to differ in their binding affinities to various α-subunit isoforms and 
between mammalian interspecies (Abeywardena et al., 1984; Crambert et al., 2000).  
In vertebrates also endogenous cardiotonic steroids are produced such as ouabain, which is 
one of the best-studied inhibitor of the Na+/K+-ATPase (Hamlyn et al., 1991). Noteworthy, 
under physiological conditions ouabain levels are very low. In addition, it has been shown 
that these concentrations cannot cause a perturbation of the overall ion concentration in 
cells. In contrast, binding of ouabain initiates a signaling cascade. Studies of Liu and 
colleagues could show that there is a subpopulation of the Na+/K+-ATPase, which resides in 
caveolae (Liu et al., 2005). In these regions the Na+/K+-ATPase is found to be closely 
associated with the non-receptor tyrosine kinase Src, a known protein acting in cell signaling 
(Liang et al., 2006). Binding of ouabain leads to a conformational change in the α-subunit 
and activates the Src kinase. This results in further transactivation of epidermal growth factor 
receptor (EGFR) that relays its signal to the mitogen-activated protein (MAP) kinase 
signaling pathway (Haas et al., 2002). It was indeed observed that binding of ouabain to the 
Na+/K+-ATPase could influence multiple cellular functions. It can alter gene expression that 
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leads to the formation of tight junctions, proliferation, differentiation, and migration in 
epithelial cells (Contreras et al., 2006).  
1.6 Aim of this thesis 
The current working hypothesis is that FGF2 directly translocates across the plasma 
membrane in a folded state. This process is highly dependent on PI(4,5)P2 for recruitment of 
FGF2 to the inner plasma membrane leaflet followed by the induction of FGF2 oligomers. 
This leads to the subsequent formation of a toroidal lipidic pore through which FGF2 can 
traverse the plasma membrane. On the extracellular side membrane proximal HSPGs drive 
directional export of FGF2 and immobilize FGF2 molecules on the cell surface (Nickel, 2010; 
Steringer et al., 2012). Recently, Tec kinase was discovered in a genome-wide siRNA 
screen. It was shown that post-translational modifications of FGF2 such as phosphorylation 
of the tyrosine residue 82 mediated by the Tec kinase is crucial for FGF2 secretion (Ebert et 
al., 2010). Based on the genome-wide RNAi screen, this thesis aimed at the identification of 
further proteinaceous factors involved in FGF2 secretion.  
One candidate, which was discovered during the RNAi screen, was the α1-subunit of the 
Na+/K+-ATPase acting as a potential positive regulator of FGF2 secretion. In addition to 
these findings, the Na+/K+-ATPase was already mentioned years ago being involved in FGF2 
export from cells. However, these studies were solely based on pharmacological evidence 
and, ever since, have not been validated by independent methods (Dahl et al., 2000; 
Florkiewicz et al., 1998). The main goal of this study was to characterize the role of the 
Na+/K+-ATPase in regard to FGF2 secretion on a molecular level. For this purpose, the first 
step was to validate the initial screening hit with several independent siRNAs in a cell-based 
(fluorescence-activated cell sorting) FACS assay to monitor FGF2 secretion after 
knockdown. The FACS assay was also applied to control pleiotropic effects that could 
compromise cellular functions as a result of siRNA-mediated knockdown of the 
Na+/K+-ATPase.  
In the second part, interaction studies of the α1-subunit and FGF2 were carried out. This 
involved an in vivo approach using a conventional immunofluorescence assay as well as a 
Duolink assay to assess their compartments of interaction in HeLa cells. Furthermore, in vitro 
experiments were applied to identify in more detail their region of interaction. For this reason 
the cytoplasmic domains of the α1-subunit of the Na+/K+-ATPase were expressed and 
purified to test for their ability to bind to FGF2 in pull-down assays. In addition, binding 
constants of this interaction were determined. In order to characterize the interaction 
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interface more closely deuterium exchange experiments as well as mutational analysis were 
conducted.  
The last part of this study aimed at the identification of small molecules that could interfere 
with the interaction of FGF2 and the cytoplasmic region of the α1-subunit of the 
Na+/K+-ATPase. This offers a huge potential to regulate this interaction and will allow for 
more detailed studies to investigate the molecular mechanism of FGF2 secretion. 
Furthermore, the identification of small inhibitory molecules may lead to the development of 
anti-angiogenic drugs. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and consumables 
1 kb DNA ladder New England Biolabs 
100 bp DNA ladder New England Biolabs 
35 mm optical dish (∅ 1 cm gals bottom) MatTek corportation 
35 mm optical dish (∅ 2 cm gals bottom) Ibidi GmbH 
Acetic acid Sigma-Adrich 
Acetone  Merck 
Acetonitrile Sigma 
ACQUITY UPLC C18 BEHcolumn Waters Corporation 
Agarose Life Technologies 
AlphaScreen® Glutathione Donor Beads PerkinElmer 
AlphaScreen® Histidine (Nickel Chelate Acceptor 
Beads) Detection Kit 
PerkinElmer 
Amicon Ultra-4 Centrifugal Filter (3K, 30K) Millipore 
Ammonium hydroxide J.T.Baker 
Ampicillin sodium salt Gebru 
Bacto Agar BD (Becton Dickinson) 
Bacto Tryptone BD (Becton Dickinson)  
Benzamidine hydrochloride  Applichem 
Bovine serum albumin (BSA) Roth 
Bromphenol blue Serva 
Cell culture plates (10cm) Corning Incorporated 
Cell Dissociation Buffer Enzyme-Free PBS-based Gibco (Life Technologies) 
Chloramphenicol Roth 
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Chloroquine Sigma-Adrich 
Collagen R Serva Electrophoresis GmbH 
Cryotrubes Cryo S Greiner bio-one 
Cuvette 10 x 4 x 45 mm  Sarstedt 
Deionized water, TKA X-CAD TKA  
Deoxycholic acid sodium salt Fulka 
Diethylaminoethyldextran (DEAE-Dextran) Sigma-Aldrich 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
dNTP-Mix (10 mM each) PeQLab 
Doxycycline Clontech 
DTT (1,4-Dithio-D,L-threitol) Gebru 
Dulbecco's Modified Eagle Medium (DMEM)          
low glucose 
Biowest 
Ethanol absolute VWR 
Ethidium bromide (EtBr) Roth 
Ethylenediaminetetraacetic acid (EDTA) AppliChem 
Fetal Calf Serum (FCS) Biochrom AG  
Formic acid Merck 
FuGene® HD Promega 
Glycerol 99 %  VWR 
Glycine AppliChem 
GSH column (GSTrapTM FF, 5ml) GE Healthcare 
Guanidine hydrochloride Sigma 
Heparin column (HiTrapTM Heparin HP, 5 ml) GE Healthcare 
Heparin sodium salt from porcine intestinal mucosal Sigma 
His column (HisTrapTM FF crude, 5 ml) GE Healthcare 
InstantBlue, protein stain Expedeon 
isopropyl β-D-1-thiogalactopyranoside (IPTG) Gebru 
Kanamycin sulfate Gebru 
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L-Glutathione reduced Sigma 
Magnesium chloride (MgCl2) AppliChem 
Methanol Sigma 
MicroAmp Optical 96 well plate (0.1 ml) Applied Biosystems 
MOPS running buffer Life Technologies 
Multiwell culture plates (6-, 12-, 24, 96-well) Greiner bio-one 
Nonidet P40 (NP-40) Roche 
Nuclease-free water Ambion 
NuPAGE 4-10 % Bis-Tris Gel Life Technologies 
NuPAGE Antioxidant Life Technologies 
Oligofectamine Transfection Reagent Life Technologies 
Opti-MEM Life Technologies 
PageRuler prestained, protein ladder  Fermentas 
PBS Biochrom AG 
PCR tubes (strip 8 x 0.2 ml) G. Kisker GbR 
PD-10 columns GE Healthcare 
Penicillin/Streptomycin Biochrom AG  
Petri dish 94 x 16 mm, sterile Greiner bio-one 
Pipette tip, Gilson, 200 µl and 1000 µl Greiner bio-one 
PMSF (phenylmethylsolfonyl fluorid) Roche 
Porozyme pepsin cartridge Applied Biosystems 
Potassium chloride (KCl) AppliChem 
Potassium dihydrogen phosphate (KH2PO4) AppliChem 
Primer and Oligonucleotides Thermo Scientific 
Protease Inhibitor tablets (complete, EDTA free) Roche 
ProxiPlate™-384 Plus, white 384-shallow well 
micorplate 
PerkinElmer 
qPCR Seal (Optical foil)  PeQLab 
Reaction tube 1.5 ml Sarstedt 
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Reaction tube 2 ml Greiner bio-one 
Reaction tube, sterile, 15 ml and 50 ml Greiner bio-one 
Silencer Select siRNA Life Technologies 
Sodium azide (NaN3) Roth 
Sodium chloride (NaCl) AppliChem 
Sodium dodecyl sufate (SDS) BioRad  
Sodium hydrogen phosphate (Na2HPO4) AppliChem 
SuperdexTM 200 pg, HiloadTM 16/600 GE Healthcare 
Syringe filter (45 µm)  Sartorius 
SYTOX green Life Technologies 
TaqMan Gene Expression Master Mix Applied Biosystems 
Tris base Roth 
Trypsin/EDTA Biochrom AG 
Tween 20 Roth 
Wester blot transfer membrane, Immobilon-FL Millipore 
Whatman 3 MM paper  Whatman 
Xylene cyanol FF Serva 
Yeast extract Roth 
β-Mercaptoethanol Merck 
 
2.1.2 Technical devices 
Äkta purifier GE Healthcare 
Blotting chamber, MiniPreotean Trans Blot BioRad 
Centrifuge 5417R Eppendorf 
Chamber for agarose gels BioRad 
Confocal Microscope LSM 510 Zeiss 
Direct Detect Spectrometer Merck Millipore 
FACSAria cell sorter BD (Becton Dickinson) 
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FACSCalibur BD (Becton Dickinson) 
Gel-Doc 2000 System BioRad 
High-pressure homogenizer Avestin 
Incubator for bacteria plates Heraeus 
Incubator for eukaryotic cells  Heraeus 
Laminar flow hood, Herasafe KS12 Thermo Scientific 
Magnetic stirrer MR 3000 Heidolph 
nanoACQUITY UPLC HDX ManagerTM Waters Corporation 
ND-1000 Spectrophotometer NanoDrop Technologies 
Odysee imaging system LI-COR 
Power supply to run gels; Power Pac 200 BioRad  
Rosys Anthos 2001 plate reader Anthos labtech 
StepOne Plus Real-Time PCR System Applied Biosystems 
Thermo cycler, Primus 96 advanced PeQLab 
Thermomixer comfort  Eppendorf 
Ultracentrifuge Optima L-90K  Beckman Coulter 
Waters XEVO G2 TOF with ESI source Waters Corporation 
XCell SureLock (chambers for SDS-PAGE) Invitrogen (Life Technologies) 
EnVision 2101 Multilabel Plate Reader PerkinElmer 
2.1.3 Kits and assays 
BCA protein assay Pierce 
DNA Ligation Kit Takara 
Duolink Kit Olink Bioscience 
DuolinkII Detection Reagent Red (92008-0030) Olink Bioscience  
ImProm-II Reverse Trascription System Promega 
MBS Mammalian Transfection Kit Stratagene  
NucleoSpin Plasmid Kit Macherey-Nagel 
pGEM-T Vector System I Kit Promega 
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Plasmid Midi Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
RNeasy Mini Kit Qiagen 
Zero BluntII TOPO PCR Cloning Kit  Life Technologies 
2.1.4 Enzymes 
High-Fidelity DNA Polymerase, Precisor BioCat 
Phosphatase, alkaline (AP) Roche 
Restriction endonucleases New England Biolabs  
Thrombin 500 units GE Healthcare 
2.1.5 Antibodies 
 
Primary Antibodies  
anti-ATP1A1 (α1-subunit) mouse monoclonal Abcam (ab7671) 
anti-ATP1B1 (β1-subunit) mouse monoclonal Thermo Scientific (MA3-930) 
anti-Cadherin mouse monoclonal Abcam (ab6528) 
anti-FGF2 rabbit polyclonal RG Nickel 
anti-FLAG mouse monoclonal Sigma (F1804) 
anti-GAPDH mouse monoclonal Life Technologies (AM4300) 
anti-GFP rabbit polyclonal  RG Nickel 
anti-GM130 mouse monoclonal RG Wieland 
anti-HA mouse monoclonal RG Wieland 
anti-transferrin receptor; mouse monoclonal Life Technologies (13-6800) 
anti-COPB1 (βCOP) B1.2 rabbit polyclonal RG Wieland 
anti-tubulin (alpha) rabbit polyclonal Abcam (ab18251) 
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Secondary Antibodies  
Alexa Flour 488 goat anti-rabbit Life Technologies (A11034) 
Alexa Fluor 546 goat anti-mouse  Life Technologies (A11030) 
Alexa Flour 633 goat anti-rabbit Life Technologies (A21071) 
Alexa Fluor 680 goat anti-rabbit  Life Technologies (A21076) 
Allophycocyanin (APC) goat anti-rabbit Life Technologies (A10931) 
IRDye 800 CW goat anti-mouse Odyssey (926-32210) 
DuolinkII PLA MINUS anti-mouse  Olink Bioscience (92004-0030) 
DuolinkII PLA PLUS anti-rabbit Olink Bioscince (92002-0030) 
 
 
2.1.6 Plasmids 
Plasmid Application Resistance Origin 
pRevTre2 
SP-GFP-CD4 
Mammalian vector stable 
expression 
Ampicillin Thesis 
pUC57 
CD1-3 
Bacterial vector amplification Ampicillin Eurofins /synthetic 
gene 
pGEM-T Bacterial vector amplification Ampicillin Promega 
pCR-BluntII-TOPO Bacterial vector amplification Kanamycin Life Technologies 
pGex2mod Bacterial vector recombinant 
expression 
Ampicillin Thesis 
pGex2mod Bacterial vector recombinant 
expression 
Ampicillin Hans-Michel Müller 
pGex2mod 
GST-CD1 
Bacterial vector recombinant 
expression 
Ampicillin Hans-Michel Müller 
pGex2mod 
GST-CD2 
Bacterial vector recombinant 
expression 
Ampicillin Hans-Michel Müller 
pGex2mod 
GST-CD3 
Bacterial vector recombinant 
expression 
Ampicillin Hans-Michel Müller 
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2.1.7 Oligonucleotides and primer sequences 
Primer Sequence (5’-3’) Origin 
S-21 eGFP_SalI HindIII GCgtcgacGGCaagcttGTGAGCAAGGGCGAGGAGCTG Thesis 
AS-22 eGFP_NotI BamHI CGgcggccgcCggatccCTTGTACAGCTCGTCCATGCCG Thesis 
S-23 CD4_BamHI GCggatccGACGTCATCAAGGTTCTGCCCA Thesis 
AS-24 CD4_NotI GCgcggccgcTCAGTTTGTTGCTGCGAATGTCTCC Thesis 
S-50 alpha1 hATP1A1 GCTGGATCAACGATGTGGAAG Thesis 
AS-51 alpha1 hATP1A1 CACCAGGTAGGTTTGAGGGG Thesis 
S-52 alpha2 hATP1A2 CCATCCCACTCCACTATGTTG Thesis 
AS-53 alpha2 hATP1A2 CCAGTCTCAGGCTCTTGCAC Thesis 
S-54 alpha3 hATP1A3 GCCCGGCAACCTGGTGGGCATCC Thesis 
pGex2mod 
GST-CD2-3 
Bacterial vector recombinant 
expression 
Ampicillin Hans-Michel Müller 
pGex2mod 
GST-CD1-3 
Bacterial vector recombinant 
expression 
Ampicillin Hans-Michel Müller 
pQE30 
hisFGF2-wt 
Bacterial vector recombinant 
expression 
Ampicillin Hans-Michel Müller 
pGex2T 
GST-FGF2  
Bacterial vector recombinant 
expression 
Ampicillin Claudia 
Seelenmeyer 
pGex2T 
GST-Δ28 FGF2 
Bacterial vector recombinant 
expression 
Ampicillin Thesis 
pQE30 
hisFGF2 K27E/D28K 
Bacterial vector recombinant 
expression 
Ampicillin Thesis 
pQE30 
hisFGF2 D99R 
Bacterial vector recombinant 
expression 
Ampicillin Thesis 
pQE30 
hisFGF2 K138E 
Bacterial vector recombinant 
expression 
Ampicillin Thesis 
pQE30 
hisFGF2 T121R 
Bacterial vector recombinant 
expression 
Ampicillin Thesis 
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AS-55 alpha3 hATP1A3 GGACAGGAAGGCAGCCAGGGCCG Thesis 
S-56 alpha4 hATP1A4 CAGTGGACCTATGAGCAACG Thesis 
AS-57 alpha4 hATP1A4 TGACGGATGAGGAGTTTTCTG Thesis 
S-68 beta1 hATP1B1  CCGTTTTCAGGGACGTTTTG Thesis 
AS-69 beta1 hATP1B1 CAGTAAAAATGGGCACGTCC Thesis 
S-70 beta2 hATP1B2 CGTGAGCCACCGCGCCCGGC Thesis 
AS-71 beta2 hATP1B2 GGTGGGGGCAGATCTGGGCTCAGGGG Thesis 
S-72 beta3 hATP1B3 AGTTATGTTCAAAATCACAGCACG Thesis 
AS-83 beta3 hATP1B3 CCTACATGTTTGGAATCAGGTG Thesis 
S-84 beta4 hATP1B4 TGTATTTTTGGCGGAGACAG Thesis 
AS-85 beta4 hATP1B4 CAGTCTTGATCAACAATGTCACC Thesis 
S-147 Δ28 FGF2_BglII GGGagatctCCCAAGCGGCTGTACTGCAAAAACG Thesis 
AS-134 FGF2_XhoI CTTCCAATGTCTGCTAAGAGCTAGctcgagCCGG Thesis 
AS-151 FGF2_EcoRI CCCgaattcTCAGCTCTTAGCAGACATTGGAAGAAAAAG Thesis 
S-156 FGF2 K27E/D28K CGCCCGGCCACTTCGAGAAGCCCAAGCGGCTGTA Thesis 
AS-157 FGF2 K27E/D28K TACAGCCGCTTGGGCTTCTCGAAGTGGCCGGGCG Thesis 
S-158 FGF2 D99R ATTACTGGCTTCTAAATGTGTTACGCGTGAGTGTTTCTTTTTTGAACGATTG Thesis 
AS-159 FGF2 D99R CAATCGTTCAAAAAAGAAACACTCACGCGTAACACATTTAGAAGCCAGTAAT Thesis 
S-160 FGF2 T121R ACAATACTTACCGGTCAAGGAAATACAGGAGTTGGTATGTGGC Thesis 
AS-161 FGF2 T121R GCCACATACCAACTCCTGTATTTCCTTGACCGGTAAGTATTGT Thesis 
S-162 K138E GCAGTATAAACTTGGATCCGAGACAGGACCTGGGCAGAAAG Thesis 
AS-163 K138E  CTTTCTGCCCAGGTCCTGTCTCGGATCCAAGTTTATACTGC Thesis 
 
Oligonucleotides Sequence (5’-3’) Origin 
S-109 Flag_AgeI PacI 
 
ccggtGATTACAAGGATGACGACGATAAGTGAttaat 
 
Thesis 
AS-110 Flag_AgeI PacI taaTAATCACTTATCGTCGTCATCCTTGTAATCa 
 
Thesis 
S-109 Yes_HindIII SalI aagcttGCCACCATGGGCTGCATTAAAAGTAAAGAAAACAA
AAGTCCAGCCATTAAATACAGACCTaagctt 
 
Thesis 
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AS-110 Yes_HindIII SalI agcttAGGTCTGTATTTAATGGCTGGACTTTTGTTTTCTTT
ACTTTTAATGCAGCCCATGGTGGCa 
 
Thesis 
S-122  Tom_AgeI PacI ccggtATGGTGGGTCGGAACAGCGCCATCGCCGCCGGTGTA
TGCGGGGCCCTTTTCATTGGGTACTGCATCTACTTCGACCG
CAAAAGACGAttaat 
 
Thesis 
AS-123 Tom_AgeI PacI taaTCGTCTTTTGCGGTCGAAGTAGATGCAGTACCCAATGA
AAAGGGCCCCGCATACACCGGCGGCGATGGCGCTGTTCCGA
CCCACCATa 
 
Thesis 
2.1.8 Small interfering RNAs (siRNAs) 
Gene Product Gene 
ID 
siRNA ID Sense sequence (5’-3’) Company 
Human Na/K-ATPase α1-chain 
ATP1A1 476 s1718 
CUCGCUCACUGGUGAAUCAtt Ambion 
Human Na/K-ATPase α1-chain 
ATP1A1 476 s1719 
GAUUCGAAAUGGUGAGAAAtt 
 Ambion 
Human Na/K-ATPase α1-chain 
ATP1A1 476 s1720 
CAUCCAAGCUGCUACAGAAtt 
 Ambion 
Human Na/K-ATPase β1-chain 
ATP1B1 2597 s1734 
 
GAAAGAACGAGGAGACUUUtt 
 
Ambion 
Human Na/K-ATPase β3-chain 
ATP1B3 481 s1741 
 
GGAUGAUCGUGACAAGUUUtt 
 
Ambion 
Human coatomer complex,   
subunit β1 
COPB1 
1315 s3371 
 
GGUCUGUCAUGCUAAUCCAtt 
 
Ambion 
Human glyceraldehyde-3-
phosphate dehydrogenase 
GAPDH 
483 s5574 
 
CUCAUUUCCUGGUAUGACAtt 
 
Ambion 
Human fibroblast growth factor 2 
FGF2  
2247 
Custom 
designed 
GGAGUGUGUGCUAACCGUUtt Ambion 
Green fluorescence protein 
GFP 
 
Custom  
designed 
CAAGCUGACCCUGAAGUUCtt Ambion 
All siRNAs were ordered as a validated version with a silencer select modification from 
Ambion/ Applied Biosystem (belongs to Life Technologies) 
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2.1.9 TaqMan gene expression assays 
TaqMan primer and probes Gene ID Company 
Hs 00167556_m1 Human ATP1A1 ID: 476 Applied Biosystems 
Hs 00426868_g1 Human ATP1B1 ID: 2597 Applied Biosystems 
Hs 0074857_mH Human ATP1B3 ID: 481 Applied Biosystems 
Hs 0074857_mH Human GAPDH ID:  483 Applied Biosystems 
2.1.10 Bacteria and media 
Bacteria and media used for molecular cloning and plasmid amplification: 
Eschericia coli (E. coli) DH5α (Life Technologies) 
LB-Medium:  10 g  NaCl 
   10 g  Tryptone  
   5 g  Yeast extract 
   ad 1 l deionized water 
For LB agar plates 1 l of LB-Medium was supplemented with 16 g of Agar and the solution 
was boiled until the Agar was dissolved. Antibiotics for bacterial selection were added at 
60°C followed by casting the plates.   
Bacteria and media used for protein expression: 
E. coli BL21-(DE3)-RIL codon plus (Agilent Technologies) expression of proteins from 
pGex2T and pGex2mod vector E. coli W3110Z1 provided from Bukau (derivate of W3110, 
Hoffmann-La Roche AG) expression of proteins from pQE30 and pQE60 vector. 
2YT-Medium:  5 g  NaCl 
   16 g  Tryptone  
   10 g  Yeast extract 
   ad 1 l deionized water 
 
To select for bacteria resistance the corresponding antibiotics were used:  
Ampicillin  final concentration of 100 µg/ml 
Kanamycin  final concentration of 25 µg/ml 
Chloramphenicol final concentration of 36 µg/ml 
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2.1.11 Mammalian cell lines 
Cell line Expression of doxycycline induced proteins Origin 
HeLaMT - RG Schwappach 
HeLaGFP-CD4 GFP-CD4 Thesis 
HeLa S3MT - RG Nickel 
HeLa S3FGF2_IRES_GFP  FGF2 and GFP  Sabine Wegehingel 
2.2 Molecular biological methods 
2.2.1 Polymerase chain reaction (PCR) 
The polymerase chain reaction (Mullis and Faloona, 1987; Saiki et al., 1988) is a 
well-established method that allows for the amplification of specific DNA fragments.  
PCR reaction:  1 µl template DNA (10-50 ng) 
   1 µl dNTPs (10 mM each) 
   1 µl  Sense Primer (100 pmol) 
   1 µl  Antisense Primer (100 pmol) 
   10 µl 5x High fidelity buffer 
   0.5 µl High-Fidelity Polymerase (1 Unit, BioCat) 
   35.5 µl deionized water 
 
 
Cycle Steps Temperature Time Cycle(s) 
Initial denaturation 98°C 2 min 1 
Denaturation 98°C 30 s  
Annealing X = 2-5°C below the 
melting temperature (Tm) 
of the lower primer 
 
30 s 
 
30 
Extension 72°C 30 s/kb  
Final extension 72°C 10 min 1 
Cooling 8°C 10 min 1 
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The annealing temperature (X) was calculated according to the following formula, where N 
represents the number of base pairs of a primer:  
Tm  =  81.5+0.41 %  GC - 675
N
 
2.2.1.1 Site-directed mutagenesis  
This method was used to introduce site-specific mutations for amino acid changes. As a 
template the pQE30 hisFGF2-wt was used and the PCR reaction was set up as described 
above. Primes were designed with the help of QuikChange Primer Design program from 
Agilent Technologies. And the PCR program was set as follows: 
 
Cycle Steps Temperature Time Cycle(s) 
Initial denaturation 94°C 4 min 1 
Denaturation 94°C 45 s  
Annealing 60°C 30 s 18 
Extension 72°C 6 min  
Final extension 72°C 10 min 1 
Cooling 8°C 10 min 1 
 
17 µl of the PCR reaction were used to perform a DpnI digestion (section 2.2.2.1) to remove 
residual template DNA. This reaction was in total transformed (section 2.2.2.7) into DH5α E. 
coli cells. As a control 17 µl of undigested PCR reaction was transformed. Mutagenesis was 
verified by DNA sequencing (section 2.2.2.10).  
2.2.2 Cloning procedure 
The general procedure usually starts with the amplification of a specific gene product by 
PCR. The PCR fragment is then ligated into a replication vector and transformed into DH5α 
E. coli cells. After selection of antibiotic resistant colonies on LB agar plates the plasmids 
were isolated and a control digestion verified the insert. At this step, further modification can 
be conducted, for example the insertion of sequences by oligonucleotides.  The construct 
can be cut out of the replication vector and inserted into the final vector. After an additional 
transformation, selection and control digestion are performed and the plasmid DNA is 
sequenced for verification. 
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2.2.2.1 DNA Digestion  
Endonucleases are used to cut double stranded DNA fragments of interest. Endonucleases 
are enzymes that recognize a specific DNA sequence for digestion generating either sticky or 
blunt-ended DNA. The DNA fragment of interest and the vector have to be treated with the 
same enzymes for directional cloning. All digestions were performed with enzymes from New 
England Biolabs according to manufacture’s instructions to ensure the right buffer conditions 
for optimal enzyme activity. Per 2 µg DNA, 2-4 units of each enzyme were used. The 
digestion reaction was incubated for 1-2 h at 37°C. Digested vectors were treated with an 
alkaline phosphatase (Roche). The digestion reaction was treated with 1 µl of the enzyme 
and appropriate amounts of buffer and further incubated for 30 min at 37°C. With this 
treatment, the 5’ phosphate of the DNA will be removed to prevent re-ligation of the vector. 
2.2.2.2 Hybridization of oligonucleotides 
This procedure was performed to ligate small double stranded DNA fragments with a size of 
≤150 bp into a predigested and phosphate-removed vector. Complementary single stranded 
oligonucleotides with a 5’ phosphate were hybridized. A dilution of 1:1000 of each 
oligonucleotide stock (100 pmol/µl) of sense and antisense sequence was prepared in water. 
An amount of 10 µl of each dilution was mixed with 1 µl of 25 mM MgCl2  and added to the 
reaction. The mixtures were incubated for 2 min at 95°C in a thermomixer.  The reaction was 
slowly cooled down to room temperature (RT). Only 1 µl of double stranded oligonucleotides 
was used for a typical ligation reaction (section 2.2.2.6). 
2.2.2.3 Agarose gel electrophoresis 
Electrophoresis is used for separation of DNA bands of different sizes. The negatively 
charged nucleic acid molecules can move in an electric field. The molecules are loaded onto 
an agarose matrix with a defined pore size. Due to the size and conformation of the DNA, 
smaller molecules can migrate faster than larger molecules, thus leading to a separation of 
DNA fragments. For the preparation of 1% agarose gel, 1 g of agarose was heated up in a 
microwave with 100 ml of 1x TAE buffer until it was solved completely. After cooling, EtBr 
was added at a final concentration of 0.5 µg/ml and the agarose solution was poured into a 
tray. The agarose was cooled with a comb until it was solid. Finally, the comb was removed 
and the DNA samples with 1x sample buffer could be loaded into the wells. The agarose gel 
containing samples was covered with 1 x TAE buffer and electrodes were placed at each end 
of the chamber (120 V, 20-30 min). EtBr can intercalate between the base pairs of the DNA, 
making the bands on the gel visible while illuminating the gel with UV light (Gel-Doc 2000 
System, BioRad). To estimate the size of the DNA fragment a marker was loaded on the gel. 
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50x TAE buffer:   242 g  Tris 
    57.1 ml Acetic acid 
    100 ml EDTA (0.5 M; pH 8) 
    ad 1 l  deionized water 
 
5x sample buffer:  0.25% (w/v) Bromphenol blue 
    0.25% (w/v) Xylene cyanol FF 
    30%   Glycerol, in deionized water 
2.2.2.4 Gel extraction 
Gel extraction is used to recover and purify DNA fragments from an agarose gel. In this way 
a DNA band with a certain size can be cut out from the gel, with ultraviolet (UV) light used for 
visualization. The obtained gel slice was treated according to manufacturer’s instructions of 
the QIAquick Gel Extraction kit (Qiagen). The DNA was eluted with 30 µl of elution buffer. 
The isolated DNA can be used in a ligation reaction. 
2.2.2.5 PCR purification 
PCR fragments were purified prior to the ligation reaction with the QIAquick PCR Purification 
kit (Qiagen) according to manufacturer’s instruction. 
2.2.2.6 Ligation reaction 
This method is employed to insert a desired DNA fragment into a vector. Therefore, the DNA 
fragment and vector have to be treated with the same restriction enzymes. Once the 
fragment is inserted into the vector a ligase catalyzes the formation of a covalent 
phosphodiester bond to join the two DNA strands together. To calculate the appropriate 
molar ratios of insert and vector, the following equation was used:  
amount of vector ng  × size of insert (bp)
size of vector (b)
  =  insert ng    (molar ratio 1:1) 
For each ligation reaction different molar ratios of vector:insert were chosen (1:1, 1:3 and 
1:6). Vector alone served as a control to estimate the background of the reaction. In general, 
50 ng of vector were used for the reaction.  
Ligation reaction performed with the DNA Ligation kit (Takara): 
Desired molar ratios of vector and insert were mixed to a total volume of 5-10 µl. The same 
volume of solution I was added and the reaction was incubated in a thermomixer for 1 h at 
16°C. Transformation (section 2.2.2.7) was performed by combining the whole reaction with 
80 µl of competent E. coli cells. 
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Ligation of PCR products  
The High-Fidelity polymerase was used for amplification with a 5’-3’ proofreading 
exonuclease activity. Here, the blunt ended PCR products were ligated into 
pCR-BluntII-TOPO vector. The instructions from the manual Zero BluntII TOPO PCR Cloning 
Kit (Life Technologies) were followed. Alternatively, the PCR product can directly be cut with 
appropriate restriction enzymes and ligated into the final vector (section 2.2.2.6).  
2.2.2.7 Transformation into E. coli 
Calcium-competent cells were thawed on ice and 80 µl of cells were combined with the 
ligation reaction and gently mixed followed by an incubation time of 3 min on ice. In order for 
the cells to take up the DNA a heat shock was performed. The cells were placed in a water 
bath for 40 s at 42°C and again cooled down for 1 min on ice. With addition of 750 µl 
LB-Medium the cells were kept for 1 h at 37°C with gentle agitation at 450 rounds per minute 
(rpm) in a thermomixer. Finally, the cells were pelleted at 2500 relative centrifugal force (rcf) 
for 2 min and the pellet was gently resuspended in 70 µl medium and plated on an antibiotic 
selective agar.  
2.2.2.8 Preparation of Plasmid DNA 
To recover plasmid DNA from transformed E. coli cells, single colonies from an agar plate 
were picked and grown over night (o/n) in liquid LB-Media at 37°C with the addition of 
antibiotics. Extraction can be performed using different volumes of bacteria o/n culture 
according to the amount and purity of plasmid DNA that needs to be obtained. Plasmid 
purification kits were used according to manufacture’s instructions.  
Miniprep: NucleoSpin Plasmid (Macherey-Nagel); 6 ml of o/n culture 
Midiprep: Plasmid Midi Kit (Quiagen); 100 ml of o/n culture 
2.2.2.9 Determination of nucleic acid concentration 
The DNA concentration can be measured photospectrometrically using a NanoDrop 
ND-1000 spectrophotometer. Absorbance is measured at an absorbance maximum of 
260 nm for nucleic acids and the concentration calculated following the Lambert-Beer 
equation: c= A 
E×b
 
c = nucleic acid concentration [ng µl-1]  E = 50 for double stranded DNA 
b = path length [cm]     E = 50 for double stranded DNA 
A = absorbance (no units)    E = 40 for RNA 
(E = wavelength dependent extinction coefficient [µl ng-1 cm-1]) 
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2.2.2.10 Sequencing of DNA 
To confirm the correctness of the cloned DNA constructs, the purified plasmids were sent 
with an appropriate sequencing primer to GATC biotech company. Sequences were verified 
by using the ClustalW alignment algorithm from the European Bioinformatics Institute.   
2.2.2.11 Overview of constructs created in this thesis 
 
Figure 6: Schematic overview of constructs generated in this work. For A) Generation of stable 
mammalian cell lines and B) protein expression. The construct indicated with an asterisk was ordered 
as a synthetic gene from Eurofins, it was re-cloned by Hans-Michel Müller to generate N-terminal 
fusion constructs to GST and his, respectively. The following constructs were generated: GST-CD1-3 
(full-length); GST-CD1 (domain CD1), GST-CD2 (domain CD2), GST-CD2-3 (domain CD2 and CD3), 
GST-CD3 (domain CD3) in pGex2mod vector and hisCD1-3 (full-length) was cloned into pQE30.  
2.2.3 Isolation of total RNA 
Total ribonucleic acid (RNA) was isolated from HeLa S3 cells after 48 h of siRNA transfection 
(section 2.3.2). Cells were grown in a 12-well or 6-well format to about 80% confluency. The 
isolation of total RNA was performed with the RNeasy Mini Kit from Qiagen according to 
manufacturer’s manual.   
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2.2.4 Reverse transcription PCR (RT-PCR) 
For reverse transcription of mRNA the ImProm-II Reverse Transcription System (Promega) 
was used according to the manufacturer’s manual. Using this procedure makes it possible to 
generate single-stranded DNA (complementary DNA, cDNA) from an mRNA template. 
Primer annealing was performed in a reaction volume of20 µl. Amounts of 2 µl oligo 
dTPrimer and 1 µg of total RNA were added and incubated for 10 min at 70°C using a 
thermomixer followed by an additional incubation for 5 min on ice. The following components 
were mixed and the reaction was transferred to a thermocycler to perform the reaction: 
5 µl MgCl2 (25 mM) 
8 µl 5 x buffer 
1 µl RNAse inhibitor (1 unit) 
4 µl dNTPs (10 mM each) 
1 µl reverse transcriptase (1 unit) 
1 µl RNAse free H2O 
add 20 µl of the previous annealing reaction 
The cDNA can be used as a template for quantitative real-time PCR (section 2.2.5) or PCR 
(section 2.2.1).  
2.2.5 Quantitative real-time PCR (qRT-PCR) 
Using quantitative real-time PCR, low amounts of cDNA can be amplified exponentially. This 
allows the relative amounts of mRNA transcripts to be quantified. For this purpose a gene-
specific TaqMan Expression Assay (Life Technologies) (section 2.1.9) was used. Every 
assay is delivered with a gene-specific forward and reverse primer and probes that are 
labeled with a FAMTM dye that consists of a reporter and quencher. Primers and probes bind 
to the region that has to be amplified. The probe itself is quenched when intact. During the 
process of elongation mediated by the polymerase its exonuclaese activity removes the 
probe nucleotide by nucleotide. This leads to a dequenching effect and allows for measuring 
the emission of the fluorophore. The signal intensity of the emission directly correlates with 
the amount of template derived from the cDNA and concomitant of the messenger RNA 
(mRNA). The samples were measured in an optical 96 well plate that were sealed with an 
optical foil to avoid evaporation. The StepOne Plus Real-Time PCR System (Applied 
Biosystems) was operated according to manufacture’s manual using the standard protocol 
for 2 hours. 
 
 
25°C 10 min 
42°C 60 min 
95°C 5 min 
8°C storage 
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Sample preparation for the TaqMan Gene Expression Assay in a 96 well plate: 
TaqMan Gene Expression Assay (Primer & Probe) 20x mix 1 µl 
TaqMan Gene Expression 2x Master Mix     10 µl 
cDNA (from previous section 2.2.4, from a 1:4 dilution)  4 µl 
         5 µl RNAse free H2O 
 
 Cycle Steps  
StepOne System: 
Temperature Time Cycle(s) 
Complete denaturation of cDNA 95°C 2 min 1 
Polymerase activation 95°C 10 min 1 
DNA denaturation 
Annealing of primer and probes 
and elongation 
95°C 
60°C 
15 s 
1 min 
 
40 
 
The amount of mRNA detected from a certain gene of interest was normalized to an internal 
endogenous control such as mRNA levels from glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). The relative differences of mRNA levels from the gene of interest, of Mock and 
knockdown conditions were calculated and plotted.    
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2.3 Cell biological methods 
2.3.1 Cell culture techniques 
2.3.1.1 Cultivation of mammalian cells and medium 
HeLa and HeLa S3 were grown on cell culture plates whereas HEK293T cells were grown on 
collagenated plates. All cell lines were cultured in DMEM complete medium and were kept in 
a carbon dioxide (CO2) incubator at 5% CO2 and 37°C. Depending on the experimental 
format cells were seeded on various sizes of cell culture dishes. 
 
Table 2: Overview of cell culture dishes  
Plate format 
 
Amount of medium 
10 cm plate 10 ml cell culture medium 
6-well plate 2 ml cell culture medium 
12-well plate 1 ml cell culture medium 
24-well plate 0.5 ml cell culture medium 
48-well plate 300 µl cell culture medium 
96-well plate 100 µl cell culture medium 
35 mm optical dish (∅ 1 cm glass bottom) 2 ml cell culture medium 
35 mm optical dish (∅ 2 cm glass bottom) 2 ml cell culture medium 
 
Preparation of complete medium:  
The DMEM cell culture medium was supplemented with 10% FCS, Penicillin (100 u/ml) and 
Streptomycin (100 µg/ml).  
2.3.1.2 Collagenation of plates 
Tissue culture plates were bathed with sterile collagen solution at a concentration of 0.02% 
and dried under a laminar flow hood.  
2.3.1.3 Splitting of cells 
Cells were passaged every 3-4 days when confluent. Old medium was aspirated and the 
cells were washed with PBS to remove old traces of medium. To adhere the cells 1-2 ml of 
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Trypsin/EDTA was added to the plate and the cells were resuspended in fresh medium and 
transferred into a new dish at the desired density.  
PBS (Biochrom):  136.9 mM NaCl  
    2.7 mM KCl 
    8.3 mM Na2HPO4 x H2O 
    1.5 mM KH2PO4 
2.3.1.4 Freezing and thawing of mammalian cells  
For freezing, cells were detached from a 10 cm plate as described above (section 2.3.1.1) 
and resuspended in 1.4 ml of freezing medium that was transferred to a cryotube. After 48 h 
of incubation at -80°C in cryoboxes (ensuring a slow cooling process) the tubes were stored 
in liquid nitrogen.  
For thawing, cryotubes with cells were removed from liquid nitrogen and rapidly thawed at 
37°C. The cells were transferred to a 10 cm plate with complete medium until they adhere 
followed by subsequent change of medium.  
Freezing medium:   DMSO 10% (v/v) 
    FCS 20% (v/v) 
    Complete medium 70% (v/v)  
2.3.2 Small interference RNA (siRNA) transfection of mammalian cells 
Transient transfection describes the transfer of genetic material such as siRNAs that are 
introduced into mammalian cells by passing through the cell membrane. In this case 
transfection reagents with cationic lipids were used, which fuse with the cell membrane and 
subsequently transfer the material into the cytosol.  
2.3.2.1 Liquid phase transfection of siRNA  
Transfection of siRNA was performed in 48-well plates. Prior to transfection 30,000 cells per 
well (HeLa and HeLa S3) were seeded in 200 µl of serum reduced Opti-MEM medium. Per 
well, 0.75 µl Oligofectamine and 3 µl Opti-MEM were mixed and incubated for 5 min at RT. In 
a second reaction 2.5 µl of the respective silencer select siRNA (3 µM in concentration) was 
mixed with 22.5 µl of Opti-MEM. The Oligofectamine reaction was then transferred to the 
siRNA mix, and briefly vortexed. For complex formation the reaction was incubated at RT for 
20 min and subsequently added drop wise onto the cells. After 16 h the medium was 
replaced with normal complete medium. 24 h after transfection each transfected 48-well was 
transferred after trypsin treatment to a 12-well. Cells were subjected to further analysis 48 h 
after transfection.  
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2.3.3 Generation of stable cell lines 
2.3.3.1 Principle of retroviral transduction 
For generation of stable cell lines a retroviral transduction system of Molony Murine 
Leukemia Virus was used to produce high titer of recombinant virus particles. Therefore, 
HEK293T cells were transfected with different vectors. The pVPack-GP vector encodes viral 
structural proteins gag and the reverse transcriptase plus integrase pol. The pVPack-Eco 
vectors express the viral envelope protein specific for the target cells to be transduced. The 
gene of interest is cloned into a pRevTre2 vector. It contains a Tet-response element (TRE), 
composed of the tetO operator sequence. Furthermore, pRevTre2 contains 5’ and 3’ long 
terminal repeats (LTRs) that promote integration into the host cell genome and the minimal 
immediate early promoter of cytomegalovirus (CMV). The cotransfection of these vectors into 
HEK293T cells ensures the production of infectious replication-defective virus particles 
carrying the viral RNA coding for the gene of interest. HeLa wild type cells constitutively 
expressing the mouse cationic amino acid transporter (MCAT) (MCAT) retroviral receptor of 
the envelope protein and the Tet-On transactivator reverse tetracycline-responsive 
transcriptional activator (rtTA) were used as target cell line. These cells, HeLaMCAT-TAM, were 
generated in this lab and previously termed HeLaMT (Engling et al., 2002), which can be used 
for virus transduction (Urlinger et al., 2000). After infection, the viral RNA genome is copied 
into DNA and eventually integrated into the host genome. Transcription of the gene of 
interest can be regulated by the addition of doxycycline (dox), a derivative of tetracycline. In 
the Tet-On gene expression system we used here, rtTA binds in the presence of dox to TRE 
and therefore activates the transcription of the gene under the control of the CMV promoter.  
2.3.3.2 Experimental procedure 
For generation of stable cell lines, the pVPack manual was followed according to 
manufacturer’s instructions, which included the MBS mammalian transfection kit for host cell 
transfection (both from Stratagene). The following procedure was performed in a period of 
five days. On the first day, HEK293T cells were seeded onto 6-well plates. An amount of 
9 µg of each DNA vector (pVPack-GP, pVPack-Eco and pRevTre2) were mixed with the 
gene of interest and subjected to sodium acetate precipitation. The DNA pellets were stored 
at 4°C with residual amounts of 70% ethanol. On the second day, HEK293T cells were 
transfected with the DNA for viral production. The DNA pellets were dried under a laminar 
flow hood and resuspended in 450 µl sterile deionized water, mixed with 50 µl of Solution I 
and 500 µl of Solution II followed by an incubation period of 10 min at RT. The mixture was 
added drop wise to the cells that were cultured in 2 ml MBS-containing medium 30 min prior 
to virus transduction. After 3 h, complete medium was replaced by complete medium 
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supplemented with 25 µM chloroquine. After 6 h, the medium was again replaced by fresh 
complete medium. On the fifth day, the virus particles were collected from the supernatant 
and filtered through a 0.45 µm filter membrane to retain the virus. A volume of 1.5 ml of the 
sterile viral supernatant plus DEAE-dextrane (dilution of 1:100) was added onto HeLaMT 
target cells, which were cultured in a 6-well plate format. Three days of viral transduction the 
efficiency was checked by FACS analysis.  
2.3.3.3 Cell sorting  
In order to isolate positive clones stably expressing the gene of interest in a 
doxycycline-dependent manner the cell lines were subjected to FACS sorting using a BD 
FACSAria cell sorter. Screening of successfully transduced cells was possible due to 
generation of fusion constructs to green fluorescence protein (GFP). HeLaMT cells were used 
to subtract GFP background signal derived autofluorescence of cells. The first round was an 
“on” sorting of cells, which were 24 h prior to sorting induced with 2 µg/ml of doxycycline and 
cells were collected according to their green fluorescence. After a period of seven days cells 
were collected that did not show green fluorescence, which were sorted in the absence of 
doxycycline. This ensures that fusion proteins are expressed in a doxycycline-dependent 
manner. The third round (after 7 days) was again an “on” sorting with doxycycline. Here, 
single cells were transferred to a 96-well plate. The single clones were expanded, again 
tested for their ability to respond to doxycycline to choose the cell clone that is used for 
following studies.  
2.3.4 Fluorescence-activated cell sorting (FACS) analysis  
For FACS analysis the FACSCalibur machine was used. With this method, single particles or 
cells can be measured when they pass the intersection of a laser beam. The signals give 
information about the relative size (forward light scatter, FSC), the relative complexity or 
granularity (side light scatter, SSC) as well as the fluorescence of a particle. The instrument 
is equipped with a laser that emits light at 488 nm to measure GFP fluorescence. A second 
laser diode emits light at 653 nm to measure allophycocyanin (APC), which is obtained from 
a fluorescently labeled antibody. 
 
Immunolabeling of cells for FACS measurement (FACS assay) 
After 48 h of siRNA knockdown, cells were induced for 16 h with doxycycline to induce 
expression of the reporter construct. Following this, cells were subjected to cell surface 
staining by immunolabeling with a primary and a secondary fluorescent labeled antibody. 
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Cells were cultivated in a 12-well format. Growth medium was aspirated and the cells were 
washed 1x with PBS. 300 µl of plain DMEM medium was added containing the first antibody 
(rabbit anti-GFP 1:500; rabbit anti-FGF2 1:200). The plates were gently shaken on ice for 
1 h. Again, the antibody solution was aspirated, 1x washed with PBS and replaced by 300 µl 
of secondary antibody (goat anti-rabbit APC 1:500) followed by a 30 min incubation on ice. 
After an additional washing step with PBS, cells were detached with 50 µl of Cell 
Dissociation Buffer (Gibco) while incubating for 10 min at 37°C. The cells were transferred in 
a 1.5 ml test tube that contained 200 µl of plain DMEM medium. After labeling, cells were 
immediately subjected to FACS measurement and gently mixed prior to each measurement. 
2.3.5 Immunofluorescence assay   
Cells were grown in small optical glass dishes to a confluency of about 70%. Medium was 
removed and cells were washed with 2 ml of PBS. 1 ml of ice-cold acetone was added and 
incubated for 6 min at -20°C followed by three washing steps of PBS. Cells were blocked 
with 1% BSA for 10 min at RT. The primary antibodies were diluted in 350 µl of 1% BSA and 
incubated for 1 h at RT (mouse anti-ATP1A1 1:100; mouse anti-cadherin 1:100; rabbit anti-
FGF2 1:100 (RG Nickel); mouse anti-FLAG 1:500; mouse anti-GM130 1:1,000; mouse anti-
HA 1:500; mouse anti-transferrin receptor 1:500). After three washing steps with PBS, cells 
were again blocked and incubated for 30 min at RT with 350 µl of secondary fluorescently 
labeled antibody solution (Alexa Fluor 488, 546 or 633 1:500, respectively). The secondary 
antibodies were diluted in 1% BSA and incubated in the dark. To visualize the nuclei, SYTOX 
green (Life Technologies) was added at a dilution of 1:100,000 to the secondary antibody 
incubation. After labeling cells were washed three times and subjected to imaging on the 
confocal microscope LSM 510 (Zeiss) with remaining PBS on top.  
2.3.6 Life-cell fluorescence microscopy  
In case cells expressed a fluorescently-tagged proteins such as FGF-GFP or GFP-CD4, cells 
were grown on optical class dishes and the medium was replaced by PBS prior to imaging at 
the confocal microscope LSM 510 (Zeiss).  
2.3.7 Duolink assay 
Duolink® is an in situ proximity ligation assay (PLA) with the aim to detect interactions of 
endogenous proteins in single cells. In this technique cells were grown on glass bottom 
culture dishes (MatTek 10 mm microwell) fixed and stained as described in section 2.3.5 with 
two primary antibodies targeting two different proteins. Importantly, the two primary 
Materials and Methods 
 
 
49 
antibodies should originate from different species, in this case from mouse and rabbit. The 
secondary antibodies are derived from the Duolink kit (Olink Bioscience) and are either 
specific to the primary mouse (PLA anti-mouse MINUS) or rabbit (PLA anti-rabbit PLUS) 
antibody (Figure 7b). Each of them is linked to a unique synthetic oligonucleotide that after 
coming into close proximity (<40 nm) can bind to each other. With the help of a DNA ligase, 
both oligonucleotides will be connected to each other forming a circularized DNA strand 
(Figure 7c). In a second step, a polymerase will amplify the DNA incorporating fluorescent 
probes. Therefore, upon antibody binding to adjacent proteins a highly fluorescent 
amplification product will be generated resulting in one red spot that corresponds to one 
interaction site (Figure 7e) (Söderberg et al., 2006). The sites of interaction can be quantified 
with a Duolink® ImageTool software that recognizes the interaction spots after assigning all 
the nuclei to the cells (Figure 7f). Staining with the secondary PLA antibodies, ligation, 
amplification as well as quantification were performed according to manufacturer’s manual 
from Olink Bioscience. Images were acquired with the confocal microscope LSM 510 (Zeiss).  
  
 
Figure 7: Principal of the Duolink assay. Image source: GEN Genetic Engeneering & Biotechnology 
News (Fredriksson et al., 2009) 
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2.4 Biochemical methods 
2.4.1 Preparation of cell lysates from mammalian cells 
Cells were washed with 1x PBS to remove residual medium. A volume of 100-200 µl of 
RIPA-buffer was added to a 12- to 6-well format of cell culture dishes and cells were scraped 
off with a cell scraper.  For lysis, the suspension was transferred to a 1.5 ml test tube and 
incubate for 15 min on ice while vortexing every 5 min. As an alternative, he suspension can 
be passed through a needle. The samples were spun down tat 14,000 g for 10 min to 
separate the total protein from the cellular debris. The supernatant was transferred to a new 
tube and the protein concentration analyzed by bicinchoninic acid (BCA) assay (section 
2.4.2). In general, 40-50 µg of total protein of the lysates were loaded onto a SDS-PAGE and 
subjected to further Western blot analysis.  
RIPA buffer:   150 mM NaCl 
    1% (v/v) NP-40 
    0.5% (w/v) Deoxycholic acid 
    0.1% (w/v) SDS  
    50 mM  Tris pH 8.0 
    in deionized water      
2.4.2 Measurement of protein concentrations 
Protein concentration of recombinant proteins 
By NanoDrop 
Protein concentrations can be measured photospectroscopically using a NanoDrop ND-1000 
spectrophotometer. Due to the absorbance of tyrosine and tryptophan residues at 280 nm 
protein concentrations can be determined. The absorbance is corrected for the protein 
specific extinction coefficient (E) and the molecular weight, calculated with ExPASy 
ProtParam tool, according to the amino acid sequence of the protein. Absorbance is 
measured and the concentration calculated following the Lambert-Beer equation: 
c=
A 
E×b
 
c = protein concentration [mg ml-1] 
b = path length [cm] 
A = absorbance (no units) 
E = extinction coefficient [M-1 cm-1]  
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By BCA assay  
After knockdown, cell lysates were prepared (section 2.4.1) to load equal amounts of total 
protein on a polyacrylamide gel (section 2.4.3) to monitor the success of the knockdown. 
Protein concentration determination was performed using a BCA protein assay quantification 
system (Pierce). For this procedure, 2.5 µl of lysate (of a 1:4 dilution) were diluted with 
47.5 µl of deionized water and 200 µl of the BCA reagent (solution A: solution B = 50:1) were 
added. The reaction was incubated for 30 min at 60°C. A volume of 150 µl of each reaction 
was transferred to a 96 well plate and the absorbance was measured at 562 nm on an Elisa 
reader (Rosys Anthos 2001 plate reader, Anthos labtech). To determine the protein 
concentration, a BSA standard curve from 2.5-10 µg/ml was also measured in parallel. 
2.4.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated according to their molecular mass using gel electrophoresis 
standard conditions of Laemmli (Laemmli, 1970). Samples were boiled with 1x SDS sample 
buffer for 7 min at 95°C and shortly centrifuged before loading onto NuPAGE 4-10% Bis-Tris 
Gel from Life Technologies. Importantly, due to the aggregation of the endogenous 
Na+/K+-ATPase cell lysates were only boiled for 7 min at 60°C. To estimate the size of 
proteins, a protein ladder was included on each gel (PageRuler, Fermentas). Separation was 
performed using 1x MOPS running buffer (Life Technologies) with 500 µl of NuPAGE 
Antioxidant (Life Technologies) at 200 V for 50 min. Smaller proteins were separated using 
1x MES buffer at 200 V and 35 min.  
4x SDS sample buffer:  24 ml   Tris-HCl pH 6.8 (0.5 M) 
     4 g   SDS 
     12.5 ml  Glycerol 
     2.5 ml   β-Mercaptoethanol 
     2 ml   Bromphenol blue (1% (w/v)) 
     ad 50 ml  deionized water  
1x MES running:   50 mM   MES, pH 7.3 
     50 mM   Tris Base 
     0.1% (w/v)  SDS 
     1 mM   EDTA 
1x MOPS running buffer:  50 mM   MOPS, pH 7.37  
     50 mM   Tris 
     0.1% (w/v)  SDS 
     1 mM   EDTA 
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2.4.4 Protein detection in SDS-PAGE  
To visualize protein bands after separation on SDS-PAGE, the gel was stained for 1-12 h 
with 20 ml InstantBlue (Expedeon) a Coomassie based staining solution. To obtain optimal 
staining the gel was washed in deionized water for at least 1 h.  
2.4.5 Western blot analysis  
Transfer of proteins to a membrane 
After SDS-PAGE (section 2.4.3) the proteins were transferred to a methanol-activated 
polyvinylidene fluoride (PVDF) membrane (Immobilon-FL, Millipore) using a wet blotting 
apparatus (MiniPreotean Trans Blot, BioRad). To set up the Western blot all components 
were soaked in blotting buffer and assembled according to the following orientation: anode – 
Sponge – 2x Whatman paper – PVDF membrane – SDS-PAGE – 2x Whatman paper – 
Sponge – cathode . An ice block and a magnetic stir bar were placed in the blotting chamber, 
which was then filled up with blotting buffer. Protein transfer was performed on a magnetic 
stirrer at 100 V for 60 min.  
Blotting buffer:    40 mM Glycine 
     25 mM Tris base pH 8.8 
     20% (v/v) Methanol 
     in deionized water 
Immunodetection of proteins 
After transfer of the proteins the membrane was blocked 1 hour with 3% BSA at RT, followed 
by incubation with the primary antibody (see also section 2.1.5) for 1 h at RT (mouse anti-
ATP1A1 1:200; mouse anti-ATP1B1 1:250; rabbit anti-FGF2 1:200 (RG Nickel); mouse anti-
FLAG 1:300; mouse anti-GAPDH 1:20,000; rabbit anti-GFP 1:500; rabbit anti-tubulin 
1:1,000). The membrane was washed 3x with PBS-Tween for 5 min. The secondary antibody 
was incubated at RT for 30 min (Alexa Fluor 680 goat anti-rabbit 1:10,000 and IRDye 
800 CW goat anti-mouse 1:10,000). After 3x of 5 min washing with PBS-Tween, the 
membrane was stored in PBS in the dark. Visualization was performed using the LI-COR 
Odyssey imaging system. All primary and secondary antibodies were diluted in 3% BSA and 
stored at 4°C with 0.02% (w/v) sodium azide.   
PBS (1x):   136.9 mM NaCl  8 g 
    2.7 mM KCl   0.20 g 
    1.7 mM KH2PO4  0.24 g 
    80 mM Na2HPO4 2x H2O 1.44 g 
    ad 1 l    deionized water adjust to pH 7.4 
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PBS-Tween:    0.05% (w/v)    Tween 20 
    1x    PBS 
2.4.6 Protein expression in bacteria 
An over night culture of 100 ml LB-Medium was inoculated with a glycerol stock and E. coli 
cells (section 2.1.10) were grown at 37°C with antibiotics. In the morning, the overnight 
culture was diluted 1:20 to inoculate a pre-culture that is grown for an additional 4-5 hours at 
37°C. Finally, this pre-culture is again diluted 1:25 to inoculate 2 liters of 2YT-Medium. Most 
constructs were purified from 6-12 liters of medium. Protein expression was induced at 
OD600 1.3-1.8 with 0.5 mM IPTG and the cells were incubated at 25°C o/n.  
2.4.7 Affinity purification of proteins 
The bacteria pellets were resuspended in lysis buffer using 20 ml of buffer per 2 liter of 
culture. The suspension was applied to a high-pressure homogenizer (Avestin) for 6 cycles 
to disrupt the cells. To clear the cell lysate, centrifugation for 1 hour, 33,000 rpm, 4°C using 
an ultracentrifuge (Beckman Coulter) with a 50.2Ti rotor was performed. All purifications 
were conducted on a Äkta purifier (GE Healthcare).  
Lysis buffer:   1x  PBS 
    1 tablet Protease inhibitor per 100 ml of buffer  
    1 mM  Benzamidine  
    1 mM  PMSF 
    1 mM  DTT 
    2%  Glycerol 
    0.1%   Trition X-100 
    in deionized water 
As a general procedure the affinity columns (Nickel, Heparin or GSH) were first equilibrated 
with the appropriated wash buffer using 10 column volumes (CV) of buffer followed by 
loading of the cell lysate with a speed of 0.5 ml/min. The columns were washed with 10 CV 
of wash buffer. The proteins were eluted with a continuous gradient with the corresponding 
elution buffer over a time of 30 min with 0.5 ml/min. Protein elution was monitored on the 
Äkta system by measuring the absorption at 280 nm. The eluted protein fractions were 
analyzed on a SDS-PAGE and stained with InstantBlue to determine their quality. Finally, 
fractions were measured with NanoDrop using the specific extinction coefficient for the 
protein that was purified. In most cases buffer exchange was performed on PD-10 columns 
(GE Healthcare) or proteins were applied to size exclusion chromatography (section 2.4.8). If 
necessary, proteins were concentrated with Amicon Ultra-4 centrifugal filters (Millipore) 
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according to the manufacturer’s manual.  The samples were snap frozen and stored 
at -80°C.     
Nickel (Ni) affinity purification 
Ni-wash buffer:  25 mM  HEPES 
    400 mM NaCl 
    40 mM  Imidazol  
    2%  Glycerol 
    in deionized water, adjust to pH 7.4 
Ni-elution buffer:  25 mM  HEPES 
    500 mM Nacl 
    400 mM Imidazol 
    2%  Glycerol 
    in deionized water, adjust to pH 7.4 
Glutathione (GSH) affinity purification: 
GSH-wash buffer:  1x  PBS 
    150 mM NaCl 
    2%  Glycerol 
 
GSH-elution buffer:  1x  PBS 
    20 mM  L-Glutathione 
    2%  Glycerol, adjust to pH 8.0 
 
Heparin affinity purification: 
Heparin-wash buffer:  1x  PBS 
    350 mM NaCl 
    2%  Glycerol 
Heparin-elution buffer: 1x   PBS 
    2 M  NaCl 
    2%  Glycerol 
2.4.7.1 Protein cleavage with thrombin 
The glutathione-s-transferase (GST) moiety of the recombinant proteins GST-FGF2 and 
GST-CD1-3 was cleaved off by the serine protease thrombin that cuts at a specific 
recognition site, which was introduced before. Protein lysates were loaded on a GSH column 
as described above. After washing, 15 ml PBS containing 500 u of thrombin (GE Healthcare) 
were circulated for 2 h with a flow of 0.5 ml/min at RT over the column. The flow through of 
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GST-FGF2 was applied to a heparin column (section 2.4.7) for further purification. The flow 
through of GST-CD1-3 was again applied to a GSH column to remove residual GST followed 
by size exclusion chromatography  (section 2.4.8.).   
2.4.8 Size exclusion chromatography 
This method is used to separate residual impurities after a first affinity purification step. A 
SuperdexTM 200 (GE Healthcare) column was used and equilibrated with one CV of 1x PBS. 
The protein samples were loaded with a 5 ml loop using an Äkta purifier. Migration of 
proteins were monitored by measuring absorption at 280 nm. Peak fractions were analyzed 
on a SDS-PAGE and stained with InstantBlue. Pooled fractions were snap frozen and stored 
at -80°C.  
2.4.9 Pull-down assay 
Performing pull-down assays means the immobilization of a protein to an affinity resin for 
capturing. In a second step a potential binding partner will be incubated together with the 
immobilized protein. Protein-protein interactions will be detected on a SDS-PAGE followed 
by staining with InstantBlue. In this experiment untagged FGF2, GST-CD1-3 and his-CD1-3 
were covalently coupled to epoxy-activated sepharose 6B (GE Healthcare). GST-FGF2 and 
GST-CD1-3 were immobilized on GSH sepharose 4B (GE Healthcare) according to the 
manufacturer’s instructions. After blocking with 3% of BSA the coupled resin was covered 
with 10 volumes of 1x PBS including 1 mM of benzamidine and 0.02% sodium azide for 
storage. For pull-downs, 100 µl of the epoxy and 10 µl of the GSH coupled suspension were 
used. The beads were washed once with 1 ml of 1x PBS and were incubated with the 
binding partner (25 – 50 µg) in 200 µl of pull-down buffer for 2 h at RT. After this incubation 
time, the unbound fraction (UB) was collected. Here, 50 µl of the supernatant were collected 
and 25 µl of 4x sample buffer were added. The resin was washed twice with 1 ml of 
pull-down buffer and once with 1 ml 1x PBS. The bound fraction (B) was eluted by adding 30 
µl of 2x sample buffer. B and UB fractions were boiled for 7 min at 95°C. A SDS-PAGE was 
loaded with 2.5-5% of the volume of the UB fraction and 50% of the volume of the bound 
fraction. B and UB bands were quantified on the Odysee infrared imaging system. The ratio 
of UB to B was calculated and normalized to wild type protein to compare the binding 
capacity of various mutant proteins.  
Pull-down buffer:   1x PBS 
     0.05% (w/v) Tween 20  
     1 mM Benzamidine 
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2.4.10 Hydrogen deuterium exchange experiments (HDX) 
A stock solution containing 50 pmol of untagged FGF2 and 280 pmol hisCD1-3 was prepared 
in PBS buffer (pH 7.2) and diluted with 15-fold of the corresponding D2O buffer (pD 7.2) to 
start the deuterium exchange labeling reaction. FGF2 was analyzed alone or together with 
hisCD1-3 after an incubation of 1 h at RT, respectively. A time course was performed taking 
an aliquot of the exchange reaction after 10 s, 1 min, 10 min, 1h and 4h. The labeling 
reaction was quenched with an equal amount of pre-chilled quench buffer and immediately 
frozen on dry ice. Samples were stored at -80°C prior to pepsin digestion and mass 
spectrometry analysis (see work flow Figure 8).  
Quench buffer:    0.8 M  guanidine hydrochloride 
     0.8%  formic acid 
 
 
Figure 8: Sequential workflow of a HDX experiment. 
2.4.11 Chromatography and mass spectrometry 
Each frozen sample was thawed rapidly and injected into a custom Waters nanoACQUITY 
UPLC HDX ManagerTM and analyzed. The protein samples were digested using a 
Poroszyme immobilized pepsin cartridge (Applied Biosystems), which was accommodated 
within the UPLC system. The cooling chamber of the UPLC system, which housed all the 
chromatographic elements, was held at 0.1°C for the entire time of the measurements. The 
injected peptides were trapped and desalted for 3 min at 100 µl/min and then separated in 
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8 min by an 8–40% acetonitrile:water gradient at 60 µl/min. The separation column was a 
1.0×50.0 mm ACQUITY UPLC C18 BEH (Waters Corporation) containing 1.7 µm particles 
and the back pressure averaged 8800 psi at 0.1°C. All experiments were performed in 
duplicates. Mass spectra were obtained with a Waters XEVO G2 TOF equipped with 
standard ESI source (Waters Corporation). The instrument configuration was the following: 
capillary was 3.2 kV, trap collision energy at 6 V, sampling cone at 35 V, source temperature 
of 80°C and desolvation temperature of 175°C. Mass spectra were acquired over an m/z 
range of 100 to 2,000. Mass accuracy was ensured by calibration with 500 fmol/µl GFP, and 
was less than 10 ppm throughout all experiments. The mass spectra were processed with 
the software Protein Lynx Global Server 2.5 and DynamXTM (Waters Corporation) by 
centroiding an isotopic distribution corresponding to the +2, +3, or +4 charge state of each 
peptide. Deuteration levels were calculated by subtracting the centroid of the isotopic 
distribution for peptide ions of undeuterated protein from the centroid of the isotopic 
distribution for peptide ions from the deuterium labeled sample. The resulting relative 
deuterium levels were automatically plotted versus the exchange time.  
2.4.12 Amplified luminescence proximity homogenous (AlphaScreen) assay  
This assay was used to perform an AlphaScreen® that allowed for the identification of small 
molecules that interfere with the protein-protein interaction of CD1-3 and FGF2. This assay is 
based on two different types of coated beads. In this particular case Glutathione coated 
Donor Beads and Nickel Chelate Acceptor Beads were used that allowed for the recruitment 
of affinity-tagged proteins such as GST-CD1-3 and hisFGF2. Donor beads were excited at 
680 nm which concomitant results in the production of singlet oxygen. These oxygen species 
can diffuse within a radius of 200 nm. If an Acceptor Bead is within this proximity the energy 
of the oxygen will be transferred and light produced that can be detected at 520-620 nm (see 
Figure 9).    
 
Figure 9: Schematic illustration of the AlphScreen principle Image Source: PerkinElmer Life and 
Analytical Sciences  
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2.4.12.1 AlphaScreen: pilot screen 
The AlphaScreen was carried out in collaboration with the Chemical Biology Core Facility at 
The European Molecular Biology Laboratory (EMBL) of Dr. Joe Lewis in Heidelberg. For the 
pilot screen a total of 4080 compounds were tested for their ability to compete for the binding 
of GST-CD1-3 and hisFGF2 that were previously immobilized onto Donor and Acceptor 
Beads at a final concentration of 30 nM and 60 nM, respectively (this was also true for the 
cross-titration experiment). The compounds were based on three commercial available 
libraries from AMRI, Enamine and Cambridge. Compounds were solved in 0.4% DMSO and 
transferred to 384-well ProxiPlate (PerkinElmer) at a final concentration of 40 µM. The 
protein partner GST-CD1-3 and hisFGF2 were added and incubated at RT for 1 h. 
AlphaScreen® Glutathione Donor Beads (Perkin Elmer) and Nickel Chelate Acceptor Beads 
(from the AlphaScree® Histidine Detection Kit, PerkinElmer), both at a final concentration of 
7.5 µg/ml, were transferred to this reaction and subsequently incubated for another 2 h until 
the plates were measured on an EnVision Plate Reader (PerkinElmer). As a buffer 0.1% 
(w/v) BSA and 0.05% (w/v) Tween 20 was used in 1x PBS. Beads were excited at 680 nm 
and the emission was measured within a range of 520 – 620 nm. The screen was carried out 
in duplicates and the percentages of derived from the compounds were calculated from a 
reaction without inhibitor. As a measurement for the quality of the assay for each plate the 
Z’-value was calculated taking into account the variation of the positive (reaction without 
inhibitor) and negative controls (without protein) applied on each plate.  
Z'value=1-
3 σpos+ σneg
µpos- µneg
    σ = standard deviation; µ = mean 
AlphaScreen cross titration assay  
2.4.12.2 AlphaScreen competition assay  
For competition the following proteins were used: untagged versions of CD1-3, FGF2 and 
Δ25 FGF2. All of them were stored in 1x PBS with 50 % glycerol. To start with, stock 
solutions of all proteins were generated and adjusted to a final concentration of 14.28% 
glycerol in assay buffer. Stocks (3x assay concentration): 90 µM CD1-3; 27 µM FGF2; 27 µM 
Δ25 FGF2. A 1:2 serial dilution was performed in 96-well storage plate with assay buffer 
containing 14.28% of glycerol (14 dilutions). In the meantime, the affinity-tagged binding 
partners were mixed in assay buffer without glycerol.  
Binding partners stock (3x assay concentration): 
GST-Tec 93.75 nM and his-FGF2 187.5 nM 
GST-CD1-3 93.75 nM and his-FGF2 187.5 nM  
GST-Titin 60 nM and His-MBP-CARP 60 nM 
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A volume of 5 µl of the protein binding pairs and 5 µl of the serial dilution of the competitor 
proteins were combined in a 384-well ProxiPlate (PerkinElmer) and incubated at RT for 
70 min. Acceptor and Donor Beads (see section above) were prepared in assay buffer at a 
concentration of 0.0225 mg/ml (3x assay concentration). Again, 5 µl of the bead suspension 
were added to the 348-well plate. After an additional incubation time of 105 min at RT the 
plate was analyzed on an EnVision Plate Reader (PerkinElmer). The median of three 
replicates was calculated and each protein pair was plotted against the final concentration of 
the competitor protein. The value half maximum of competition (IC50) can be determined with 
a non-liner regression one site IC50 fit with GraphPad 5.0c. Based on the equation from 
Cheng and Prusoff (Cheng and Prusoff, 1973) it is assumed that the determined IC50 value 
corresponds to the Kd value. This happens when the tracer (L) molecule in this case hisFGF2 
has a 10x lower concentration then the binding partner GST-CD1-3 or GST-Tec, both 
immobilized on beads. Furthermore, the protein concentration of both immobilized proteins 
has to be at least 10x less than the expected Kd value. With this assumption L/KdLT equals 
zero and leads to Kd = IC50 (see Figure 10).  
 
 
Figure 10: Calculation of the Kd value by the AlphaScreen competition assay. 
(http://www.perkinelmer.com/resources/technicalresources/applicationsupportknowledgebase/alphalis
a-alphascreen-no-washassays/determiningkd.xhtml#DeterminingKdwithanAlphaassay-
CompetitionbindingassaysfordeterminationofKd) Adapted from PerkinElmer Inc. Copyright 1998-2013. 
 
Assay buffer:    1x PBS 
     0.1% (w/v) BSA 
0.05 % (w/v) Tween 20 
The proteins GST-Titin and His-MBP-CARP were provided by Peter Sehr (EMBL). GST-Tec 
from Giuseppe LaVenuta (BHZ) and Δ25 FGF2 from Julia Steringer (BZH).  
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3 Results 
Previous experiments revealed that FGF2 binds PI(4,5)P2 at the inner leaflet of the plasma 
membrane (Temmerman et al., 2008). Only phosphorylated FGF2 can be secreted from cells 
and only in a fully folded state directly across the plasma membrane. Subsequently, it is 
immobilized on the cell surface via HSPGs (Torrado et al., 2009; Zehe et al., 2006). Our 
laboratory conducted a genome-wide RNAi screen where core components of FGF2 
secretion have been identified (Ebert et al., 2010). Ebert and co-workers revealed that Tec 
kinase, which is a direct interaction partner of FGF2. Phosphorylation of FGF2 at tyrosine 82 
was found to regulate FGF2 secretion in cells (Ebert et al., 2010).  
The aim of this work was to identify additional components of the FGF2 secretion machinery 
derived from the genome-wide RNAi screen, with the final goal to functionally characterize 
their role in FGF2 secretion on a molecular level.  
3.1 Identification of the screening hit ATP1A1 from the genome-wide 
RNAi screen  
In the genome-wide RNAi screen a total of 9102 human genes were screened (doctoral 
thesis, Antje Ebert 2009). Each gene product was targeted with three independent siRNAs. 
As a readout, the secretion of a doxycycline-inducible reporter FGF2-GFP was monitored 
and quantified by using the On-Cell-Western assay after siRNA mediated knockdown (Ebert 
et al., 2010). Each well of a 384-well plate was spotted with one gene-specific siRNA using 
the solid phase reverse-transfection method (Figure 11).  
 
 
Figure 11: Workflow of solid phase reverse-transfection with siRNAs in a 384 multi-well format. 
The illustration represents a single well of a 384 plate, each spotted with one specific siRNA.   
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A mix of siRNA, transfection reagent and glycerol was added to each well and dried in a 
SpeedVac to preserve the coated siRNAs. This was performed in collaboration with the RNAi 
screening facility at the BioQuant. A selection of siRNAs termed “druggable genome” 
(targeting 9102 human genes) from Ambion was spotted on 384-well plates in four replicates. 
For the screening procedure HeLa FGF2-GFP cells were plated and allowed to attach on this 
pre-coated wells for siRNA uptake. After a knockdown period of 48 h cells were induced for 
16 h to initiate the expression of the reporter gene. Afterwards, an antibody staining against 
GFP and a secondary fluorescently labeled antibody was applied to detect and quantify 
surface-associated FGF2-GFP using a LI-COR infrared imaging system. 
 
Figure 12: Representation of 384-well screening plate analyzed with a LI-COR infrared imaging 
system. In channel 1 (red) signals are obtained from nuclei staining reflecting the total cell number. In 
channel 2 (green) signals correspond to cells surface associated FGF2-GFP obtained through 
antibody staining. The left panel represents controls to demonstrate the principle of this assay. 
Considering the cell surface signal (green), no signals were obtained when the plate is empty or with 
HeLaMT cells not expressing any construct. A strong surface signal was obtained with FGF2-GFP 
expressing HeLaMT cells. Only a minor background signal was observed when cells expressed GFP 
alone due to a small portion of unspecific cell lysis. In contrast each cell line can be detected in the red 
channel for the nuclei staining with Syto 60. The panel represents a typical screening plate showing 
both channels.  
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Cell surface signals were corrected for the amount of cells, which were visualized with a 
fluorescent dye (Syto60) that stained the nuclei. The right panel of Figure 12 represents a 
typical screening plate from the genome wide RNAi screen. 
Mean scores of the hits were calculated and classified according to criteria’s published by 
Ebert at al., 2010. Shortly, for a positive regulator, a hit had to meet the following criteria: if 
one siRNA out of three was functional the mean score should be smaller than -3. If at least 
two siRNAs were functional the mean score should be -1.5 or lower. In both cases a p-value 
lower than 0.05 was required to reach sufficient significance. From this screen a list of 113 
gene products could be generated representing the most potent genes affecting FGF2 
secretion in a positive or negative way (doctoral thesis, Antje Ebert 2009), unpublished. In 
this study we focused on the identification of positive regulators of FGF2 secretion. Among 
those, the gene product ATP1A1, α-subunit isoform 1 (α1-subunit) of the Na+/K+-ATPase was 
found as a putative positive regulator of FGF2 secretion.  
 
 
Figure 13: Primary screening hits of the Na+/K+-ATPase knockdown obtained from the genome-
wide RNAi screen. Initial screening data of isoforms α1-4, β1-4 and of control siRNAs FGF2 and 
GFP. The numbering corresponds to the siRNA ID of Ambion, GFP siRNA was custom designed. 
Values represent the average of four separate experiments. Errors show the standard deviation of the 
mean. A positive regulator of secretion was defined as a hit when one siRNA out of three had a score 
smaller than -3. When at least two siRNAs out of three were functional, the threshold was lower 
than -1.5. In both cases p-values were <0.05.   
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In general, the Na+/K+-ATPase consists of two subunits the α- and β-subunit. For the active 
transport of ions across the plasma membrane it is known that both subunits have to be 
assembled in a 1:1 stoichiometry (Scheiner-Bobis and Farley, 1994). In mammalian cells the 
existence of four different isoforms have been shown for the α- and β-subunit, respectively 
that are termed ATP1A1 (α1), ATP1A2 (α2), ATP1A3 (α3) and ATP1A4 (α4). This is also true 
for the β-subunit ATP1B1 (β1), ATP1B2 (β2), ATP1B3 (β3) and ATP1B4 (β4). As a result, 
only the knockdown of the α1 isoform showed a reduction in FGF2 secretion for one siRNA 
with a mean score of -3.1 and a p-value of 0.04 (Figure 13) (doctoral thesis, Antje Ebert 
2009). In contrast, none of the β-isoforms were found to have any significant impact on FGF2 
secretion after siRNA-mediated knockdown. Furthermore, control siRNAs are depicted in 
Figure 13 targeting the reporter gene. Two siRNAs against FGF2 were found to be functional 
with a score of -3.1 and -4.6 and the siRNA against GFP with a score of -4.1, all of them with 
high significance (p-value <0.05).  
3.2 Analysis of Na+/K+-ATPase isoforms in HeLa cells using RT-PCR 
The main finding of the screen was that exclusively the siRNA targeting the α1-subunit 
resulted in a significant down regulation of FGF2 secretion. To investigate this in more detail, 
HeLa cells were analyzed for the expression of different isoforms of the α- and β-subunits. 
For this purpose, cDNA was prepared (section 2.2.4) from HeLa and HeLa S3 cells and 
isoform specific primers were used according to the study of Yoshimura et al., 2008. In 
agreement with this publication we found the isoforms α1, β1 and β3 in HeLaMT and HeLaMT 
S3 laboratory cell lines (Yoshimura et al., 2008). The origin of these cell lines are described 
in section 2.3.3. In short, they are carrying the doxycycline trans-activator as well as the 
receptor, for viral transduction a prerequisite for the generation of stable cell lines. Following 
these findings all further analyses will focus on the isoforms present in these HeLa cell lines. 
 
 
Figure 14: α- and β-isoforms of the Na+/K+-ATPase present in HeLa and HeLa S3 cells. Total 
RNA was isolated from HeLaMT and HeLaMT S3 cells and the mRNA was translated into cDNA. Isoform 
specific primers were used to check with PCR for the presence of mRNA isoforms of the α- and 
β-subunits.  
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3.3 Validation of the Na+/K+-ATPase phenotype in FGF2 secretion by 
FACS analysis 
In addition to the On-Cell-Western assay (see section 3.1) the validation of α1, β1, and β3 
was performed to obtain a second independent readout to monitor FGF2 secretion. The 
siRNAs, which were chosen in the validation procedure, differ in sequence from the siRNAs 
that have been used during the primary screen. Concomitantly with this, optimized silencer 
select siRNAs were received from Ambion, which allowed for the reduction of siRNA 
amounts and transfection reagent. This minimizes additional stress and toxicity for the cells. 
As described in detail in section 2.3.4, the flow cytometry (FACS) assay was used as a 
readout to detect secreted FGF2 after siRNA knockdown of the Na+/K+-ATPase subunits.  
3.3.1 Characterization of the HeLa FGF2 cell line for FACS validation 
To carry out the FACS assay HeLaMT S3 cells were generated as cells expressing untagged 
FGF2 additional to GFP from an internal ribosomal entry site (IRES) construct in a 
doxycycline-dependent manner (HeLa S3FGF2_IRES_GFP, Figure 15). After virus transduction, 
cells bearing the reporter construct stably integrated in their genome were enriched by 
sorting, according to their GFP fluorescence (section 2.3.3.3). Cell surface associated FGF2 
could be detected with antibody staining and quantified by flow cytometry (Figure 15). For 
this experimental setup HeLa FGF2_IRES_GFP S3 cells were grown as adherent cells. The 
advantage of having the S3 derivate of HeLa cells is that they can be tightly regulated with 
doxycycline. 
 
 
Figure 15: Principle of a doxycycline-inducible cell line. After 48 h of knockdown cells were 
stained with a primary anti-FGF2 antibody and a secondary fluorescently labeled antibody (APC) to 
quantify the cell surface signals by flow cytometry.  
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In general, the expression level of GFP was very low as there is only a moderate change 
observed by FACS after the addition of doxycycline. In contrast, cell surface staining of FGF2 
is considerably increased after expression of FGF2 (Figure 16). Showing a broad dynamic 
range of this assay that allows for the detection of secreted FGF2 after siRNA-mediated 
knockdown. Moreover, this cell line mimics the natural secretion mechanism by having FGF2 
expressed as an untagged version.   
 
 
Figure 16: Flow cytometry analysis of HeLaMT S3 cells stably expressing FGF2 from an IRES 
construct (HeLa S3FGF2_IRES_GFP). In the left panel GFP expression is depicted and the right panel 
shows the population of FGF2 that is found on the cell surface, both in absence and presence of 
doxycycline (dox). Cell surface attached FGF2 could be quantified by antibody staining against FGF2 
with a primary antibody and a second fluorescently labeled antibody for visualization in flow cytometry. 
3.3.2 RNAi-mediated down regulation of the α- and β-subunits of the 
Na+/K+-ATPase analyzed by FACS 
In order to perform the knockdown experiments, HeLa S3FGF2_IRES_GFP cells were seeded on 
the first day and subjected to siRNA transfection on the next day for a period of 48 h. 
Subsequently, doxycycline was added for 16 h to induce expression of the reporter construct. 
Secreted FGF2 was quantified by flow cytometry (section 2.3.4). Using a siRNA against 
GAPDH served as a negative control whereas a siRNA against FGF2 was used as a positive 
control to monitor the functionality of this assay by directly down regulating the FGF2 reporter 
gene. Three independent siRNAs were used to target the α1-subunit #1 (ID: s1718), 
#2 (ID: s1719) and #3 (ID: s1720), respectively. Figure 17A shows that knockdown of the 
α1subunit indeed leads to decreased FGF2 secretion. This was true for all three siRNAs 
used and was also the case when FGF2 was directly down regulated. No effect was 
observed with a siRNA targeting GAPDH. To monitor the knockdown efficiencies cell lysates 
of the various knockdowns were prepared and subjected to Western Blot analysis. As 
depicted in Figure 17B, the three different siRNAs against the α1-subunit substantially 
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decreased the amount of protein expressed in the cells after 48 h of knockdown time. This 
was also the case for protein levels of GAPDH and FGF2 after knockdown of the 
corresponding gene. Antibody staining of tubulin was introduced to show as loading control. 
FGF2 expression was not affected by knockdown of the Na+/K+-ATPase α1-subunits.  
 
 
Figure 17: RNAi based validation of the α1-subunit as a factor involved in FGF2 secretion.  
Stable HeLa S3 cell lines expressing FGF2 in a doxycycline-dependent manner were subjected to 
48 h of siRNA knockdown followed by quantification of cell surface located FGF2. A) Knockdown of 
the α1-subunit was performed using thee independent siRNAs (#1, #2, #3). GAPDH and FGF2 
siRNAs served as controls. FGF2 on the cell surface was quantified with flow cytometry assay and 
mean values were plotted from five separate experiments. Results were expressed as a percentage of 
mock treated cells. Error bars show the standard deviation of the mean and asterisks indicate the level 
of statistical significance calculated with GraphPad Prism 5.0c (unpaired two-tailed t-test; ns = not 
significant; * = p-value ≤ 0.05; ** = p-value ≤ 0.01; *** = p-value ≤ 0.001). B) After knockdown cell 
lysates were subjected to Western blot analysis. The membrane was decorated with antibodies 
against α1 (ATP1A1), GAPDH and FGF2 to show knockdown efficiencies. Staining with an 
anti-β-tubulin antibody was used as loading control. 
 
In order to address whether knockdowns of the two isoforms of the β-subunit (β1 and β3) in 
HeLa S3 cells can confirm the data obtained from the On-Cell-Western screening assay, the 
β1 (ID: s1734) and β3 siRNAs (ID: s1741) were used separately as well as in combination. 
The controls, GAPDH and FGF2 were kept the same. In this case, no significant difference 
between the GAPDH control and the knockdowns of the β-subunits were observed. 
However, the β3-subunit seemed to be slightly up regulated (Figure 18A). Due to the lack of 
isoform specific antibodies, quantitative real-time PCR (qRT-PCR) was performed showing 
sustainable knockdown efficiencies of the mRNA levels of β1 and β3 (Figure 18B). 
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Figure 18: RNAi based validation of the β-subunit as a factor involved in FGF2 secretion.  
Stable HeLa S3 cell lines expressing FGF2 in a doxycycline-dependent manner were subjected to 
48 h of siRNA knockdown followed by quantification of cell surface located FGF2. A) Flow cytometry 
was used to quantify FGF2 secretion after knockdown of the β1 and β3-subunit as well as in a double 
knockdown. GAPDH and FGF2 were used as control siRNAs. Mean values were calculated from n = 5 
experiments. Error bars show the standard deviation of the mean and asterisks indicate the level of 
statistic significance calculated with GraphPad Prism 5.0c (unpaired two-tailed t-test; ns = not 
significant; * = p-value ≤ 0.05; ** = p-value ≤ 0.01; *** = p-value ≤ 0.001). B) To analyze knockdown 
efficiencies the mRNA of β1 and β3 was detected and quantified by performing qRT-PCR. Mean 
values represent three independent experiments. Error bars show the standard deviation of the mean. 
 
In summary, we could confirm with a different secretion assay (FACS assay) and by 
distinctive siRNAs targeting the α1-subunit of the Na+/K+-ATPase that secretion of FGF2 was 
significantly reduced (to almost 50% of mock treated cells). On the other hand, secretion of 
FGF2 was not impaired when neither the β1 nor the β3-subunit was subjected to siRNA 
knockdown. In both cases kbyenockdown efficiencies were proven either on the protein by 
Western Blot analysis or mRNA levels by qRT-PCR. These results point to the likelihood that 
only the α-subunit and not the β-subunit plays a role in FGF2 secretion.  
3.4 Establishment of a cellular system to monitor pleiotropic effects 
after RNAi knockdown  
To ensure that siRNA-mediated knockdown of the α1-subunit has a specific impact on FGF2 
secretion, a cellular model system was established. In this system, secretion of a protein that 
passes through the classical secretory pathway was monitored. This assay was used to 
determine whether pleiotropic effects that could be triggered by RNAi treatment occur. Such 
pleiotropic effects could compromise cellular function and thus, have an impact on protein 
secretion. 
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3.4.1 Characterization of GFP-CD4 cell line for FACS analysis 
For this reason a GFP-CD4 tagged stable HeLaMT doxycycline-inducible cell line was 
generated (HeLaGFP-CD4). For the establishment of this cell line the extracellular portion of the 
CD4 receptor was replaced by GFP. A signal peptide was fused N-terminally for delivery of 
GFP-CD4 to the plasma membrane throughout the classical secretory pathway (see Figure 
19A).  
 
Figure 19: Illustration (A) and live cell images (B) of the HeLaMT GFP-CD4 cell line. In (A) the 
secretion pathway of the GFP-CD4 construct is depicted. In panel (B) images of GFP-CD4 expressing 
cells show that the construct localizes to the plasma membrane.   
 
The generation of stable cell lines is described in detail in materials and methods (section 
2.3.3.3). Cells having the GFP-CD4 DNA successfully integrated into their genome were 
enriched by three sorting steps, according to their fluorescence (“bright”, “dark” and “bright” 
sorting). From this pool of cells single clones were generated and analyzed for their ability to 
be regulated with doxycycline. As depicted in Figure 19B, both the GFP-CD4 cell pool and 
the single clone 27 showed identical localization within HeLaMT cells. The protein GFP-CD4 
localizes mostly at the plasma membrane but is also found at perinuclear regions where it is 
stuck in the secretory pathway. However, from FACS analysis it was evident that the 
GFP-CD4 single clone could be more tightly regulated with doxycycline than the pool. This is 
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depicted in Figure 20, which shows that the cell population of the single clone is well 
separated after induction with doxycycline, which is not the case for the pool. This can be 
observed for the expression level (green) and the population, which is detected on the cell 
surface (red). Therefore, the single clone was chosen to perform further FACS analysis for 
siRNA-mediated knockdowns. 
 
 
Figure 20: Flow cytometry analysis of HeLaMT cells stably expressing GFP-CD4. In the left panel 
GFP expression is depicted (green) and the right panel (red) shows the population of GFP-CD4 that is 
found on the cell surface, both in absence and presence of doxycycline (dox).  This can be detected 
by antibody staining against GFP and a second fluorescently labeled antibody. 
 
3.5 RNAi-mediated down regulation of the α1-subunit in the GFP-CD4 
HeLa cell line using FACS analysis 
In order to investigate whether pleiotropic effects occur the described HeLaGFP-CD4 cell line 
was used to perform knock down experiments. Since GFP-CD4 is a protein secreted via the 
classical ER/Golgi-dependent pathway it was not expected that secretion would be affected 
after α1-subunit knockdown. The procedure was the same as described in section 3.3.2 and 
also equal amounts of siRNAs were used targeting the α1-subunit. As a control a siRNA 
against GFP was introduced which down regulates the reporter construct. Furthermore, also 
a siRNA against β-COP was included. β-COP belongs to the protein complex coatomer, a 
structural component of COPI vesicles that mediate retrograde transport from the Golgi to 
the ER and also in the Golgi apparatus between Golgi cisternae (Rothman and Wieland, 
Results 
 
 
70 
1996). Thus, β-COP knockdown blocks transport through the classical secretory pathway. As 
represented in Figure 21, none of the siRNAs targeting the α1-subunit had an impact on 
GFP-CD4 secretion (red bars) as well as on the total GFP-CD4 expression level (green 
bars). There were also no general effects observed that had an influence on, for example, 
cell viability.  
 
 
Figure 21: Investigation of pleiotropic effects after RNAi-mediated down regulation of the 
α1-subunit in HeLaGFP-CD4 cell line. Stable HeLaMT cells expressing GFP-CD4 in a doxycycline-
dependent manner were subjected to 48 h of siRNA knockdown followed by quantification of cell 
surface located GFP-CD4. A) Knockdown of the α-subunit was performed using thee independent 
siRNAs (#1, #2, #3), β-COP and GFP siRNAs served as controls. GFP-CD4 on the cell surface was 
quantified by flow cytometry assay where the green bars represent the total expression levels of 
GFP-CD4 and the red bars the GFP-CD4 population that can be detected on the cell surface after 
antibody staining. Mean values were plotted from three separate experiments where error bars were 
calculated according to the standard deviation. Results were expressed as a percentage of mock 
treated cells.  
 
Only the control siRNAs showed decreased GFP-CD4 secretion. As expected, the GFP 
siRNA reduced both the expression level and the GFP-CD4 population that can be detected 
on the cell surface, whereas the β-COP knockdown only reduces the secreted population 
detected on the cell surface. Knockdown efficiencies were controlled by Western blot 
analysis. Equal amounts of lysates were loaded and visualized by GAPDH signals as loading 
control. As it is shown in Figure 22, all siRNAs directed against the α1-subunit (ATP1A1), 
GFP and β-COP were functional as they show reduced levels of the corresponding proteins.  
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Figure 22: Western blot analysis of HeLaGFP-CD4 cell line after RNAi-mediated knockdown. 
After knockdown cell lysates were subjected to Western blot analysis. The membrane was decorated 
with antibodies against α1 (ATP1A1) and GFP (A). On the right panel (B) knockdown efficiency of β-
COP was monitored. In both cases staining against GAPDH served as a loading control. Showing that 
siRNAs directed against the various genes specifically reduce the protein levels of the respective 
targets. 
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3.6 Co-localization of endogenous α1-subunit and FGF2 in HeLa cells 
by conventional immunofluorescence staining 
For the next step in this study it was of great interest to analyze the localization of 
endogenous α1-subunit of the Na+/K+-ATPase and FGF2. For this purpose HeLaMT cells were 
fixed and co-immunostained with an anti-FGF2 antibody and an anti-α1 (ATP1A1) antibody. 
A secondary fluorescently labeled antibody was directed against the primary antibody and 
images were taken with the confocal microscope (section 2.3.5.). The results show that both 
proteins are located on the plasma membrane. This could be an indication that the 
α1-subunit interacts with FGF2 on the plasma membrane to facilitate FGF2 secretion.  
 
Figure 23: Co-localization of FGF2 and α1-subunit (ATP1A1) on the plasma membrane of HeLa 
cells. FGF2 (green) and α1 (ATP1A1) (red) of the Na+/K+-ATPase were antibody/immunostained in 
HeLaMT cells. Pictures were taken with the confocal microscope with 60x (upper panel) and 40x (lower 
panel) of magnification. Both channels were merged and yellow regions indicate co-localization of both 
proteins on the plasma membrane. 
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3.7 Co-localization of endogenous α1-subunit and FGF2 in HeLa cells 
using an in situ Duolink detection method 
As described in section 2.3.7 the Duolink assay was applied to detect and quantify close 
interactions of proteins less than 40 nm apart from each other. Another advantage of this 
method is that also endogenous and transient interactions can be visualized due to the 
amplification step of the secondary antibodies. The aim of this assay was to quantify the 
interaction between FGF2 and ATP1A1 (α1-subunit). First, normal immunofluorescence 
stainings were performed to optimize fixation conditions and dilutions of the antibodies. 
 
Figure 24: Co-localization of FGF2 and the marker proteins on the plasma membrane and 
Golgi. HeLaMT cells were stained with antibodies against FGF2 (green) and plasma membrane 
markers such as the transferrin receptor (TfR) and cadherin in red, respectively. The cis-Golgi marker 
is visualized in the lower panel (red). Pictures were taken on the confocal microscope with a 40x 
magnification. Both channels were merged and yellow regions indicate co-localization of both proteins 
on the plasma membrane. 
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Besides the co-staining of ATP1A1 and FGF2 (Figure 23) control antibodies were used that 
target either the plasma membrane or the Golgi apparatus. Consequently, the membrane 
markers cadherin and the transferrin receptor (TfR) were chosen. The Golgi was stained with 
an antibody targeting the cis-Golgi matrix protein GM130. As seen in Figure 24, FGF2 is 
mainly found in the nucleus and on the plasma membrane (green). The latter is also the case 
for TfR and cadherin (red). GM130 shows a typical Golgi staining (red). Following this 
procedure, the primary antibody pairs were used for immunofluorescence staining after 
fixation of the cells. Secondary antibodies from the Duolink assay were used, which carry a 
small DNA linker that can be ligated upon interaction and subsequently be amplified (section 
2.3.7). Thus, red spots correspond to the amplified signal and represent one protein-protein 
interaction within 40 nm. As depicted in Figure 25, signals were observed when the cells 
were co-stained with an antibody against the α1-subunit (ATP1A1) and FGF2. This was also 
the case for the TfR and FGF2 as well as with cadherin and FGF2. Only minor background 
staining was observed with GM130 and FGF2 or when the FGF2 and ATP1A1 antibodies 
were applied alone.  
 
Figure 25: In situ Duolink proximity assay. Cells were co-stained with the antibodies ATP1A1 (the 
α1-subunit), transferrin receptor (TfR), cadherin and GM130 in combination with FGF2. To visualize 
background staining FGF2 and ATP1A1 antibodies were used separately. Red spots represent an 
interaction, which is observed when the protein pairs are in close proximity (≤40 nm). Nuclei are 
depicted in blue (Sytox green).  
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A Duolink software tool was used, which can automatically identify the cells by the nuclei 
staining and quantifies the sites of interaction. The quantification is plotted in Figure 26, 
which represents an average of absolute counts of interaction sites (red spots) per cell. As a 
result, most of the interactions sites are found between the α1-subunit and FGF2 but no 
significant difference was observed to another plasma membrane resident protein, namely 
TfR. Applying single antibody staining against ATP1A1 shows the background of this assay, 
which was in the range of the co-staining with the Golgi protein GM130 as well as for the 
membrane protein cadherin and FGF2.  
 
 
Figure 26: Quantification of the in situ Duolink proximity assay. The absolute interaction sites 
were counted per cell using the Duolink software tool and a mean was calculated from n = 4 
experiments. In each experiment about 30 – 50 cells were analyzed. Error bars represent the standard 
deviation of the mean and asterisks indicate the level of statistical significance calculated with 
GraphPad Prism 5.0c (unpaired two-tailed t-test; ns = not significant; * = p-value ≤ 0.05; ** = p-value ≤ 
0.01; *** = p-value ≤ 0.001). 
 
This data implies that the α1-subunit (ATP1A1) is indeed found in close proximity to FGF2 on 
the plasma membrane. However, also the TfR in combination with FGF2 result in similar 
signal intensity.  
3.8 Interaction studies of subdomains of the α1-subunit with FGF2 
In order to investigate whether there is a direct interaction between the α1-subunit of the 
Na+/K+-ATPase and FGF2, recombinant proteins of the α1-subunit cytoplasmic domains 
were expressed and their binding to FGF2 was tested in conventional pull-down assays as 
well as in the AlphaScreen assay (section 2.4.12). The α1-subunit of the heterodimeric 
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complex of the Na+/K+-ATPase is a transmembrane protein with 10 membrane-spanning 
α-helices. As visualized in the illustration of the Na+/K+-ATPase (Figure 27) the α1-subunit 
contains three prominent cytoplasmic domains that are mainly involved in ion transport 
across the plasma membrane to maintain the electrochemical gradient of the cell (Kaplan, 
2002). One hypothesis is that a potential interaction of FGF2 with the α1-subunit might occur 
in the cytoplasm, prior to FGF2 export. Therefore, only the cytoplasmic domains were 
expressed in E. coli and analyzed for their capability to bind FGF2. 
 
Figure 27: Illustration of the Na+/K+-ATPase representing the α- and β-subunit. The regions 1, 2, 
and 3 are indicating the three cytoplasmic domains (CD), which were expressed in E. coli. 
For this reason, the cytoplasmic domains (CD), termed CD1, CD2 and CD3, were expressed 
separately as well as fused together. Fusion constructs of the domains were connected with 
a small linker region. An overview of the proteins that were expressed is depicted in Figure 
28. In further experiment the cytoplasmic domains were mainly expressed as N-terminal GST 
fusion constructs.  
 
Figure 28: Overview of the fusion constructs obtained from the cytoplasmic domains (CD) of 
the Na+/K+-ATPase. Image source: Dr. Hans-Michael Müller, BZH Heidelberg 
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3.8.1 Pull-down experiments of the cytoplasmic domains of the α1-subunit 
and FGF2 
The pull-down experiments were performed with untagged FGF2 that was coupled to epoxy 
beads. The coupled beads were incubated with different N-terminal GST fusion constructs of 
the cytoplasmic domains that consist of the three major loops of the α-subunit of the 
Na+/K+-ATPase. After subsequent washing steps the input (I), unbound (UB) and bound (B) 
fractions were loaded on a gel, subjected to Coomassie staining and analyzed for their 
capability to bind to FGF2 (section 2.4.9).   
 
 
Figure 29: Pull-downs of the cytoplasmic domains of the Na+/K+-ATPase with FGF2. N-terminal 
GST fusion constructs of the cytoplasmic domains (CD) of the Na+/K+-ATPase were incubated with 
FGF2, which was immobilized on epoxy beads. 2.5% of the input (I) and unbound (UB) fractions and 
50% of the bound (B) were loaded on the gel for subsequent Coomassie staining.   
As a result the cytoplasmic domains CD2 and CD3 were found in the bound fraction (Figure 
29). This implicates that both domains are capable to bind to FGF2. Consequently, also 
CD1-3 as well as CD2-3 was bound to FGF2.  
 
Figure 30: Pull-downs of FGF2 with GST-tagged cytoplasmic domains of the Na+/K+-ATPase. 
Untagged FGF2 was incubated with the cytoplasmic domains (CD) of the Na+/K+-ATPase that were 
immobilized on GSH-beads. 2.5% of the input (I) and 50% of the bound (B) were loaded on the gel 
and subjected for subsequent Coomassie staining. 
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In contrast, the cytoplasmic domain 1 (CD1) as well as the GST control do not bind to FGF2. 
To prove the results obtained from the epoxy pull-down experiments in a second approach, 
the GST fusion variants of the cytoplasmic domains were immobilized on GSH-beads. The 
coupled beads were incubated with untagged FGF2 and unbound (UB) and bound (B) 
fractions were loaded on a gel, which was stained with Coomassie. Figure 30 shows that 
also here FGF2 can bind to the cytoplasmic domains CD2 and CD3 of the Na+/K+-ATPase 
but not to CD1 and GST. Unspecific binding of FGF2 to empty BSA coated GSH-beads was 
not observed. 
To summarize this section: when having the three major cytoplasmic domains or loops 
expressed alone (CD1, CD2 and CD3) it is clearly indicated, that the domains CD2 and CD3 
have the capability to bind to FGF2. This can be also observed when fusion constructs such 
as CD2-3 and CD1-3 were used in the pull-down experiments. This indicates, that there is a 
direct interaction between FGF2 and the cytoplasmic domains of the Na+/K+-ATPase.  
3.8.2 Establishment of an AlphaScreen® assay to detect protein interactions 
between the cytoplasmic domains of the α1-subunit and FGF2 
In order to have another readout to determine protein-protein interactions, the AlphaScreen 
assay was applied and established with the help of the Chemical Biology Core Facility at the 
European Molecular Biology Laboratory (EMBL) in Heidelberg.  A detailed description of the 
method is found in section 3.8.2. Instead of using single cytoplasmic domains, CD1-3 will be 
used in this assay to investigate the binding constants of FGF2 to the cytoplasmic domains 
(Figure 28). The CD1-3 construct was chosen because it is well expressed and remains 
sta9ble during purification. To perform this assay GST-CD1-3 was immobilized on 
Glutathione coated Donor Beads and hisFGF2 was immobilized on Nickel Chelate Acceptor 
Beads as depicted in Figure 31.  
 
 
Figure 31: Illustration of the AlphaScreen setup. To perform the AlphaScreen assay GST-CD1-3 
was immobilized on Glutathione-coated Donor Beads and hisFGF2 on Ni-chelate conjugated Acceptor 
Beads. Only upon protein-protein interaction of GST-CD1-3 and hisFGF2 beads come in close contact 
and excited Donor Beads (680 nm) can transfer their energy to Acceptor Beads, which emit light at 
520-620 nm that can be detected and quantified.  
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If the Donor Beads are excited they produce singlet oxygen that can diffuse within a radius of 
200 nm. If an Acceptor Bead is within this range, due to protein-protein interaction, energy 
will be transferred and the emitted light can be measured (for more details see section 
2.3.7.). Establishing this method requires optimization of protein as well as bead 
concentration. Hence, a cross titration experiment was performed where the concentration of 
hisFGF2 and GST-CD1-3 were varied while the concentrations of Donor and Acceptor Beads 
were kept constant. 
 
 
Figure 32: Cross-titration experiment for optimization of the AlphaScreen assay conditions. As 
indicated above, varying amounts of GST-CD1-3 and hisFGF2 were added to the reaction plate and 
incubated for 1 h at RT. Donor and Acceptor beads were transferred to each reaction on the plate at a 
final concentration of 30 nM and 60 nM, respectively. After an additional incubation time of 2 h at RT 
the plate was applied for measurement.  
 
With this experiment a reasonable signal to noise ratio was determined. In Figure 32 the 
result of a cross-titration experiment is depicted. It can be observed that with increasing 
amounts of proteins also the total signal increases. However, this occurs only to a certain 
extent due to the ‘hooking effect’. This effect is generated because of reached saturation of 
the beads, which in turn leads to an inhibitory effect of free binding partners. The following 
experimental setup was used for all further AlphaScreen tests. AlphaScreen assays were 
performed in this thesis with protein concentrations of 30 nM for GST-CD1-3 and 60 nM for 
hisFGF2. In cross-titration experiments (Figure 32), by using these conditions, a signal of 
10328 arbitrary units was reached that was still 23 times elevated over the background signal 
of 449 arbitrary units, having no proteins bound to the beads. This resulted in an optimal 
signal to noise ratio of the assay with a moderate concentration of proteins. 
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3.8.3 Determination of binding constants of the interaction between the 
cytoplasmic domains of the α1-subunit and FGF2 using an 
AlphaScreen competition assay  
To obtain binding constants of the interaction between, GST-CD1-3 and hisFGF2, a 
competition assay was performed based on the AlphaScreen principle. In this case 
protein-binding pairs after conjugation with the corresponding beads, were pre-incubated 
with increasing amounts of either untagged CD1-3 or untagged FGF2 that act as free soluble 
competitors of the interaction. For a detailed description of this method see section 2.4.12.2. 
Untagged CD1-3 and untagged FGF2 were derived from cleavage of N-terminal GST fusion 
constructs. In addition, a Δ25 FGF2 construct lacking the first 25 N-terminal amino acids that 
was expressed and purified without any affinity tag from E. coli was included as competitor. 
This could be obtained by using a heparin affinity column, as FGF2 has high affinity to 
heparin. Beside competition for the interaction between GST-CD1-3 and hisFGF2 the protein 
pairs GST-Tec/hisFGF2 and GST-Titin/hisCARP were used as a control. Tec kinase is a 
well-characterized binding partner of FGF2 with a determined Kd value of ∼0.5 µM 
(unpublished data, Giuseppe La Venuta, BZH Heidelberg). Titin is a structural component of 
the sarcomere, which is the basic contractile unit of muscles. Titin is known to interact with 
the cardiac ankyrin repeat protein (CARP) in the heart sarcomere (Miller Bang Labeit 2003). 
This protein-protein interaction was used as a control to rule out unspecific binding effects 
that could occur when CD1-3 or FGF2 were applied as competitors.  
Figure 33 represents a summary of the results obtained from the competition experiments, 
which shows that CD1-3 as well as FGF2 and Δ25 FGF2 can compete for the interaction of 
GST-CD1-3 and hisFGF2. The concentrations for the half maximum of inhibition (IC50) were 
determined and the following values were obtained: IC50 of 141.1 nM for the competition with 
CD1-3; 967.5 nM for the competition with FGF2; and 657.1 nM for the competition with 
Δ25 FGF2. Furthermore, also the interaction between GST-Tec and hisFGF2 could be 
outcompeted by CD1-3 or both FGF2 variants. The median IC50 value obtained was 
551.4 nM, which was similar to the Kd value experimentally tested by Giuseppe La Venuta. If 
we apply the approximation introduced by the method of Cheng and Prusoff we can assume 
that the determined IC50 values corresponds to Kd values (for detailed explanation see 
section 2.4.12.2).  
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Figure 33: AlphaScreen competition experiments. The protein pairs GST-CD1-3/hisFGF2; 
GST-Tec/hisFGF2 and GST-Titin/hisCARP were immobilized on either Glutathione Donor Beads or 
Nickel Chelate Acceptor Beads. Increasing amounts of untagged CD1-3 and FGF2 as well as 
Δ25 FGF2 were titrated into the binding experiment. As readout the AlphaScreen setup was used. The 
median of three replicates was calculated and each protein pair was plotted against the concentration 
of the competitor protein. IC50 values were calculated with GraphPad Prism 5.0c (non-linear 
regression analysis, one site fit IC50; n/a = not available)  
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When considering the control proteins GST-Titin and hisCARP, there was a minor 
background observed when high concentrations of the competitor proteins were used. This 
was only the case when CD1-3 or FGF2 were used as competitors because both proteins 
were derived from N-terminal GST fusion constructs. We assume that residual impurities of 
GST after cleavage can at high concentrations compete for the binding of GST-Titin to the 
Glutathione Donor Beads. In contrast, this was not the case when Δ25 FGF2 was used as a 
competitor, which was not purified from a GST-tag. These data conclude that GST-CD1-3 
and hisFGF2 are interacting with a Kd value of 657.1 nM when Δ25 FGF2 was used as a 
competitor. 
3.8.4 Development of a small compound screen using an AlphaScreen based 
detection method 
With having the AlphaScreen assay in hand it was possible to screen for a subset of small 
molecules or chemical compounds that could block the protein-protein interaction of 
GST-CD1-3 and hisFGF2. This small molecule-screening library contained a total of 4,080 
compounds, which were composed of three commercially available libraries. The ultimate 
goal of such a screening procedure would be to identify initial leading compounds, which can 
be further developed and finally applied as a drug that potentially can inhibit FGF2 secretion. 
A drug that could block FGF2 secretion is of particular interest to be applied in cancer 
because FGF2 has been shown to be a crucial factor involved in tumor-induced 
angiogenesis (Seghezzi et al., 1998). With the AlphaScreen setup, both proteins were 
pre-incubated with inhibitors before the Donor and Acceptor Beads were added to the 
reaction plate for conjugation. After measuring the AlphaScreen signal the percentage of 
inhibition was calculated from each inhibitor. To make a statement about the assay quality, 
the Z’-value was calculated for each screening plate (13 in total). With this formula (see 
section 3.8.4) four different parameters were taken into account that are the mean and 
standard deviation calculated from both, the positive and negative controls found on each 
screening plate, representing the upper and lower limit of the assay. A good Z’-value is only 
obtained when the mean of both controls are strongly different to each other and the 
standard deviation of both are as small as possible. An excellent assay quality is reached 
when the Z’-value is close to 1 to have a good dynamic range of the assay.  
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Figure 34: Z’-values of the pilot screen calculated for each screening plate. Calculation of the Z’-
values (section 3.8.4) was performed from each screening plate taking into account the mean and 
standard deviation of the positive and negative control on each plate. A Z’-value between 0.5 and 1 
shows an excellent assay quality. (A) and (B) representing replicates of the screening procedure.  
In Figure 34 the Z’-values of each screening is depicted. The pilot screen was carried out in 
duplicates. Apart from the outlier of the replication plate 6 almost all Z’-values were between 
0.9 and 1 showing an excellent assay quality. In addition, when the percentages of inhibition 
were plotted against each other it was shown that there was a high reproducibility between 
the two runs with a correlation coefficient (R2) close to 1. 
 
Figure 35: Determination of the correlation coefficient of the pilot screen. The values for the 
percentage of inhibition of two independent runs were plotted against each other and the R2 was 
calculated.  
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From this pilot screen 5 compounds could be extracted showing an inhibitory effect of the 
interaction between GST-CD1-3 and his FGF2 that was in the range of 35.5 – 53.5% 
(Table 3). In general, these compounds were not found to be positive in other AlphaScreens 
(indicated by the corresponding small median) giving some evidence that these hits are no 
false positive candidates. In the future, these compounds will be tested in a secretion assay 
to assess whether they can block FGF2 export from cells.  
 
Table 3: Hits derived from the pilot screen 
Compound # Supplier % of Inhibition 
(Average of duplicates) 
Median of 
AlphaScreens 
#1 ChemBridge 53.8 6.5 
#2 AMRI 46.0 3.5 
#3 ChemBridge 53.8 9.9 
#4 AMRI 37.0 3.8 
#5 ChemBridge 35.5 1.9 
 
In summary, it was possible to establish an AlphaScreen assay that was used to determine a 
binding constant between GST-CD1-3 and hisFGF2, which was determined with a Kd of 
657 nM. Furthermore, with this setup it was possible to screen an initial compound library 
that allowed for the identification of 5 drug-like components that could inhibit the interaction 
of GST-CD1-3 and hisFGF2 to a certain extend (35.5 - 53.5% of inhibition).  
3.9 Hydrogen Deuterium Exchange (HDX) experiments  
The aim of this method is to determine the binding region between CD1-3 and FGF2. This 
technique was carried out in collaboration with the John Engen Laboratory in Boston. A 
detailed workflow of this method is described in materials and methods (section 2.4.10). The 
principle of this reaction is based on the rapid exchange of amide hydrogens in the peptide 
bonds of proteins that are exposed to a solvent. If the solvent is changed from water (H2O) to 
deuterated water (D2O), deuterons will be incorporated into the solvent-exposed regions of 
the protein of interest and the increase of mass can be followed after peptic digestion with 
pepsin and subsequent mass analysis with a mass spectrometer. If proteins interact with 
each other there will be protected regions that are less accessible to the solvent and 
consequently, to deuterium exchange. Hence, there is less incorporation of deuterium in the 
protected binding region. Peptides that are engaged in the interaction with the binding 
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partner result in lower masses respect to the same peptides of the protein incubated in 
absence of binding partner (see illustration Figure 36). In order to investigate the binding 
regions between FGF2 and the cytoplasmic domains of the Na+/K+-ATPase the CD1-3 
construct was used. In this case, a histidine-tagged version of CD1-3 (hisCD1-3) was used 
as binding partner in combination with untagged FGF2 that was generated after cleavage of 
the N-terminal GST moiety. For this purpose FGF2 was first applied alone and subjected to 
pepsin digestion to obtain peptides that were evaluated for their relative deuterium uptake.  
 
 
Figure 36: Principle of a HDX experiment to investigating the interface of protein-protein 
interactions. Image source: Hentze N., Mayer MP., ahead of print in Journal of Visulized Experiments 
(JoVE).  
 
As depicted in Figure 37 there are regions of FGF2, especially on the N- and C-terminus (red 
and orange), showing high exchange rates with deuterium. This can happen to exposed 
surfaces and/or very flexible regions. On the other hand there are other parts such as the 
black beta sheet that is buried inside the molecule, which shows only moderate exchange 
rates.  
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Figure 37: Relative deuterium uptake of FGF2. Untagged FGF2 was incubated for 4 h with 
deuterated buffer and subsequently subjected to a pepsin digestion. The peptides were separated and 
analyzed with a mass spectrometer. The relative deuterium uptake was calculated from each peptide 
and was assigned to the FGF2 molecule. Color code visualizes deuterium uptake.  
3.9.1 HDX experiment of FGF2 in complex with the cytoplasmic domains of 
the α1-subunit 
The final goal of this experiment was to investigate the binding region on the side of the 
FGF2 molecule when in a complex with hisCD1-3. For this reason FGF2 in absence of the 
binding partner was continuously labeled with deuterium, the reaction was stopped and the 
protein was subjected to pepsin digestion to analyze the incorporation of deuterium into 
FGF2 peptides. This was compared to a reaction were FGF2 was pre-incubated with 
hisCD1-3 at conditions were both proteins form a complex. Subsequently, deuterium uptake 
of FGF2 peptides alone and in a complex with hisCD1-3 was compared. These results are 
summarized in Figure 38 representing parts of the peptides of FGF2 (the full analysis is 
depicted in the appendix). The red line represents peptides that were generated from FGF2 
alone and the blue line corresponds to FGF2 peptides obtained after 1 h of incubation with 
hisCD1-3. The regions where differences in deuterium uptake was observed are shown in 
red, yellow, green, and blue (Figure 38). Almost all peptides obtained from the complex have 
less deuterium incorporated. This effect was pronounced in the very N-terminal part of the 
molecule (red) in regard to other regions were only less than 1 Da of mass change was 
observed. Drawing the conclusion that hisCD1-3 might protect the N-terminus of FGF2 from 
hydrogen deuterium exchange, possibly by binding to this specific region of the FGF2 
molecule.  
 
N-term 
C-term 
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Figure 38: HDX experiment of FGF2 without and in complex with hisCD1-3. FGF2 was analyzed 
either separately or in complex with hisCD1-3 subjected to HDX. Parts of the peptides covering FGF2 
are depicted above where FGF2 was analyzed alone (red) or in complex with hisCD1-3 (blue). For 
both reactions proteins were incubated for 1 h at RT before the continuous labeling with D2O was 
initiated. Samples were taken at the following time points: 10 s, 1 min, 10 min, 1 h and 4 h and 
immediately afterwards subjected to pepsin digestion, peptide separation and mass spectrometry. The 
colored regions show peptides that have incorporated less deuterium because FGF2 was incubated 
together with hisCD1-3. 
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3.10 Verification of the HDX experiments by mutational analysis of FGF2 
FGF2 mutants were generated according to the data obtained from the HDX experiments. As 
described in section 3.9.1 there were four regions in FGF2 observed showing a protection 
respect to the deuterium incorporation after pre-incubation with hisCD1-3. As depicted in 
Figure 39 these regions were assigned to the FGF2 crystal structure and charge reverse 
mutations were generated on amino acids that were exposed on the surface of these parts of 
the molecule. In total four mutants were cloned and purified from E. coli: hisFGF2 
K27E/D28K; hisFGF2 D99R; hisFGF2 T121R and hisFGF2 K138E.  
 
Figure 39: Overview of the reverse charge FGF2 mutants cloned after the HDX analysis. 
3.10.1 Pull-down experiments of the FGF2 mutants 
In order to verify the ability of the FGF2 mutants to bind to CD1-3, pull-down experiments 
were carried out. In addition to the point mutations described above, further mutants were 
included in this analysis. This was a truncation mutant where 25 amino acids were removed 
from the N-terminus of FGF2 (Δ25 FGF2). This mutant was expressed without affinity tag 
and was purified with a heparin column from cell lysates (kindly provided from Dr. Julia 
Steringer, BZH Heidelberg). Beside the 25 amino acid deletion construct of FGF2 a second 
N-terminal deletion construct was generated lacking the first 28 amino acids. In this case, it 
was expressed as an N-terminal fusion to GST.  
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Figure 40: Pull-down experiments of FGF2 mutants with CD1-3 coupled Epoxy-beads. 100 µl of 
slurry Epoxy-beads coupled to either GST-CD1-3 or hisCD1-3 (∼100 µg) were incubated for 1 h at RT 
with 50 µg of FGF2 variants and control proteins such as GST and hisGFP. 5% of the unbound (UB) 
and 50% of the bound (B) fraction was loaded on a SDS-PAGE and subjected to Coomassie staining.  
 
Pull-downs of histidine-tagged FGF2 mutants as well as Δ25 FGF2 were tested for their 
ability to bind to GST-CD1-3 immobilized on epoxy beads. In case, GST-FGF2 proteins were 
applied in the pull-down experiments, hisCD1-3 coupled epoxy beads served as a potential 
binding partner. As a control the proteins hisGFP and GST were used. Bound (B) and 
unbound fractions (UB) fractions were loaded on a gel, which was subsequently subjected to 
Coomassie staining. B and UB bands were quantified using a LI-COR infrared imaging 
system (section 2.4.9). A ratio was calculated between B/UB to compare the binding ability of 
mutant FGF2 to that of FGF2 wild type (FGF2_WT) protein. For this reason his-tagged 
mutants were compared to hisFGF2wt wild type protein and GST-FGF2 mutants to 
GST-FGF2 wild type (GST-FGF2_WT). 
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Figure 41: Quantification of pull-down experiments of FGF2 mutants with CD1-3 coupled 
Epoxy-Beads. Bands were quantified using the LI-COR infrared imaging platform. A ratio of B/UB 
was calculated and the signals were expressed as a percentage of hisFGFwt (for his constructs) or 
GST-FGF2wt (for GST constructs). Error bars show the standard deviation of the mean of five 
independent experiments.  
 
The results obtained from this binding experiment of the various FGF2 mutants did not reflect 
the initial HDX experiments, which suggested a strong protection at the N-terminal region of 
FGF2. Neither the 25 nor the 28 amino acid deletion construct had an influence on binding to 
CD1-3 when compared to the binding affinity of wild type FGF2 to CD1-3 (see quantification 
in Figure 41). Also no difference was observed for the hisFGF2_K27E/D28K mutant. 
Interestingly, the mutants of hisFGF2_D99R, hisFGF2_T121R and hisFGF2_K138E had 
even an increased binding affinity to bind to hisCD1-3 when compared to wild type FGF2. To 
this extent, no FGF2 mutants could be identified that had a reduced binding affinity to CD1-3. 
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4 Discussion 
Most secretory proteins are transported in vesicular intermediates along the classical 
secretory pathway to reach their final destination. Typically, these proteins carry a 
hydrophobic signal sequence that allows them to be targeted to the ER/Golgi-dependent 
export route followed by vesicular fusion with the plasma membrane to be released into the 
extracellular medium (Nickel and Wieland, 1998).  
More than 20 years ago a different export pathway has been described and was later termed 
as “unconventional protein secretion”. This class of proteins are characterized by the 
absence of a signal sequence, they do not reside within the ER or Golgi compartment, and 
thus lack ER/Golgi specific modifications (Muesch et al., 1990; Nickel and Rabouille, 2009). 
A couple of unconventional routes for protein secretion have been described so far ranging 
from vesicular intermediates such as lysosomes, autophagosomes, or multivesicular bodies 
to release by membrane shedding or direct translocation across the plasma membrane 
(Nickel, 2005). Recently, a class of membrane proteins have been identified that bypass the 
Golgi apparatus to reach the plasma membrane even though being targeted to the ER 
(Grieve and Rabouille, 2011; Rabouille et al., 2012).  
One of the best-characterized examples of unconventionally secreted proteins is fibroblast 
growth factor (FGF2), which is a strong mitogen involved in tumor-induced angiogenesis. 
Moreover, this protein is important for the maintenance of cellular processes such as cell 
proliferation and differentiation (Bikfalvi et al., 1997). Its secretion is mediated by direct 
translocation across the plasma membrane through the formation of a transient lipidic pore 
(Steringer et al., 2012; Torrado et al., 2009). Hallmarks of FGF2 secretion are the 
phosphoinositide PI(4,5)P2 at the inner leaflet of the plasma membrane for recruitment and 
HSPGs at the extracellular side for directional export and immobilization of FGF2 molecules 
on the cell surface (Temmerman et al., 2008; Zehe et al., 2006). In addition, phosphorylation 
of FGF2 by Tec kinase regulates FGF2 secretion, which might be du to the stabilization of 
the hydrophilic pore consisting of molecules in the plasma membrane (Ebert et al., 2010).  
This study aimed at the characterization of further proteinaceous factors involved as either 
core components or regulatory factors of FGF2 secretion. Following a genome-wide RNAi 
screen, which is documented in the doctoral thesis of Antje Ebert (this department), a subset 
of such components was found. Among those the α1-subunit of the Na+/K+-ATPase was 
identified. In order to determine a possible role of this protein in FGF2 secretion, the data 
presented in this study focus on the molecular characterization of the α1-subunit.  
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4.1 Characterizing the role of the Na+/K+-ATPase in FGF2 secretion 
In the genome-wide RNAi screen the α1-subunit was revealed as a potential positive 
regulator of FGF2 secretion. The α1-subunit is part of the Na+/K+-ATPase, being closely 
associated with the β-subunit to build up the functional heterodimeric complex, which acts in 
ion transport. The energy required for the transport of three sodium ions out of the cell for 
every two potassium ions pumped in, is provided by hydrolysis of ATP. Simultaneously, the 
Na+/K+-ATPase maintains the electrochemical gradient across the cell membrane. Prior work 
has documented that ouabain, a specific inhibitor of the Na+/K+-ATPase, leads to reduced 
FGF2 secretion (Dahl et al., 2000; Florkiewicz et al., 1998). Ouabain belongs to the group of 
cardiotonic steroid and is a well-known inhibitor of the Na+/K+-ATPase. It exerts its function 
while binding to the extracellular portion of the α-subunit und thus interferes with the ion 
transport function of the sodium pump (Palasis et al., 1996; Schoner and Scheiner-Bobis, 
2007).  
The studies of Dahl and Florkiewicz revealed the Na+/K+-ATPase as a factor involved in 
FGF2 secretion. However, prior results were mainly based on pharmacological evidence. 
When they applied ouabain to different cell lines including human embryonic kidney cells 
(HEK293T) and two monkey kidney cell lines (CV-1 and COS-1) FGF2 secretion was 
reduced in comparison to untreated cells (Dahl et al., 2000; Florkiewicz et al., 1998). In these 
studies the high concentration of ouabain (100 µM) was controversial exceeding many folds 
the half maximum inhibitory concentration (IC50) to block the pumping function of the 
Na+/K+-ATPase. In literature for example, IC50 values for HEK293T and CV-1 cells were 
found to be in a sub-micromolar range of 0.3 and 11 µM, respectively (Kockskämper et al., 
1997; Schulz and Cantley, 1988). It remains questionable, whether the decrease in FGF2 
secretion was due to the specific inhibition of the Na+/K+-ATPase or to possible side effects 
that could occur as a result of the high concentrations of ouabain. Interestingly, it has been 
reported that ouabain can induce endocytosis of the Na+/K+-ATPase (Cook et al., 1982; Liu 
and Shapiro, 2007; Núñez-Durán et al., 1988). If this would have been the case in these 
studies, it might be possible that internalization of the Na+/K+-ATPase leads to a reduction of 
the α-subunit at the plasma membrane where it is hypothesized to support FGF2 secretion. 
On the other hand Dahl and colleagues obtained remarkable data, which showed that 
ouabain resistant α-subunits from rat could rescue the secretion defect of FGF2 from CV-1 
and HEK293T cells (Dahl et al., 2000).  
In order to carry out the validation procedure of the Na+/K+-ATPase from the genome-wide 
siRNA screen, it had to be determined, which isoforms of each subunit are expressed in 
HeLa cells. It was demonstrated that among the four possible isoforms of the α-subunit 
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(α1, α2, α3, α4) and β-subunit (β1, β2, β3, β4), respectively, only α1, β1- and β3 subunits are 
expressed in these cells. This was important to know because early data demonstrated, that 
in a monkey kidney cell line not only the α1-subunit but also the α2- and α3-subunits from rat 
were capable to rescue FGF2 secretion (Dahl et al., 2000). For this reason, both isoforms of 
the β-subunits were taken under consideration in the validation procedure.  
To address the role of the α1-, β1- and β3-subunits in FGF2 secretion, in vivo secretion 
analyses were performed using HeLa cells stably expressing FGF2. In this case, siRNAs 
were chosen, which differed in sequence from those used during the genome-wide RNAi 
screen. After RNAi-mediated knockdown of the encountered isoforms of the α- and 
β-subunits, FGF2 secretion was quantified and compared to the secretion efficiency of 
control cells. This approach confirmed the initial screening data. Knockdown of the 
α1-subunit, which was targeted by three independent siRNAs showed a reduction of FGF2 
secretion up to 50% compared to control cells. In order to exclude pleiotropic effects, 
knockdowns of the α-subunit were repeated in a stable HeLa cell line. As an additional 
control, export of GFP-CD4, a protein that passes the classical secretory pathway, was 
monitored showing no impaired secretion. This result indicates that down regulation of the 
α1-subunit has a specific effect on FGF2 and does not compromise any other cellular 
function such as protein transport or cell viability.  
For the β-subunit down regulation neither of the β1- nor the β3-isoform had an effect on 
FGF2 secretion. In contrast, when the β3-subunit was depleted from HeLa cells, a slight 
up-regulation of FGF2 secretion was observed. In most tissues the Na+/K+-ATPase is 
predominantly expressed and assembled in a α1β1 isoform complex. Down regulation of the 
β3-isoform might favor the assembly of the α1-subunit with the β1-subunit and hence 
increase the number of α1-subunits being delivered to the plasma membrane and thus 
triggering FGF2 secretion. Noteworthy to mention, that Na+/K+-ATPase only assembled as a 
heterodimeric complex can leave the ER. Studies in MDCK canine kidney cells for example 
showed, that the α1-subunit predominantly assembles with higher affinity to the β1-subunit 
than to the β2-subunit (Tokhtaeva et al., 2012).  
Effects of ouabain on FGF2 secretion could not be tested in HeLa cells due to toxic 
consequences after addition of the Na+/K+-ATPase inhibitor. Supplementation of ouabain at 
nanomolar concentrations induced cell detachment and morphological changes in HeLa cells 
(data not shown). This happened already a few hours after the addition of ouabain, which 
was not compatible with the FACS secretion assay to measure FGF2 export. It was shown 
that treatment of HeLa cells with rather low concentrations (70 - 100 nM) of ouabain induced 
morphological changes and apoptotic cell death, which might be due to the very low 
IC50 value of 18 nM determined for these cells (Ramirez-Ortega et al., 2006).  
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In summary, the results obtained from the siRNA-mediated knockdowns of the α- and 
β-subunits are in agreement with pharmacological studies where the Na+/K+-ATPase was 
inhibited by ouabain. However, the data of this study provides clear evidence that only the 
α-subunit not the β-subunit is involved in FGF2 secretion.  
4.2 Co-localization of the α1-subunit and FGF2 in HeLa cells 
Data obtained from the siRNA-mediated knockdowns of the validation procedure provided 
strong evidence for a role of the α1-subunit of the Na+/K+-ATPase in FGF2 secretion. 
Therefore, it was of particular interest to localize both proteins in HeLa cells to investigate 
whether there is a potential cellular compartment for the interaction of FGF2 and the 
α1-subunit. 
Immunofluorescence analysis of endogenous protein levels of the α1-subunit and FGF2 
could clearly demonstrate that both proteins are localized at the plasma membrane of HeLa 
cells. Moreover, co-staining of cells with antibodies directed against both epitopes of FGF2 
and α1-subunit, gave raise to a co-localization signal at the plasma membrane.  
In order to investigate whether the plasma membrane could be the compartment of a 
potential direct interaction between these two proteins, a novel protein interaction assay was 
carried out. This so-called Duolink assay is an in situ proximity ligation assay that should 
resolve subcellular protein interactions at a distance of 0 - 40 nm. Therefore, protein-protein 
interactions of FGF2 and the α1-subunit were analyzed. As controls, other plasma 
membrane resident proteins, which are known not to interact with FGF2, were chosen and 
examined including transferrin receptor and cadherin. Since FGF2 is absent from the Golgi 
compartment the Golgi protein GM130 was additionally tested. 
Quantification analyses showed that there were almost as much interaction sites observed 
for FGF2 and the α1-subunit as for FGF2 and the transferrin receptor. Interaction sites of the 
protein pairs FGF2/Cadherin and FGF2/GM130 caused only minor signals that were in the 
range of background. The background of the assay was defined by signals that were 
obtained when only one antibody either against FGF2 or ATP1A1 (α1-subunit) was used. 
Although there is no known evidence for an interaction of FGF2 with transferrin receptor 
there were similar amounts of interaction spots detected for transferrin receptor as for the 
α1-subunit of the Na+/K+-ATPase. It seems likely that there is a certain limitation of the 
assay. This implies that also proteins that are in close proximity (in a range of 0 - 40 nm), 
which reside for example in the same sub-domains at the plasma membrane, can give a 
signal even if there is no direct interaction.  
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From these data, also including the conventional immunofluorescence assay we can 
conclude that both proteins are in close proximity at the plasma membrane. Although a direct 
interaction between the α1-subunit and FGF2 cannot be postulated it can be hypothesized 
that a potential role for the α1-subunit to act in FGF2 secretion might be carried out at the 
plasma membrane.  
4.3 Interaction studies of the cytoplasmic domains of the α1-subunit 
and FGF2 
Subcellular co-localization experiments showed that the α1-subunit and FGF2 are both 
enriched at the plasma membrane in HeLa cells. In addition, Dahl and co-workers performed 
co-immunoprecipitation experiments and were capable to either co-purify FGF2 or the 
α1-subunit from cell lysates of CV-1 cells. However, at these conditions both proteins were 
over expressed in cells. These experiments provide only qualitative data on the protein 
interaction of the α1-subunit and FGF2, which binding capacities were not further quantified. 
In addition, co-immunoprecipitation experiments cannot rule out that the nature of this 
interaction is indirectly mediated through an additional binding partner.  
According to the data obtained from the immunofluorescence assay we hypothesize a 
potential interaction site for FGF2 at the cytoplasmic regions of the Na+/K+-ATPase. In order 
to investigate whether there is a direct interaction between the α1-subunit and FGF2 we 
expressed and purified the cytoplasmic domains from the human α1-subunit in E. coli. This 
approach was chosen, because the α1-subunit naturally consists of 10 transmembrane 
domains, which represents a major obstacle for protein purification. In particular the first 
three cytoplasmic domains (CD1, CD2, and CD3) that are involved in ion transport and ATP 
hydrolysis of the Na+/K+-ATPase were further analyzed. The domains were either separately 
expressed (CD1, CD2, CD3) or as fusion constructs (CD2-3, CD1-3) with a short linker 
region between the domains. Pull-down experiments were performed where either the 
various cytoplasmic domains or FGF2 were immobilized on beads acting as a binding 
partner for the other protein. Both experiments lead to the same conclusion: FGF2 directly 
interacts with the cytoplasmic domains CD2 and CD3 as well as to the CD2-3 and CD1-3 
fusion constructs of the α1-subunit. In conclusion, it is highly probable that a direct interaction 
of FGF2 and the α1-subunit occurs at the cytoplasmic site and presumable at the plasma 
membrane of a cell.    
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Analyses of the binding interface between FGF2 and cytoplasmic domain of the 
α1-subunit 
In order to investigate the interaction interface of FGF2 and CD1-3 hydrogen deuterium 
exchange (HDX) experiments were performed. Regions that take part in the binding reaction 
are less accessible to incorporation of deuterium at their amide hydrogens in the peptide 
bond.  
When FGF2 was applied for HDX experiments the relative deuterium uptake of the molecule 
was analyzed over time. In particular, the N- and C- terminal parts of FGF2 showed up to 
50% of deuterium incorporation, which demonstrates that these regions are very flexible. In 
addition, FGF2 was analyzed after pre-incubation with CD1-3 to shift most of the free FGF2 
molecules to form a complex with CD1-3. This experiments revealed that when FGF2 is in a 
complex with CD1-3, an increased protection of the N-terminus of FGF2 can be observed, 
which was pronounced for the first 28 amino acids of FGF2. Three other parts of the 
molecule showed only subtle changes in deuterium uptake after binding to CD1-3. The 
findings indicate that after binding of FGF2 to CD1-3 the N-terminal flexible region of FGF2 
becomes stabilized, thus being involved in binding to CD1-3. 
To test this hypothesis, FGF2 deletion mutants were generated lacking either the first 25 or 
28 amino acids. In addition, further charge reverse mutants were designed comprising all 
regions that showed protection from deuterium uptake. For this reason surface exposed 
amino acids of this areas were chosen and replaced by amino acids with opposite charge 
states. The following mutants were generated (hisFGF2 K27E/D28K; hisFGF2 D99R; 
hisFGF2 T121R and hisFGF2 K138E) also including Δ25 FGF2 and analyzed by pull-down 
experiments for their ability to bind to GST-CD1-3.  
None of the tested mutants showed impaired binding efficiency to GST-CD1-3 when 
compared to hisFGF2 wild type protein. Even the N-terminal truncation mutant of FGF2 
(Δ25 FGF2) as well as the mutant that carried two point mutations at the N-terminus 
(hisFGF2 K27E/D28K) did not show any difference in binding to GST-CD1-3. Since not only 
the 25 amino acids were suggested to be involved in binding but rather the first 28 amino 
acids, an additional mutant was created lacking the fist 28 (GST-Δ28) amino acids of the 
N-terminus of FGF2. Because this mutant could not be purified as an untagged version such 
as Δ25 FGF2 it was N-terminally fused to GST. Subsequently, binding of this mutant was 
tested to hisCD1-3. The binding efficiency of GST-Δ28 was compared to GST-FGF2 wild 
type protein again, showing no difference.  
Taken together, mutational analysis could not confirm the obtained data from HDX 
experiments, which predicted the N-terminus of FGF2 as the most probable region for 
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binding to CD1-3. Since in pull-down experiments reduced binding affinities could not be 
demonstrated for the truncation mutants, the N-terminal part of FGF2 is not considered to be 
directly involved in binding to CD1-3. Moreover, no other region determined in HDX 
experiments could be confirmed with charge reverse mutants of FGF2.  
These experiments could be extended to create not only charge reverse mutants but also 
mutations to neutral amino acids such as alanine. In addition, also more quantitative 
methods to measure protein-protein interactions such as fluorescence polarization 
experiments or the AlphaScreen assay could be applied. This would allow detecting also 
subtle changes in binding affinities, which might be incapable of measurement by 
conventional pull-down experiments. Furthermore, it would be of great importance to repeat 
the HDX experiments not only looking into the interaction interface of the FGF2 molecule but 
also into the one of CD1-3. With this approach the binding region between CD1-3 and FGF2 
could be investigated and verified by a mutational analysis.  
 
Binding affinities of the cytoplasmic domains of the α1-subunit to FGF2 
The AlphaScreen assay was applied in order to obtain binding constants for the interaction 
between hisFGF2 and the cytoplasmic domains (GST-CD1-3). Different proteins were used 
as competitors: untagged CD1-3, untagged full-length FGF2, and untagged Δ25 FGF2. To 
compete for the binding of GST-CD1-3/hisFGF2 the following IC50 values were determined: 
For untagged CD1-3 it was 141.1 nM, for untagged FGF2 967.5 nM and 657.1 nM were 
obtained for untagged Δ25 FGF2.  
As a control an unrelated protein binding pair GST-Titin/hisCARP was used to monitor 
unspecific binding effects. The binding of GST-Titin/hisCARP was affected at very high 
concentrations of the competitor proteins CD1-3 and FGF2, respectively, which was not 
observed for Δ25 FGF2. An obvious explanation for these observations are the origins of 
FGF2 and CD1-3. Both constructs were derived from N-terminal fusions to GST, which were 
cleaved after purification. Following cleavage there was still a faint band of residual GST 
visible on a Coomassie gel. For this reason, free GST could compete at high concentrations 
of both FGF2 as well as CD1-3 for the binding to the Glutathione Acceptor Beads, thus 
leading to elution of the immobilized GST binding partner. This small impureness would 
explain the sensitivity towards the control proteins GST-Titin/hisCARP. Notably, this was not 
observed for the Δ25 FGF2 construct, which was not purified starting from a GST fusion 
protein but by affinity chromatography using immobilized heparin.  
From these results we can conclude a specific competition for full-length FGF2 and CD1-3 
proteins, because the control proteins GST-Titin/hisCARP were only affected at higher 
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concentrations. Moreover the observed behavior occurred at concentrations where the 
competition curve of GST-CD1-3/hisFGF2 almost reached a plateau. However, due to this 
issue the IC50 values might be not fully reliable. Since the control was not affected by 
Δ25 FGF2 as a competitor, we assume a Kd value of 657.1 nM for the interaction between 
hisFGF2 and the cytoplasmic domain GST-CD1-3. In this experimental setup the determined 
IC50 value (657.1 nM) corresponds to the Kd value (for detailed explanation see 
section 2.4.12.2). As shown by previous pull-down experiments, binding of Δ25 FGF2 to 
CD1-3 is comparable to wild type FGF2, thus concluding that the absence of the N-terminal 
amino acids should not cause any artifacts in this competition assay.  
Furthermore, a binding constant of GST-Tec and hisFGF2 was also determined with a 
Kd value of 217.3 nM, which is in good agreement with the Kd value of 500 nM observed in 
previous studies (personal communication, Giuseppe La Venuta). Interestingly, not only 
FGF2 but also CD1-3 was able to compete for the interaction of GST-Tec and hisFGF2. This 
observation suggests that Tec kinase and CD1-3 might share the same binding region of the 
FGF2 molecule, which may prove to be relevant for mechanistic details of the overall process 
of FGF2 secretion.   
4.4 Small compound screen to identify inhibitors of the interaction 
between the cytoplasmic domains of the α1-subunit and FGF2 
The AlphaScreen assay, which was used in this thesis to determine binding affinities 
between the cytoplasmic domain CD1-3 of the α-subunit and FGF2 was further employed to 
screen for small compounds able to interfere with this interaction. The rational of this 
approach was to identify lead compounds serving as the starting point for the development of 
inhibitors blocking the FGF2 secretion. The long-term aim of this approach is to achieve 
pharmacological tools able to act against the pro-angiogenic effects of FGF2. In addition, 
FGF2 is an important target since it was recently demonstrated to have an anti-apoptotic 
effect, which leads to resistance of tumor cells towards chemotherapeutic drugs (Salm et al., 
2013). However, such a drug-developmental process involves many steps. If a compound 
can be identified from such a screening procedure it first has to be optimized in order to 
improve its potency. Furthermore, cytotoxicity tests have to be performed as well as 
pharmacokinetic studies and toxicological investigations, which eventually lead to a potential 
drug candidate. In this study the experimental basis for a large-scale small molecule screen 
was established and a “lead screen” was performed.     
The initial pilot screen included a total of 4,080 compounds that were tested for their ability to 
compete for the binding of GST-CD1-3 and hisFGF2. These compounds covered 13 
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screening plates. Statistical parameters were calculated for each plate. Z’-values close to the 
theoretical optimum of 1 for almost every plate proved the excellent quality of the assay. In 
addition, the screen was performed in duplicates showing a very good reproducibility with a 
correlation coefficient that was likewise close to 1.  
From this pilot screen 5 compounds could be identified that were able to inhibit the 
interaction between GST-CD1-3 and hisFGF2 from 35.5% to up to 53.8%. In the meanwhile 
also the lead screen was carried out, which covered 75,000 compounds and also showed an 
excellent assay quality represented by the Z’-values close to 1. In summary, 161 hits were 
identified as capable of inhibiting the interaction of GST-CD1-3 and FGF2 with more than 
35%. Among those 13 compounds showed an inhibitory effect of more than 70%. In addition, 
it was possible to cluster these hits into 7 different compound classes according to their 
chemical structures. The fact that the hits are not randomly distributed among the screening 
library but rather cluster into several chemical subgroups indicates high significance of the 
obtained screening hits. Beyond these observations, the 5 hits from the pilot screen could be 
reconfirmed. This comprehensive analysis provides the possibility to test the hits of the lead 
screen in a cell based secretion assay to assess the ability of these inhibitors to block FGF2 
secretion. 
4.5 Model of the α1-subunit as a part of the FGF2 secretion mechanism 
In the current study, RNAi-mediated down-regulation demonstrated that the α-subunit 
independent of the β-subunit of the Na+/K+-ATPase might play a role in FGF2 secretion from 
cells. Interaction studies of the cytoplasmic domains of the α-subunit and FGF2 using an 
in vitro biochemical assay showed a direct interaction between these two molecules, which 
interaction can be specifically blocked by small compound inhibitors. In addition, both 
proteins co-localize in cells at the plasma membrane. For this reason, it is most likely that a 
direct interaction of FGF2 and the α1-subunit occurs at the cytoplasmic site close to the 
plasma membrane to drive export of FGF2 in vivo.  
Based on this study it could be clearly demonstrated that FGF2 secretion (as far it concerns 
the contribution of the Na+/K+-ATPase) is only dependent on the α-subunit. Since exclusively 
the heterodimeric complex of the Na+/K+-ATPase, composed of both the α-subunit and the β-
subunit, can act in ion transport functions we conclude that the enzyme activity is not 
important for FGF2 secretion. This is in line with previous studies, which showed that 
compounds perturbing the ion gradient without inhibiting the Na+/K+-ATPase, have no 
influence on FGF2 secretion (Florkiewicz et al., 1998). Furthermore, it was demonstrated that 
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FGF2 could traverse the membrane of inside-out vesicles derived from plasma membrane in 
the absence of ATP (Schäfer et al., 2004). 
A recent study presented remarkable data in HeLa cells where a pool of unassembled 
α1-subunits was detected in the plasma membrane of these cells (Yoshimura et al., 2008). 
This is of particular interest because the Na+/K+-ATPase leaves the ER assembled in a 1:1 
stoichiometry complex consisting of the α- and β-subunit en route to the plasma membrane. 
It was shown that the β1 and β3-subunits have a much faster turnover than the α1-subunit, 
which can remain in the plasma membrane. Since the function of such a pool of 
unassembled α1-subunits still remains elusive, one possibility could be that they act in FGF2 
secretion. It is commonly accepted that the Na+/K+-ATPase plays a role in other cellular 
processes besides carrying out ion transport functions to maintain the electrochemical 
gradient of a cell. For example, it is well-established that a subset of Na+/K+-ATPases which 
reside in caveolae do not take part in ion pumping but rather act as signal transducers after 
binding of cardiotonic steroids (Liang et al., 2007; Xie and Cai, 2003). 
So far, it remains unclear how the α-subunit participates in FGF2 secretion. One possibility 
could be that the α1-subunit is involved in the recruitment of FGF2 molecules to the plasma 
membrane prior to PI(4,5)P2 binding. Due to the interaction between FGF2 and the 
cytoplasmic domains 2 and 3 of the α1-subunit, it is conceivable that one or even two FGF2 
molecules could simultaneously bind to the α-subunit on the cytoplasmic site close to the 
plasma membrane. In a second step FGF2 might be transferred to PI(4,5)P2, where it gets 
phosphorylated by Tec kinase following oligomerization that leads to the formation of a lipidic 
pore.  
Another possible scenario is that the α1-subunit might stabilize and control the integrity of 
such a transient lipidic pore formed of FGF2 molecules in the plasma membrane. The 
α1-subunit with its 10 transmembrane segments might act as a scaffold stabilizing the pore 
and even contributing to a certain microenvironment of lipids enriched in PI(4,5)P2 and 
cholesterol, which are essential for FGF2 secretion (Temmerman et al., 2008). In addition, 
the α1-subunit might be involved in regulation of pore formation processes preventing the 
uncontrolled passage of ions or small molecules that could penetrate the pore during FGF2 
secretion. This would point to the direction that the α1-subunit can open and close such a 
lipidic FGF2 pore to control the entry and release of FGF2 molecules that continuously 
traverse the lipid bilayer prior to extraction by membrane proximal HSPGs and immobilization 
in the extracellular space.  
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Figure 42: Model of FGF2 membrane translocation. FGF2 is secreted by direct translocation 
across the plasma membrane. FGF2 is recruited to the inner leaflet of the plasma membrane where 
the α-subunit might function as a docking platform followed to binding to PI(4,5)P2. Subsequently, 
FGF2 gets phosphorylated at tyrosine 82 by Tec kinase, which leads to the stabilization of PI(4,5)P2 
induced oligomers forming a toroidal lipidic membrane pore through which the molecules can traverse 
the plasma membrane. HSPGs in the extracellular space extract FGF2 molecules from the plasma 
membrane due to much higher affinity and immobilize them on the cell surface. Moreover, the 
α1-subunit might act as a scaffold by stabilizing such a transient lipidic pore, or even control the 
opening and closing of such a pore. Adapted from Nickel 2010. Current Opinion in Biotechnology 
2010, 21:621-626 
4.6 Future perspectives 
In this study the involvement of the α1-subunit in FGF2 secretion has been shown by in vivo 
and in vitro experiments. However, the exact mechanism by which the α1-subunit facilitates 
FGF2 secretion remains to be ascertained.  
In vitro reconstitution experiments could be a way to address the question whether the 
α1-subunit is involved in either recruitment of FGF2 to the plasma membrane to function as a 
docking platform prior to PI(4,5)P2 binding or whether it controls and stabilizes the pore. The 
generation of proteoliposomes in a plasma membrane-like lipid background containing the 
α1-subunit and PI(4,5)P2 might answer these questions. In a different approach the 
cytoplasmic domains CD1-3 could be anchored to liposomes either through a lipidated 
version of the molecule or through recruitment of his-tagged CD1-3 by a Nickel-NTA lipid 
incorporated in the liposomes.  In case that the α1-subunit is acting as a docking platform for 
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FGF2, recruitment and pore formation might be accelerated showing different kinetics that 
could be monitored by the leakage assay.  
When hypothesized that the α1-subunit acts as a gate to control the opening and closing of 
such a pore, reconstitution of this protein might hamper the entry of small fluorescent tracer 
molecules into liposomes. The same experimental setup can be used as a negative control in 
absence of the α1-subunit. The incorporation of HSPGs inside the lumen of such 
proteoliposomes might even contribute to a process where FGF2 molecules completely 
traverse these artificial membranes (and end up inside their lumen). In addition, 
electrophysiology methods can be applied to measure the influx of divalent calcium ions into 
the cell by calcium imaging. This would allow comparing untreated cells with those subjected 
to siRNA-mediated knockdown of the α1-subunit. Such information might suggest whether 
cells are less susceptible to control the entry of small molecules or ions such as calcium in 
absence of the α1-subunit.  
Another future aspect would be to investigate the distribution of FGF2 and the α-subunit in 
polarized cells. In polarized tissue the Na+/K+-ATPase localizes towards the basolateral 
membrane (Farr et al., 2009; Muth et al., 1997). Therefore, it is of particular interest to 
investigate whether FGF2 secretion also occurs at these sites of the cell and shows the 
same distribution pattern.  
Furthermore, future work is planned to continue with the verification of the small compound 
screen, which aimed to identify inhibitors of the interaction between the cytoplasmic domains 
of the α1-subunit and FGF2. This will implicate to test the inhibitors in a FGF2 secretion 
assay to examine their functionality in vivo. Such an inhibitor could be a valuable tool in 
research to block FGF2 secretion in many cell types to investigate FGF2 specific effects as 
for example in cell development or angiogenesis. In addition, such an inhibitor might help to 
elucidate further details of the secretion mechanism of FGF2. In particular, it might be 
possible to study whether membrane binding to PI(4,5)2 can still occur even when the 
interaction between the α1-subunit and FGF2 is interrupted. Finally, such an inhibitor would 
pave the way for the future development of a novel anti-angiogenic drug and could help to 
prevent resistance to chemotherapies where autocrine FGF2 signaling has been seen to 
inhibit apoptosis of tumor cells. 
Finally, it would be of great interest to investigate whether the α1-subunit of the 
Na+/K+-ATPase is a common regulator in unconventional protein secretion. In this way other 
unconventional secreted proteins such as Tat, which seems to be secreted in a similar way 
than FGF2, can be tested for their dependence on the α1-subunit in secretion.  
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6 Appendix  
6.1 Abbreviations  
%    percent 
°C    degree Celsius 
3’    three prime 
5’    five prime 
α    alpha 
β    beta 
A    alanine 
ABC-transporter  ATP-binding cassette-transporters 
Acb1    acyl-CoA-binding protein 
A-domain   actuator domain 
ADP    adenosine diphosphate 
APC    allophycocyanin 
ArfI    ADP-ribosylation factor (small GTPase) 
ATP    adenosine triphosphate 
ATP1A1   α-subunit isoform 1, of the Na+/K+-ATPase 
ATPase   adenosine triphosphatase 
B    bound 
BCA    bicinchoninic acid 
BFA    brefeldin A  
bp    base pairs 
BSA    bovine serum albumin 
Ca2+    calcium ion 
cAMP    cyclic adenosine monophosphate   
cDNA    complementary deoxyribonucleic acid 
CFTR    cystic fibrosis transmembrane conductance regulator 
CGN    cis-Golgi network 
CHO    chinese hamster ovary 
cm    centimeter  
CMV    cytomegalovirus 
CO2    carbon dioxide 
CoA    coenzyme A 
COP    coat protein  
C-terminal   carboxy-terminal 
CUPS    compartments for unconventional protein secretion   
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CV    column volumes 
D    aspartate 
D2O    deuterated water 
Da    dalton 
DMEM    Dulbecco’s modified eagle medium 
DMSO    dimethyl sulphoxide 
DNA    deoxyribonucleic acid  
dNTPs    desoxyribonucleotide	  triphosphatedox  
dox    doxycycline 
DTT    1,4-Dithio-D,L-threitol 
E. coli    Escherichia coli 
EDTA    ethylenediaminetetraacetic acid 
en route   on the way  
ER    endoplasmic reticulum 
ERAD    ER-associated degradation 
ESCRT   endosomal sorting complex  
et al.    at alii (and others) 
EtBr    ethidium bromide 
f    femto 
FACS    fluorescence-activated cell sorting  
FCS    fetal calf serum 
FGF    fibroblast growth factor  
FGFR    fibroblast growth factor receptor 
g    gram 
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
GFP    green fluorescent protein 
GRASP   Golgi reassembly and stacking protein 
GST    glutathione-s-transferase 
GTP    guanosine triphosphate 
h    hour 
H+    proton     
HEK    human embryonic kidney 
HeLa  Henrietta Lacks (human epithelial cell line derived from cervical 
cancer cells) 
HeLa S3 derivate of HeLa cell line 
HIV-1    human immunodeficiency virus type 1 
HMW    high molecular weight 
HSPGs   heparan sulfate proteoglycans 
IPTG    isopropyl β-D-1-thiogalactopyranoside 
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IRES    internal ribosome entry site 
k    kilo 
K    lysine 
K+    potassium ion 
kb    kilobase 
kDa    kilodalton 
KCl    potassium chloride 
KH2PO4   potassium dihydrogen phosphate (KH2PO4) 
l    liter 
LB    lysogeny broth 
LMW    low molecular weight 
LTRs    long terminal repeats 
m    milli 
M    molar 
m/z    mass-to-charge ratio 
MCAT / MT   murine cationic amino acid transporter 
MDCK    Madin Darby canine kidney  
MgCl2    magnesium chloride 
min    minutes 
mRNA    messenger RNA 
n    nano 
N    asparagine 
Na+    sodium ion 
N-domain   nucleotide binding domain  
N-glycosylation  asparagine-linked glycosylation 
N-terminal   amino terminal 
Na+/K+-ATPase  sodium-potassium pump / sodium-potassium ATPase 
Na2HPO4   sodium hydrogen phosphate 
NaCl    sodium chloride 
Ni    nickel 
NLS    nuclear localization signal 
nm    nanometer 
NP-40    nonidet P40  
O- linked glycosylation oxygen-linked glycosylation 
o/n    overnight 
PI(4,5)P2   phosphatidylinositol-4,5-bisphosphate 
PI(3,4,5)P3   phosphatidylinositol-3,4,5-triphosphate 
PAGE    polyacrylamide gel electrophoresis 
PBS    phosphate buffer saline  
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PCR    polymerase chain reaction 
P-domain   phosphorylation domain 
PMFS    phenylmethylsolfonyl fluorid 
psi    pressure per square inch 
Q    glutamine  
R    arginine 
rcf    relative centrifugal force 
RNA    ribonucleic acid 
RNAi    RNA interference 
rpm    rounds per minute 
RT    room temperature 
rtTA    reverse tetracycline-responsive transcriptional activator 
s    second 
SDS    sodium dodecyl sufate  
siRNA    small interfering RNA 
SRP    signal-recognition particle 
T    threonine 
Tat    trans-activator of transcription 
TGN    trans-Golgi network 
TRE    tet-response element 
t-SNAR soluble N-ethylmaleimide sensitive factor attachment protein 
receptor on the target membrane 
u    unit 
UB    unbound 
UV    ultraviolet 
VEGF    vascular endothelial growth factor 
v/v    percent volume per volume 
v/w    percent weight per volume  
µ    micro 
W    tryptophan 
Y    tyrosine 
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6.2 Comprehensive analysis of the HDX data 
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Figure 43: Total analysis of the HDX experiment of FGF2 without and in complex with hisCD1-3. 
FGF2 was analyzed either separately or in complex with hisCD1-3 subjected to HDX. FGF2 was 
analyzed alone (red) or in complex with hisCD1-3 (blue). For both reactions proteins were incubated 
for 1 h at RT before the continuous labeling with D2O was initiated. Samples were taken at the 
following time points: 10 s, 1 min, 10 min, 1 h and 4 h and immediately afterwards subjected to pepsin 
digestion, peptide separation and mass spectrometry. The colored regions show peptides that have 
incorporated less deuterium because FGF2 was incubated together with hisCD1-3. 
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